var title_f18_24_18816="MPS I cord compression A";
var content_f18_24_18816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spinal cord compression in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome) A",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sagittal T2-weighted MR image of the spine in a 25-year-old with Hurler-Scheie syndrome and spinal cord compression, making him unable to walk. Little or no CSF (white) is anterior to the cord (gray) in the thoracic and cervical region. In the upper cervical region, CSF is completely excluded by meningeal thickening, which also compresses the cord.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emil Kakkis, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18816=[""].join("\n");
var outline_f18_24_18816=null;
var title_f18_24_18817="Scheie brain MRI";
var content_f18_24_18817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brain MRI in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sagittal T1-weighted MR image of the brain in a patient with Hurler-Scheie syndrome. The ventricular system is prominent. Numerous white matter cysts (representing accumulation of GAG around vessels) are arrayed along the grey-white interface of the cortical white matter and within the corpus callosum and other white matter tracts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emil Kakkis, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18817=[""].join("\n");
var outline_f18_24_18817=null;
var title_f18_24_18818="Preventing severe infection after splenectomy";
var content_f18_24_18818=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Preventing severe infection after splenectomy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/24/18818/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/24/18818/contributors\" id=\"au535\">",
"       Mark S Pasternack, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/24/18818/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/24/18818/contributors\" id=\"se6247\">",
"       Peter F Weller, MD, FACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/24/18818/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/24/18818/contributors\" id=\"de1919\">",
"       Anna R Thorner, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?18/24/18818?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     The spleen is an organ that removes damaged red blood cells from the bloodstream. It also functions to protect the body against bloodstream infection by removing bacteria from the blood. If the spleen is surgically removed or does not work correctly, a minor infection can potentially develop into a life-threatening infection known as sepsis. Fortunately, treatments to prevent minor infections from becoming life-threatening can be effective when taken as soon as symptoms appear.",
"    </p>",
"    <p>",
"     This topic reviews how the spleen works, why it might be removed or not function correctly, and ways to prevent serious infections.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS THE SPLEEN?",
"     </span>",
"    </p>",
"    <p>",
"     The spleen is an organ located in the upper left side of the abdomen that filters bacteria from the bloodstream and is important for fighting infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Reasons the spleen may be removed or not function",
"     </span>",
"     &nbsp;&mdash;&nbsp;The spleen may be surgically removed as a result of an injury, accident, or following damage during an abdominal surgery; an underlying medical condition such as thrombocytopenia (low platelet levels), certain leukemias, or lymphomas; or overactivity of the spleen.",
"    </p>",
"    <p>",
"     In other cases, the spleen may not work properly due to an underlying condition such as:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Sickle cell disease or another inherited blood disease",
"      </li>",
"      <li>",
"       Disease or conditions in which there are abnormalities in the breakdown of red blood cells",
"      </li>",
"      <li>",
"       Collagen vascular diseases, such as systemic lupus erythematosus (rare)",
"      </li>",
"      <li>",
"       Absence of the spleen at birth (rare)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHAT IS SEPSIS?",
"     </span>",
"    </p>",
"    <p>",
"     Sepsis is a severe and potentially life-threatening condition in which infection-causing bacteria spread throughout the bloodstream",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     tissues. In people whose spleen is removed or does not function properly, the most common cause of sepsis is infection with a bacterium called Streptococcus pneumoniae, also known as the pneumococcus. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"      \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Less commonly, sepsis develops as a result of infection with other bacteria, such as Neisseria meningitidis or Haemophilus influenza type B (Hib). N. meningitidis and Hib were previously common causes of meningitis and other serious infections in children before vaccines to prevent these infections became available. Hib can also cause upper respiratory tract infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Symptoms of sepsis",
"     </span>",
"     &nbsp;&mdash;&nbsp;In people without a spleen or with abnormal spleen function, symptoms of sepsis may develop quickly following a minor infection, such as a respiratory tract infection. Early symptoms of a respiratory infection can include throat or chest pain, coughing, ear pain, or sinus pain and congestion.",
"    </p>",
"    <p>",
"     In other cases, sepsis develops abruptly without any early symptoms. Symptoms can become severe quickly. People without a functional spleen should begin antibiotic treatment and seek medical care at the earliest sign or symptom of sepsis (see",
"     <a class=\"local\" href=\"#H13\">",
"      'Antibiotics for fever'",
"     </a>",
"     below), including the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Fever greater than 100.4&ordm;F or 38&ordm;C",
"      </li>",
"      <li>",
"       Uncontrollable chills",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       shivering",
"      </li>",
"      <li>",
"       Headache",
"      </li>",
"      <li>",
"       Drowsiness, confusion,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       disorientation",
"      </li>",
"      <li>",
"       Nausea, vomiting,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       diarrhea",
"      </li>",
"      <li>",
"       Severe abdominal pain",
"      </li>",
"      <li>",
"       Pinpoint purplish red spots on the skin (petechiae) or larger, bluish bruises",
"      </li>",
"      <li>",
"       Low blood pressure, lightheadedness or fainting (syncope)",
"      </li>",
"      <li>",
"       Rapid heart rate",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Risk of sepsis",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the spleen stops working normally or is surgically removed, the body&rsquo;s immune system can usually compensate. However, there is a small but significant risk of sepsis.",
"    </p>",
"    <p>",
"     The risk of sepsis is highest in the following groups:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Children whose spleens are removed during infancy",
"      </li>",
"      <li>",
"       People with lymphoma who are treated with splenectomy, radiation, and chemotherapy",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Sepsis can also develop in otherwise healthy adults who have had their spleen removed, particularly in the first few years following splenectomy. The lifetime risk of sepsis after splenectomy is about 1 to 2 percent.",
"    </p>",
"    <p>",
"     Fortunately, taking certain precautions can reduce the risk of developing sepsis. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Preventing sepsis'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      PREVENTING SEPSIS",
"     </span>",
"    </p>",
"    <p>",
"     All people without a functional spleen are advised to take certain precautions to help reduce the risk of developing sepsis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Inform healthcare providers",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Inform all doctors, dentists, and other members of the healthcare team that the spleen has been removed or does not function properly, especially when seeing new providers in an urgent care setting or emergency ward.",
"      </li>",
"      <li>",
"       Carry a patient identification card, a Medic Alert bracelet or necklace, or other medical identification indicating that the spleen has been removed or does not work properly.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Immunizations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Experts recommend that people without a functional spleen have certain vaccinations to reduce the risk of sepsis. Although these vaccines do not prevent all infections with pneumococcus, Haemophilus influenza type B (Hib), and meningococcus, they can protect most people and reduce the severity of infection in others. When possible, vaccines should be given at least two weeks before planned surgical removal of the spleen. The vaccine should be given 14 or more days after emergency removal of the spleen (eg, due to trauma). The following recommendations are intended for people in the United States without a functional spleen; recommendations in other countries may differ:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pneumococcal vaccine &mdash; The pneumococcal vaccine is recommended for all people who do not have a functional spleen. Two types of pneumococcal vaccines are available, PPSV23 and PCV13. Young children receive PCV13 as part of their routine infant immunizations. PCV13 is also recommended for adults who do not have a functional spleen. In addition, PPSV23 is recommended for adults and children &ge;2 years. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"        \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"        \"Patient information: Adult vaccines (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Hib vaccine &mdash; Most adults have been exposed to Hib and are therefore immune. However, because there is a small risk that the person is not immune, experts advise people without a functional spleen to have the Hib vaccine if it was not given previously (it became available in the United States in 1988). If a person is unsure if the vaccine was given during childhood, a blood test can be done to determine if he or she is immune. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"        \"Patient information: Adult vaccines (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Meningococcal vaccine &mdash; The meningococcal conjugate vaccine (MCV4, Menactra or Menveo) is recommended for people without a functional spleen who are between 2 and 55 years of age. People who are greater than 55 years of age should be given the meningococcal polysaccharide vaccine (MPSV4, Menomune).",
"      </li>",
"      <li>",
"       Influenza vaccine &mdash; Influenza (the flu), a highly contagious viral infection, is a common cause of pneumonia and other bacterial infections. Therefore, a once yearly influenza vaccination (usually given in the fall) is recommended for people without a functional spleen. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"        \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Booster vaccines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Additional (&ldquo;booster&rdquo;) doses of the pneumococcal and meningococcal vaccines may be recommended to help maintain immunity. The need for a booster depends upon the individual&rsquo;s situation and the type of vaccine previously given. A booster dose of the Hib vaccine is not routinely needed, but is occasionally given to those who do not develop a good antibody response to the vaccine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Preventive antibiotic therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antibiotics are recommended in some people without a functional spleen to reduce the risk of developing sepsis. Two approaches are common:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Daily preventive antibiotic therapy",
"      </li>",
"      <li>",
"       Antibiotic therapy for fever when needed",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Daily therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Taking an antibiotic on a daily basis can significantly reduce the risk of infection and death, especially in children who have undergone splenectomy. Children with sickle cell anemia who have impaired spleen function may also benefit from daily antibiotic treatment. Because the risk of sepsis is low in adults, the value of daily antibiotic treatment for adults is debated.",
"    </p>",
"    <p>",
"     The ideal duration of daily therapy for children remains unclear. Many experts advise treatment of children for three to five years after splenectomy (or until adulthood).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Antibiotics for fever",
"     </span>",
"     &nbsp;&mdash;&nbsp;People without a functional spleen are usually advised to keep a full course of antibiotics on hand in case of illness. The antibiotic should be taken at the first sign of infection, such as fever, chills, sore throat, or cough. After taking the first dose, the person should seek care",
"     <strong>",
"      IMMEDIATELY",
"     </strong>",
"     at the nearest urgent care facility to determine if further testing or treatment is needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Recommendations for international travel",
"     </span>",
"     &nbsp;&mdash;&nbsp;Before traveling abroad, people without a functional spleen should consult their healthcare provider or a travel medicine center. In some cases, additional vaccinations will be recommended; one or more medications may also be prescribed to prevent or treat certain travel-related infectious diseases. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"      \"Patient information: General travel advice (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      BABESIOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Babesiosis is a tick-borne infection that is caused by a parasite. If infected with babesiosis, people without a functional spleen can develop a flu-like illness leading to potentially life-threatening complications. Treatment for babesiosis is available and is usually effective.",
"    </p>",
"    <p>",
"     In the United States, most cases of babesiosis have occurred in the following areas:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Coastal areas and islands off of Massachusetts, particularly Cape Cod, Nantucket, and Martha&rsquo;s Vineyard",
"      </li>",
"      <li>",
"       Islands near New York City, particularly Long Island, Shelter Island, and Fire Island",
"      </li>",
"      <li>",
"       Block Island, off of Rhode Island",
"      </li>",
"      <li>",
"       Focal areas in Connecticut",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     There have also been reports of infection in New Jersey, Minnesota, Maryland, Virginia, California, Washington State, Georgia, Wisconsin, and Indiana.",
"    </p>",
"    <p>",
"     Measures to avoid tick bites and steps to take after a tick bite are described in detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=see_link\">",
"      \"Patient information: Lyme disease treatment (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=see_link\">",
"      \"Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413250698\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15455554\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Basic content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15455562\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=see_link\">",
"      Patient information: Lyme disease treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=see_link\">",
"      Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=see_link\">",
"      Clinical features and management of sepsis in the asplenic patient",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/002944.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/002944.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Children&rsquo;s Hospital of Boston",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.childrenshospital.org/az/Site1631/mainpageS1631P0.html\">",
"      www.childrenshospital.org/az/Site1631/mainpageS1631P0.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?18/24/18818/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?18/24/18818?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18818/abstract/1\">",
"      Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet 2011; 378:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18818/abstract/2\">",
"      Davies JM, Lewis MP, Wimperis J, et al. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. Br J Haematol 2011; 155:308.",
"     </a>",
"    </li>",
"    <li>",
"     Immunocompromised Children. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th edition, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.74.",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f18_24_18818=[""].join("\n");
var outline_f18_24_18818=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS THE SPLEEN?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHAT IS SEPSIS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           PREVENTING SEPSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           BABESIOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f18_24_18819="Breast MRI extensive noninvasive cancer";
var content_f18_24_18819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Breast MRI extensive noninvasive cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The screening mammogram of the breasts in the MLO (A) and CC views (B) reveal concerning extensive pleomorphic calcifications in the upper inner central right breast.",
"    <div class=\"footnotes\">",
"     MLO: mediolateral oblique; CC: craniocaudad.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Priscilla J Slanetz, MD, MPH, FACR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18819=[""].join("\n");
var outline_f18_24_18819=null;
var title_f18_24_18820="Mechanisms linkng periprocedural bleeding and death";
var content_f18_24_18820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Possible mechanisms linking peri-procedural bleeding with increased mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 598px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyrighted and used with permission of the Mayo Foundation for Medical Education and Research, all rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18820=[""].join("\n");
var outline_f18_24_18820=null;
var title_f18_24_18821="Hemoglobin tetramer";
var content_f18_24_18821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Three-dimensional representation of the hemoglobin tetramer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 442px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG6AdUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKcBk8UANpycmrNzY3UEUck9tNHHIMqzIQGH1qvGDu4oBNPYMcUo5YYq/pWlX+qT+TYWsk7d9o4H1Nd/p/gbTdLhFz4ivEYBc+WrbFz6E9T+FVCDm9DlxGNo4aym9X0WrfyPMWBJzim4r17xp4T0y98KLrHh62EckIDyqhyGTHp2xXknUnAonBw3DBY2njaftKd1Z2ae6IqKWjFSdQlFLijB9KAEopcH0owaAEopSMUlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFLSUoGRQACg1PaW011KI4Inkc9lGa09b8NatpEEU19ZSRwOAVlHK89s0WZm6sIyUG1dmJU1qQJ0J6Bh/Oo9rc8U5AQTnig0tfQ9xvZ/s3hsX8txFc2G1Q8Mo3DnjIFYNlovhDUw2ovOtpFEMtB5vySH+Y+lWbq2mufhaywRl2WNWIHYDqa8lyQCoP4etdNWSTTaPmstw0q0KihUcWpNadvT9T0zUPHOnaVaPZeHbcAj7rgYQH6dTXBapq17q0wkv7hpWHQE8L9B2rNwR2pRknpWMpue+x7WFwNHDe9BXl3er+89R+E/icxXA0m9KtAwwoYZDZ7H1rA+JXhw+HvELmAH7BdfvYWUcDPUVl+DIzJ4is1IYjdk7eMe9eu6v4b/4SfU7S2u2kWws4zI0gbBLHsfatop1abT6bHjYipDLsw9re0ZJuS9OvqeC7d5woJPpWrp/h/Vr+QLa6fOxK7gShAI+pr0O91/wxoFzJDZ6fC1xD8gMUeTn6modL8fPqeqx2jRfZ4JDtVt2WFZqnFO0mdk8wxM4OdGjotbvt6HMXHgLxDBbxTtZh0kIXEbglSexFOtvAHiCcsGt0hK8fvZAM/SvYrq5ktvBF9NCQJ7MNICwzuPvXjF5431u5QKLoRc7v3a4P51dSnCDOTAZjjcepciirO19fyNTV/hvq1ppz3VnLDfJGu6WOLO9foO9cKcqx4+oPau78C+NbjTb1/wC0riaSKZsmRmztNenaT4c0dZbi/soLe5hvBmZJgHK56kex60KlGorwHVzavlzccaub+VrRPuvkfOUmS3NMrpfHugtoPiGeBFYWznfCT/dPb8K5zafSsHHldj3qNaNaCqQ2eo2inFSOopMGkaCUUuDjNFACUUtJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH278PvBfha68A+Gri68NaJNcTaZbSSSyWETM7GJSWJK5JJ5JNb//AAgfhD/oVdA/8F0P/wATVDwpqtvofwc0TVbzP2ez0O3ncL1IWBTge5xiuO1Pxt8Q9M0fT9dv9L8OW+lX9zBElvvme5hSVsAvyFJx6HjI46igD0D/AIQPwh/0Kugf+C6H/wCJo/4QPwh/0Kugf+C6H/4muH/aP07V5fBF7f2muva6VbpELjTkt1P2lmmVQTLncANw+XkHFeuUAfn/APEG3htfH3iW3tYo4beLU7mOOKNQqoolYBQBwABxgVz9dJ8S/wDko/ir/sLXf/o5q5ugAooooAKKKKACiilxQAlSp9056UzacZp6qdnWgex654B0uCbwRdaiABNbh2GRw2Oea1/h5rl1rGhyrdxpOd5Xy/LDhgPY1W+ELxah4P1DTAzKzK6ucdMjtWH8J5ha6lqFl5xARzsUnGcZGa7I+6oNdUfEYuHtfrXtNXCSa8kdRbeGdGeCR7TQ47oAlnyctnPIx/QViDxLoGlXaafbaKjOrbWie2+YN6HPNegeCfh7epZyak2vGKS8mdoY9uUDAnKknn05FQ+IY9P0O/F34tsYbPVEjzHNu3CYD0YcH+dLmT02fobVaFenHnrKVWnLWPK3v5r9VsRXcmjRadjUrU6ba3SbPlbYDn0HauMu/hfpV4N2g62pJ+bZNhsD6iuJ8b+KJ/EWouzMwtA37tD/ADxWDaXk9rLvt55ImHdGINTOrGUveV7HZgsoxVGnzwrckpatWuvnf9Dqdb+HOv6ZHuFul2pzzbNuP5da43ayMcjBBwQfWvYvhRrWoarJcR3UkssgI/enqAeMA/TNeZ+KbWOy8RalbwM3lxTMFDHJ696zqQSjzR2PRwOMrVK08PiLc0eq6r0Og+FltLNrkkwGUVNrAHnk+ldl4/8AGJ0iwOn6aUF3MWExxkqvavKtD1m/0eVpNOlKPJwQBnNdhoHhO81e6l1LxFvIyGaN22u4xnPsKqE3y8sTix+EpfWfrWLa5ElZd2cAUmdGlMbsmeXwcZ+tWNGuGtdVtZwoYpIMZ6da9Qg8e6ToUw023s1uLFPlfEYKH8D1xU8vh7wh4wiefRrkafeOc4H3QfdO34UlSv8AAzaeaOKaxNJxg9nuredtvxOlMb33g7W4Lcb7iSJiEB9q+eWTDbQpyOMe9fQ+lwvoUVxYTFZpGtgquh4bg81geF/CWneErR9b8USR/aBlkibkL+Hc1vUpuo15LU8XK8fTwKrN+9zNcqW79Dj/AA58P73UNMF9qEjWVo5xHuTJJPQkeldP4dtta8IySQ3Ub32k4J+1WzFhGO+R1HvXL+MPiFqOuu0NqxtbJWyipwxHbNVdC8eanpjJHLIbmEdQxwfz71lGcIuyPUq4bH4qk3XjFp/Z6r0ff8D0Pxnptn4u0KSbS3aa4gAkiIGS57g1xOj/AA41e7ill1BorCOLqJTliPXA7V6I2tLY+F5tTW1iguhGHUqQA2exxxmvItV8Xazqbt5l20YI5Efy5qqvJdORx5T9ddOdHDtKEXu9X52todXf/DKKaBH0bV4pX25ZJhjn2Iri9b8L6zo5b7bYSrEP+Wqjch98iqmm6hqFnKWsZ5kdjyFOd34V2mj/ABM1G0WOK/iW4iHD46kfTpWT5H5HrWzHD7NVV/4C/wDI87P3QPSggjqMV7jpulaB47s5biLTmtjHnM8I8vH4dDivH/ENrBZatdWtpP8AaIIn2rLjG78KmdNxV+hvg8wp4qUqfK4yjun0Ms0lOPem1B3hRRRQAUUUUAFaXhyNJvEOlxyoskb3USsrDIYFxkEdxWbWp4W/5GbSP+vyH/0MU47mVd2pS9H+R7o+g6JGjO+laaqqMljboAB69Kr2WneGr4M1lZ6PcheGMMUT4+uBUHjpBNptlbOT5NxfQQyqDjcpbkVmeH/sL+MWe0sm0nZbNGLaSHyWn+YfMFxggY9c13NpO1j8+pQqToOq5yvr6ad9b6/gdH/wj+jf9AjTv/AZP8KzvEeh6TD4e1SSLS7BJEtZWV1t0BUhDgg44NUZra9g+IOmvd6g11FKlw0MXlBBCuOnB+bqOTzxW/4p/wCRZ1f/AK85v/QDT0aehN6lKpStUbUrPr3tbX0PnaiiivPP0gKKKKACiiigAooooAKKKKACiiigD7q8M6RDr/wY0bSblmSG90K3gZl6rugUZHuOtcjqHgn4iavo+naPqureHG0/T54JEaKOUS3CxsMGQkYUgD+Ecnr610Pw+8aeFrXwD4at7rxLokNxDpltHJFJfxKyMIlBUgtkEHgg1v8A/CeeEP8AoatA/wDBjD/8VQBgfF/w74s8V6RLovh+TQotLuY0+0PetKswdZA42FAVx8o6j1rrfC/9vf2Uv/CVf2X/AGlvbP8AZvmeTt7ff5z61R/4Tzwh/wBDVoH/AIMYf/iqP+E88If9DVoH/gxh/wDiqAPif4l/8lH8Vf8AYWu//RzVzddB8QbiG68feJbi1ljmt5dTuZI5Y2DK6mViGBHBBHORXP0AFFFFABRRRQAU4DOKbSg0AbfhXRv7c1aOyMpi3AksBnpXe3/wugXC2mpybgORLF3/ADrzTS9TudLu1ubKQxzL0brW3e+OtcvMeZdbT1+RQM1rB0+X3lqeZi6WNlWTw80o+Z6l8PdHm8Krfx3EsUiTH5WDbcjHWs7w94Xi0bU7vUZtQSXeSwEa8AE9Cay/hHqK654oEXiXV3js4gJBCSoEzehzXo3xw0vU54tKTw/aw2+g3OIruWxiG8HPG/HO3H4VftYKyS2OBZRiZzqTnUSdS17Lt2PNviV4wvo9RsLPSdQZLOzHmIsT5AkJ53f4V23gb4saf4ksm0LxvaWrQupXzJB8rDGOCfutXFeP/hkmheG4tc0a9lvbM7RMrp8yZGC2Rx97IxXmC+9YSk5S5j3MPRVClGkne3c9f+IXwZutNt21XwhO2saWzbjBGuZoFPTI/iHuK8ntLOa4vktUjbznfZtIwQa+ifgyNa0Tw42oatqU8NmE3x20i8QxjncSeefSsgJaar4j1LxWYI7dZifLVUCjYBy+P7zU4Q52ZY3GRwlL2j17LzM0fZPAvhfJffcsDsO3HmSH+grx25nkuJ5Jp2LyyMWYk8kmvS7S3Tx9rUlxfTyw6TbnZCqKN2O+f51U1n4Y3YLS6HdRXkHZHIWTH071rUTklyrQ8rAVqGElKOJn+9lq79PL5HO+AJbOPxFAL9QySZRS3QE9DXcfFu21CxSylsJ5Dp86bH2dS/oce1eY3mn3+l3axXdtNbzg8K6kE89q+hvCpbVdBtLfU7Qi5hCzBZB3Hfmqox5k47GOc1vqleljV70dmunqjyOz+G+t3enm8xBHIVDrbyPh2X19Afauav7C/wBEv9l5FPaTjoSMZ+h712vjbx7qNx4iYaVKYLSAlAhHDEdc+1dFoGu2/jLSZLfWdI8wAYa5K5Cn1Ddj9KjkjJ8sXsbxx2NoU1XxME4PWy3jf8zlPD/i6aO323twJpkztMnUjoATVbx3q15r08Mvk3C2ca7QGbcGb+9S/EHwpZeH0guLC7eWKdyoilA3qAOvuKztLkuJdJJW6VDFyF9QK5q06lPd3v3Po8pwuX5io1aVNKSTs1pd+aen3HNyxvE2HVl9mGKltIzNcwxDOHYLx161Y1TUZdQdWnAygwMVoeCLWS68SWIiK5Ri53HsBVwu2rmeKcKKnKm7pJ67HdfEJobDwZa2al2MrrsJHoO9cf4b8G6jrAWZ1+y2eRmWXgkf7I716l4j/siGOK71plKQYEcbjcuT1O3ua5bVfFcuq6fL9gnNhAAUDd5B/wCy/hXRXcab5pnzuRxxmLo+xwcddW5PZenc07WTw54Pmgt4ij3pIDM6guQT1PYCpPHPghdc1jTtR0pVigusLclFA2ejAV5rb6fa3EZYXryXhP3eua9a+H2vzNBb6VfA+a/ypLj7pGcE57VNOtSm+Rq19jXMMnx+AisZh588km5Xktrb2v03sVvHet2ngvw/DoWkbRdumHIHRe5OO9eISSb2LHkk5JrpPG1rq0nie+XUVee8V/m8tCRt7ED0rDbT7sKXa1nVBySYzilWnzStskdOVYSGFoJ3vKWrfdv9OxUJptSBcnsPrQUxnkY9ayPVsR0U4jFNoEFFFFABWp4W/wCRm0j/AK/If/QxWXWl4ckSHxDpckrrHGl1EzMxwFAcZJPYU47mVdXpS9H+R7J49Erafpwt2VJjqEARmGQG3cEj0zTrHS9YudatdQ12awH2NXEMVmrYJcYJYtz07Vdm1nQJwgn1LS5AjB1Dzxnaw6EZPBHrUn/CQaN/0F9O/wDAlP8AGu+ybvc/OozrQpKnGDvrrbXXt8jD1PTfE0+vw6hbtowW28xIFkMuSjf38DrgDpW14l3f8Itqu/G/7FLnb0zsPSnf8JBo3/QX07/wJT/Gs7xHrmkzeHtUji1SweR7WVVRbhCWJQ4AGeTS0SepUfbVZ01KFuW2y8zweiiiuA/SAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopwXOOtADaKWlAzQA2pbeCW5lSK3jeWVztVEUsSfQAUzbXq3wDt3TV7u+tj/pcQVIwRkZb/PWgDD8P/CnxnrJhe20S4ihkPEs/7sLjuc8j8q+hfhr4Y8ZeHLVF8Saxp/kKCqRM24ge7d68l8e/GrxS+uX9lp10LW2iYwqdg3jHBOeleaan4p13VmJv9WvJsjaQZSBj6DigD65Wx0MQz6Yt6l/b3xlV7eADau4fdHXaK8I8AfDc3Him/OsRB9OsJ2iCCTiRweAf9kd6810nU9Q02ZpdOvp7WQjBaNyM16Z8PvioNHtksPEFi17aHKtOGO/BPJb1+tA7Mf8AGTx0J2fw9o77LaFgLieN+JcfwDH8IrA8OfEe9sYorW8toruJcKpxgj/GvSdf+GXhbx1ZNqfgG9gsrwqT9lLZhkb6nlD+leVp4W1Hwh4ssrfxbYSWaMx2O/KP7qw4IqoNxehxY2hRrUmqsb218/kesTa1pdpYRz6lZW9lBMcbogEJJ9cVhX+gm20mfU/BGq3MkcYMrW8pEqtjrgnpWZ8YbCddI0y4tSX0/nfgD5WPQ/Sk+Ceqx5udMmIKEZCkcEHrn1+ldjnzTUGfIUsO6WCeOoyvr70d1ZO1rPqjpPCOqXniDRYry+t7SVoCSqMN7cf3cjr7VpR6za3V4t3HemKeFPKa3cY5z0x1BryvUL2+8B+M7uKLebVpDIIyNoKk5yB2rt1/sLxjPZal5LNcRj960b7CfTd6miFRvRboMXgIQl7Zq1KSumle1+jT79yDX/D/AIdl1a61m+EkcWRJJEThFb3A559BXN+IPH8SRfZvD8KxoF2+YU27P90f1Nd3c6/4W025W2upZop4eArj/wCtzVOXSPBF0huzp0+yYl/MyVB/D+lKcWvgaXcvCYhJxeLpzmlbl0uvu0/U8Ru725vJWkuZZJpCc7nOTVrw+wW9IlICOpU56GvTtR8O+DBeQvAZI4yoyhlO1vQdM1h3tnosms29rpFn5JPH7xid4Pf2ArhrJcrjfU+4yjGe0qwqqDjCOrclaMfJv/I4XU7dLa5eJJA4HcCrnh6TU9OuU1DTYiSnG7buGK3vEekaZouoTJdSJcNgENASVye2a519Vnx5UBEEZPRPSsYzk17q1Xc9KthcLNOVSScJ3sldu3S9+nqaWrzanq939r1yQpGBnBG0D6AUvlafewgRStFFGMAt0Y0moS2cy232i8eaNfvIBj9ar+IIGRYZLVHWz2jGemaycpVJK7s/67npRw9DAUpqlCMoK2l1fXb4XokWNJ1Sx0+fbHG2Af8AWAZb/wDVXo+heI7XV0C6dZSJNG4JuZep9sjtXkk909pa2IgSAb4S7FoEYk+Y4zkgnoBUsPiDWtPjVYJ2tUkG8BIUQMD3GF5+tdVGpKnflXXq9dD5/OMDSx8IxnJpxStaKsuaz/mV+2p7X4p8VWWi2xnnRE1C5wECoCxUdz7Vi+HvG6atfrahkUuPuyJw3tXll1q2r3ssJux9olcYiMlsjlh/s5XkfSnxya3bsJY7JomTkOtiqlfx28VrLFyv0+//AIB5VDhPDewcE5uXfk27faPX9Yu4dJ1G0s59JtXa6YBZEhUoCexOOvtXI/GvTbewvdLa1tbaDzYmZjCm3ec9TXKXHifxE9pC1xdztbBsxF4lKbh3XIxn6VDf67repxLcX8rXcUXyCSaBZFT2BKnH0olXcotWX3/8AMHkccNWhUVSWifMuXdW0fxaIxiflxio61TM13pU7SpAHSaMBkhRCAVfI+UD0H5VBY6Xe37hLK2mnY5xsUnpWUW5X0PXxEI0lGSfutXV9OrXd9u5Roqee2lt2ZJ0eJ1OCrqQR+FQVRitdQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACloHUZrp/AfgvVPGmsx2OlRNs3fvZ2HyRj1J9fagDI0bRtQ1q8FrpNpNd3B52RLn8/SoL6wubC7e1vYJbe5Q4aKRCrA/Q19leEfCmi+GLRvD2gGN9T2iW6umOWUjucfoKpaRd+HfHNw800FjJrlg7QmeSIFgykjBz9ODQB8t+C/C9z4l16CwjWSOInMsu04Rfr0z6Zr3yf4F+Er2CCOy1HU7OdUy74Eqv6k+n4V1vhg3Gqabqd9crFpFvayMhlRVYPs6njgisH4feJL/AF6UzXsEH2Gd5I4WjkOZUBxuYds0k7jscFqH7POqCJ20jX9Lvnz8kbZjLL+uDXbeEfhJovg3R1v/ABFZvq+rnGEWNnjiJPoOuPWsj4jfEaw8JWx8O6Lowi1aJVMk0pJCHr1zk/nVH4P+OfFfiPUJ7a+vUksIU+bjDbmPHuaYjM+OPgC1s7WLxL4btorfT2AS6tYlP7p/7/0NUPgx4h0TT4DZ6peGxuTNvEhXqO2D0/OvVrTxjp2q+MNa8La1HBcwFVhKOd4mXbyfYivn74peD5PBfiaSyD+dZTfvrWbbjcnp9R0oA7fxl8G76+nuNV8LanDqyzOZWgkIjl554/hb9K8j1PSr7SLp7bU7Wa0uF6pKhU/rWl4c8W634enDaZfSIgIJic7kP4H+le2+C/HC/EGM6Vr/AIZGo7VJZ9m5F993VSfrQCPGvh7bQ3XiKJLmJJUAJCuMjNeieJvE9joOo/ZLzSl+6GRhCMMParHjrwR4e8H+ItLn0LU5Uu55graezhvLGOSG6kVx/wAYW3arYFySfI4z2reFlC9jwcZS9tmEKU2+VxezaNa2+I2nRvtttPljZjgCNAMn8DXbaX4uVoobbVrGaKOZ1dVvId6sMds55r55sBKb2AWqNLOXARFGSxz0xX0b4bu7qG3QX0Wy9tsLLG3Uen6elVTm5XTOXMsJSwXLOLkk3Zvmen+ZZXT4b7T7qwvIopNPumJSMN9znIX2qt/wrvw5oWnw67pd09peRBmWF5t4kIHKHOMYrEtrjxBc+I570RWen6cZTthwS5Udx6E9c1V8Qa1oNvMs+pPFdXEIwqfeIPqF6Z7Zq52klJaNHFhOfCVq1D+JGa+z3f4arcofGfTFvdM0/X7ZeQBFNhc5HYk/pSeBI00jwi984jBZGlznr6AmuZ17xnda/ANHtYVt7GZwDv5JOePpXZ+LtNvrPwMttYWhlLhUcRJn5QOSAKOaPPKce34ms6VWjhaOAru3NLv9nfUpTeMNA1S1tL67jh+3Wi8K8eXPHQetcl4i8aTamxitYFgtFfeAeWY9ifT8KzdC8JaxrV15VjaSgfxyOpVU+pr0nS/AHh3QI47jX9QjvLgDIhDYTJ9uprJ81RNaJfmekvqeW1YuDcpr4Yq8mvRLb5nmEdxqOoNvjJ2r1ZeMfjXc+CtCTxLcGQTtEsAKTTD72MdFHSszxC1lba9P9ghFrpsigCJAcM3cgGpdJ1W903Tnt9Ommis2J3RHhn75zXm81ONT3ldLax91Uo4/F4HloS5ak/i51dx80u/qc/4tmhm1yextZD9hgk8tGY5OO5qvJoBlIFhcJOcZbOBimXWmTzTT3TKIIWcn5z0zVmNrBYora2nlSVz8zIauc+tMMPhZtNY68nort2b6ad7kWmaXbi4xeShnXkRpz+dJcR399O0AR0izhQeB+tPvymlNGdPIkZ+fNfls1lT6jdSybnmfIOeD0NTFTnLnLxFShhoLDWaaetnuvN9fyJdetpLM2VvMAJEgIODkf6xzWnqNrYz22mNeaj9lcWiAJ5DPkc85FY+qO0kOnu7FmMByT/11kqPUb37YtqPL2eRAsP3s7sZ59utHJKXLZ2s32/UX1qhQ9qpRUlKMLKV+y6xa2XmdFIkcereHkgl86MIoV9pXcNx5welQ30kO+4H/AAktznLfuvLkx/u9ce1Ziattn02Xyf8AjzULjf8Afwc+nH61LPqWly+Y39jYkfJ3fan4J74xWKozTV0/ly933/Q9F5lh6kJqMoq7Ts/ar7EVpyeaa95s0IGWfRNN0+UgLcxyeWT/AAyBzt/PkfjSXciL4f1CzhIMVq8Sbh/E+Tub8/0ArCurzz7Kzt9m37OGG7Od2Wz07UsF75Wm3Vp5efPZG37vu7fb8av6u9/O9vnv9xzf2vTfuf8ATvl5tf8An3bltbbn6/odD4DuNLtUvpdajWSBWiKKy5+f58cfTNdppHj+1l1azs7K1+zwM/MjYUD6AV5bbf8AIIuv+u8X/oMlQ207W11DKhBaNgwz0yDXdSqOLdu/6I+SzLLaWKpwlUu7xslfT4pdD0r44ad5Os2moIieVdQ4OOpYdzXlde6+Po11z4ZQ6hHJEz2+2Qvjlh0IFeFVriI2nfueZkFZ1MGoT3g3F/L/AIAUUUVie0FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFKBk4pKUdaAO1+GHgK78c619mhkWCziI8+Zj0HoPU17N488baP8K9FPhfwXbp/aYXbLMV+4e7E92rwHwt4n1Pwxem50ufYW+8jcq31Fe7WPiPwr8VvDsOkeINlrq44ilAAlibuVP8AEPY0Ac7+zTq9/eePb1bu4eb7QnnSs5yzNnrn8azPGM+rWvxv1mz8OzvazXV0se2HCg8Cup8B+Bta+HnxISSOP7dos48tdRjGFUdcMOze1W/ij4Z0/wDt678WW9/FpdyzDBlchGIUgkMP4zxwOBSl8LNKPxp3t5vocvqsuvaBBrHhq6ufJNyoWYK+9GJ5DAjofWsj4WXOs6J4gtLe5gum0ueQrG+D5e/1VsY7VzcnihTeiaWA3fzEv5khG8/XrXaaL8aJrO0NjPpEP2FQAkUTZAI9iK58PCcb82x7GcYjDV+Xk1mt5JWTPUvH/gTSfGllIjRjTtYQeZa3jD/XZGSr+oz+Vc98LfC9x4N02/k1WOOPUI2bfg5A/uqSOoPBz715r40+KV9rs+nNpscuniyyVYSkl89iOmK27T4zyyw20Gpaahy4+0TK+dyjp8uPzrpPDLem/DTV4dffXtQ1C3tZ/tBm8i1+dipOeD0/nXovjbRbfxj4Jl09limvIzmxu1QDDDsWPQH0pmiXWn3Yjv7OQTWcxwszuWFvkdCvue9ZnjGH4gyTiHQLbT1tCoxKso3c5wNrdOnoaAOI0b4OwWsIn8U6ukGGBMVuQFx3Bdu/0rX8W/EjRPC2hR6B8PvL6fvp1HAbvk/xfyrz7xF4U+IF7esmr6fqdy8ZwP4kx/s4OMVz+o+E/EGl2xuNQ0e9gtwcGRojtH1PagDofCulat4s1mTWH1GH7VG4JM55PsB2GK6n4qaVd3nhq1ukVH+yNmXavzAHjOfSvN/C2tyaLqcVyCfKz84HJIr3zTtStdd0oXSqk0Uy7Gg2/fB4/wD111UVGVNx6nymcVa2FxlPENJwW1vxRlfBTwSthYprkoF3eToGjEce4wqfQ/3jXKap8Q7y38dXf2mxFtCH8gJIhR1UHGW9TVzQdP8AGHhzxVNF4WLvppbI81/3Srnp14I5r0fxdd6XrtrbW3i6DSpbsY+aPCyE56Bzg49qinTmnpoehjszwNSgoTfPzL4Vq/uPN/iVBcyeHIL/AEy4lW3U/wCkIjY3A9G/pXjwzkjPXvX0p4/8O+IbXwpLL4d021ubR4StxFbybpIl7FU/i49OleC6b4X17Ukf7DpV5MqHa2I8EH05qa7Tl7rNMkpVqWH5a0ba6d7eZixyPHIjxsVZDkEdjXunghrzUvCTStrM5vTGRH5a5Kfl1NeJX9ld2Fy0F/bzW86nmOVCpH5113w18Sf2PqAtp3YQysMd9pooyUZWZec0J1aHtKPxRaa0XTp1LsfiWGWU21/q1/BBExIjQYG/JGTWtLb6Fdaa14mpyTXMIDFVwNw6Yx1FTeJvAqan4stLvT8C0vW3zpkfIR1wB2NbfiKXwfY30Wg6vbw4QBlkjUIYz6bhzn60LCwV+ZLTZu5z1eIpVZRVCc/e96Sgktt76LXdfieYeIdQa1mdLdAI3OULHcVFdH8LpFntLyS7CSsCVQuAcZHT86PEXw4aeVrjwtctqEbguYZGAZR7N0an/CTQr6HX7oXttNCIiA4kXHIPTB61FCh7OSi1qzrznO4Zjg5zpVHZJaN6q3R7P70XbnwPZJCker6tcxM+X2EBR17Z7VXg8B2UV1Dc6dqkcqKDlZVB5+orD+Lur/2n4slhRj5VmPJX6964yC8ureMrBcSopOcK2K0mqUW4cuhhg3mVWnTxTrtS0aTSdux6H4j8BXk0E99ZXcEywJnyFBBwOuK8225fABz6V6p8JtVuvJnF1vlgDj5n5GD1BJrT12PQPBc7XRsPMmuizxNt35yecZ4AFCoR5U4aIy/tjErEzo4n95Ubumklf16KxwOheH9S1iK3A0yH7NGu0XNwXQY3E9mGeSe1W/F3hOXw3bw3Mtpp9xaynaHjaXKn0Yb+KNb+IGoXimOwC2keevVv8BXX+A/EFv4j0ifSNZ/eO67XyBkjswz3qFRpS0Td/U6cRm2ZYdRr1IR5FZNcqbtte9uhi+A/COleINFu9Qv4Y4lhz8sTSdB65Y1XtLbwFPOYz56nnBMrAV36WEfg7wFqyRIpdFbBZvv56fpXg1pbveXiQxYDOcfSqqU40Ulb8X/mc+AzDEZhOtV9paCdo2jBaW/wnqFv4Y8F3iMLaYiQEctMWGPpkU2f4dWkkvmafLYSWoK5EhlDYPoQ+M1Z0XwdpVpp6XU0P2qRMGTLdR3wK6qztrGxaODSl8qzkizGCd+T3PPNYYOpRxik4LZ23f5XOGtn+IoytQqcy86cLeetrnDeOvA8VjHZaf4Ys7ie4ncPOAxcKQDt56D7xrB/4Vp4mW2WaSx8vLbWRmG5R/eI9K9R8U6/4ktvJTw/p63Mbx4aVB90/TjNV/DWuapbuj+IZQ5PyyKqEiP2OOM10N4VScea3+f5mcc4zL6tGpPldvvereijZL+u5Qv9QXwt4FksLxoZHeEwInXecdR9K8O+leh/F6GceIRIk7TWDKPJGMCPIB2/XBB/GuFNlP8AahbiP98RuC5HTG7r9KmrVjN76L9D1snowp0PbX1qe8/6/MrUlWFtZmt/P2qsXOCzhd2OuATk/hUv9mXWxWEasWQSBVkUsVIznbnPT2rFziup6rqRW7Ire1luEd4/LCoQCXkVBk5x1I9DT/7Pm/v23/gTH/8AFURf8gm5/wCu8X/oMlVKV5Nuwrybdn/X3lv+z5v79t/4Ex//ABVH9nzf37b/AMCY/wD4qpdO0e+1KC4lsLdrgW4BkWMguAe4XqRx2FUWUqxVgQwOCD2pJttpNaf13Em22lJXX9dyz/Z839+2/wDAmP8A+Ko/s+b+/bf+BMf/AMVVvXdI/suPT5o5vPt723WdH2bcHoykZPIPFLqejNYabpU7ylrm/RpRbhOUTOFOc87ueMVKqXtZ7+RCq3s1Ja7aP/Mp/wBnzf37b/wJj/8AiqP7Pm/v23/gTH/8VW14t8LP4fgtZRdrdLIxim2pt8mUAEoeTnr19qoX+kfZNA0rU/P3/bmmXy9mNmxgOuec59BShWU0pRlvto/66ChXU1GUZKz0Wj8/8ismm3DuqIbdmY4AFxGST/31VKrekf8AIWsv+u6f+hCqlaRbu0zaLlzNMKKKKssKKKKACiiigAooooAKKKKAFzUlvNJBOksLtHIhDK6nBBqKlFAH0J8DfiLd3ksmj63cCYkZQyYzIvcH1IriPjjoOraL4qZ7+6mu9NuyZbOR5Aw291wOAR0rzuxu5bG9hurdts0Th1PoRX0vpE2mfFrwA2m3flx6hGN0DNLjyJcY5x2NAHzDk00k+taOuaXc6Lqt1p19HsuLZzG/1Hce1Zx60AGTjFGTSUUAb/hnxDq+kSCDTL14Y52EbIRuU5OOlfSPhy8m0Wy8jVtW+0TFCRK8YUDoPkGfQmvLPgDpvh3WL+7sdcsorm5k4id8koP9kA8nNdt8X2DfCucPGjPBdKiSMg3gBsdexx1oA6bWJtUudXWPQ9XtLWBhjFyrOMgA5BHbmovjPq0vhj4UfYJphcXt+fIaUKdsgPJwfp0ryf4Cz6vqXiGXT4pIp7NYtzrctkL2G0npXu32KWfRJ9N8U6f9r0WVijlhnyz2IPt2YUAfGQJAAya6/wACeMZfDc5EsbTW7cbQ3K/Stb4q/DK78HT/AG2xZr7QJm/dXIHMf+w/offoa86bI4HUU4ycXdGOIw9PE03SrK8Wena38T9V1W4Wy0WOOxilYRqx+9k8fhXZaZ8GLKexg1Lxn4uEc0x3YjOQPUbm/mK8q8K+D9e1KKHV7HTpp9PgnQySrjAGeT9BjmvSvj9bzyeFNCuIo3MMLESOOi56ZqpTlP4mZYXA4fBx5aEbfn952ll42+HXgO2+w6bqN7fbdx4maT8M9MVzGrftCiLfH4e0GGKPaQjzEDJPcgf41885pVPIqDrvpY3PFniXUvFWrPqOsyLLclQmVXaAo6CsVS24FSdwPGPWl61u+C47OXxFaDUSq26tuOeAT2ppXZFaapQlN9Fc9w8FRXdj4Yt7vVG3XzoFjU9s9Cf61xmo+CLe51O5vtc1hj5jbiEXb+GTXR+PrTUdYisG0O/ht7OBgThiGGeAeOorOvPA2kJGJfEviO7leU5Ulwo9+DXdNc3uJXSPg8FWVJvEOpyyqX0UbyWuy6Ifpeo6dZRG18OQTT+VyDE+QSOvzHgmuv8AD89xd6UdSuFZZ7gBERuGRf8AOa5YaXpGnabK1ghFohzGyt8z54z9a3dHmmnto4o2cbVOwOMFfX/PvVQk1uc2OVOpHmprrq3u0eRXGgXfi7xhqp0YqYROdzyMFAHT+ldfbeC/CnhSPz/E+oLdzj/lj0UH6Dk1k6NouveHfEy3i2cktpcSMWMR3AAnPPpW18UvDJ1y1TXNHj3yRrtni7n3ArGENHK2p7tfFSlXp4VVeWk0leNr3XRvpc2vCWv6X4l1Ge106z+zWUMXlKNoUtk+gpniHRx4h0C70uUAXtqS0R77h2/Gszwrpi+E7fTJ50driZGkdR1J7CrF9r0lrqSTLvk1Cc4S3gXJVc960TTh727PKdOSxfPg22lqm3d3Wjv5PqzxC6hktLloLiN45UOGVhgg1c0See01a1ltXCSbwAT05OK+hrjSdNntY7jWNLg81iMFlDTSn0yegrF+IvhmG58KyS6bp0MV1a7XiW2XbIBnnI6ng5rKWGlFc3Y9mnxJRryjRnC3NpurD7+0/wCEs8NzaY1x5d1H8ylBw7Dsc9jXiFnIdM1keeCTExRx6djUy6/q0UXlR30q4G3KnDfTPWswFndmYlnJyWPOTWNaaqrbU9LLctng1OlJpxeyXTue4eH7l5LcBE3YGVz0FXGjmt5YJUQ+WrncFGcE+/ofSuV8H+KkfTEhlgUyxDB2HH0NdNZa6ij76gHs1eJOrDLI2oLmm9/RHyeLoVqNSS5TqrCZXgkhZwMEkMeOCK5a5tLiLT5bZop2Cszh0h3Kxz8p3YI/ka2tEvnl0eTymEjQk4D/AHce/rViHV98XFqmCMeYjYH0A9a2nllsRKrhqlvaatWfX0PLpqdGcuWN1f8AFHJ6ppset6Pqen3EMxuyUkgkjjZwGVAOcDvjFeVzqsGsfapZIlSOLayFxvDBNu3b1zn8K9ys1S2uF/e+UcFi7A8iuH+IPhvR5Le41KG62agR5rEtlJfbHY/SvUnhG4r3u6+/U+iynGxjU+rzvaW2nff02OBWWGWC3MjWptVtijq23zA4B6fxdcHjimkJ9tsLo3EKwwwxFiJVLZUDI2g5z26Vht16YptcvsbbM+r+r22f9f5l9mD6feOowGuIyB6cSVf0TU9EtLMx6p4f/tGcuSJvtrw4XjA2qMevPvVG0gluNMuUgieVhNEcIpY42yc8VF/Zt9/z5XP/AH6b/ChqDvGTt87dF2CShK8JO2vdrouzRf0XTb3ULua60xksobdtzXEk/lpADnGX65+nNa/inWNNudNNq7DVdVBH/EyEQhwAeRxy/HGW+tc1/Z1/jH2O6x/1yb/Ck/s2+/58rn/v03+FTKMJTUnLbb/h9yJQhOanKW23/Be/5Lvc63w5YN4p8LLpUfN3p94jxnuIZSFfHsDhjVqyktdY+Ikt5MwTRtJXeDglUhhGE6cnLYOO+TXI2UOsWMjSWUeoW0jLsLQq6EqexI7cCmRWuqwxTRRQX0ccwCyIqOA4ByAR3/GspUk3K0lZ7eV9/wDgGMqCbnaas728r7/8A7trbS9U0LXrOy18apfTOdSjj+xvCVdclyC3XKnGKyb/AE2/1HwF4Z/s+yubry3ut/kRM+3LrjOBx0Nc1a2uq2k6zWkF9BMucSRo6sMjBwR7Vbs7nxJZQLBZzavbwrkiOJ5EUZ5PA4pKk4O8Zp631t2a6WJVBwacJp2d9bdmulvIrWtnc2OuWcN7bzW8wmjOyVCjY3DnBrMrdgj1a71m0udQS+ncSpulnDsQAR1J7VhV1Qld+dl+p205czd3rZbfMKKKK1NgooooAKKKKACiiigAoopaAEoqSGN5JUjjUs7EAADqa98sPg9oOjeGbHWPF2oyRSzEO0LSCNMYztz1/rQB4BXe/BrU7mw8cWUVsW8q5YRSAZxj1rul1H4V6S73dtaQTSKpAiIaUHPoD/M1d0Xxz4Wu7g6foGnx2E0/zl1hCZZeRz1z+lAGN+1PaW9t4306WCJUlnslaVu8hBwCfwrxQ9a+i/2po420Twrcsim5YMrS4+YjA4z6V8/6faPf30FrFnzJXCg4JxnucdqAKlFe2R/BWxjgj+1eJVSYruO2D5c+2TnFbmmeC/AOg3KC/uorq5TaxFzICuf90HofQ0AeTfDBdVg8W2FzpNldXDI4D+TGT8pPr2+tfSE+h2evaNeaNrtpP5K3CvKFcq0fOSTj0BrotB1qwvtMktfDGpaXaXKLtjSKFdq46ZAOcVxHhe68Y6H4wnHjmxWe3vGwtzBhrdvxH9aAM6L4kfDvwTOmm+EtJWf5tkl2EB56ZLHk0742XPiHVvB0WqaLqN09io/0qG34Gw9+OcD8q8u+OPgtvCnitpoEUaZqIM9uyfdUn7yj6V2HwF8YtNFPoGpXDsrIVQk/ejPBX8KAIfhb8VoxbHQvF5iuLKZfLLzjKOvTD/41103wr8D3pey0+2nT7UpmhvPPP7okcAZ4IqObwb8OPhwZdW8RXA1C4eUyW9qefLBJKgJ3+prldY+M194l8S6bYaPZQ2WleeiojqC/pwR90UAeh61plt4H+CmqW5twksKmBnUAO5JwG+vINcz4w0bU/EHwp0+x0q3ku7pnjcoDyQB1ya6v4haDe+NvBkukR3C2Oq2xE4ifIW4wPuk/yPNfOul+OPE/hvzbFL2QCJihiuAW2EH86AMLWNB1bR52g1TTbq0kBIxLERnHoe9ZQ619NfDvxr4k8URMNS0qJLOPDC6mBKM3oARk/hWn4k8NeE554LyTSLcyLmR3hg2oCT3xwR9aAPlPvzU9vDLPMkMEbySsdqogySfQCvR/jfqei6je6X/Yosg8MbJMLaMLyMY3EdeK4vwbcRW3inS57iQRxJOpZj2GaAudxoPgvx/YvDt0y7S0cq7q7KcKec4J44rvPEGkQz2Ea63p8lyFHlqpRt8LevHQetdz8QLXxBPJolx4YvYLSynTbdGYFioA4YfgcY96o674juvDdjc3Uckt7IBgwxx5PzAAk9ee+K1jUsmtzysfl9OtONVScWu3n/X6eZxslmDbWtosSbUbeyr0GOmK878Y+MryLXDDo1yY4LdTFx0Zu5/pXodpdWGtI0txYajGpXDlg0Zceg5rL1Dwj4OnKq0FxY4bmRpcAjv16mumalNXgfOYGdLDVn9ajJvXpda9f6R59ZePtZttytKkg7ZGMflXY/D7xbLq1xPY37xwRuQzbT98Z5ArzfxTZWFhrMtvpV4b21XG2XGPqPwrPs7l7O6juLc4kjO5T71zRqyhLVn0VfLMNiqDdOKTa0dte6PozV/Nu9YgaFYZrRYisKq3zbvcVOZrLSNJuNUsrNDOvM7rHucY64H9K8r8MeLrrUfEdgt20NvEn32X5Q31r0y+1e10vVDcRTw+RNgNHuGGJ9u+a66dRTvI+PxmAq4WUaElfRaLquqZmeC9Vl8VahJfPCU0+3Y4aRslj9O1T6Zr51XX9Q+yTqrwybEAbjGPSr9zJa6H4bnungFpHdSbmWNfuAnnpXJ6FeaCuoE+H7d5LyY7pCoJAHqzHgCm5OLWuvUUaUK/talOD5VpHsrb3ZZ1rQtB8aPObeSOz1mHMTGIAIzD+8P6ivML7whr1nq6aa2nSvdSZ8sR/MJB6gjtXp+vXekaBPNqlxGgvLoBdsXys4HoOw9+9ed6h451WbXYtSs5zbGAbIkHO1fQn3rlxHwv2dub10+Z9JkksRdRi26K2vuvR9UYrR33h/VjHeW81tcREb4ZAVOPQivUfDEcWq3kMVw6RQygZYjOM9hWbe+Hr34h2R8TWDxR3R+W7juJQB8vBdT6e1b3wy8OR2180F1q9vcqoOz7MNxT6k18zmGJpVKDk2lOO63af9eR7WKwSrTjK2z+9HS2mjLZJMljdtPC0ojdcfL7MfbrxWjZ6YJNRycLaQquQBwzEfdz6DNYttqlppus3OnXHmkspMiqpBxngntn/GtrWNSa0htmmsmS3mbesjnCscZ4wc569fan7fE4agk6iaS9227v/kvLQ+cnh6MZOpUptWvda2Vr2+/TX1LrW7NFO8xUsDsVCPlVewFeGeNYhrUmszG6hgbSFyLQRsXkBdFLE4CgfP6k8dMc17HceI9OjtZpp5SicOeAcHHPcd68Svda0Ke/8SSzXF+i6kvkp5NmjBVDxvuOZRzlCMe+c9q4ssderiJ4ipdvTX5/5HTk+Doxr+0papJq/nd209DKh0DTF0vSLnUdXmtZNSWRkH2QPFHtkZPnfeDj5c8KetYmr6fPpWp3NheKBPbyGN9pyMjuD6VvjUtBvNE0O21N9SWTTo5UkiggQrLulZxiQvleGA+6axtd1OTWtbvNRnRY3uJC+xTwo7D8BgV9HSdRyfNtr+elvkfTStbQzaKU9aSuggKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigByjmvQPh78Ldb8bJ9otZLa1sATm4mf8Ako5NefCvoH4aSSQ/B/U5IXaORYJSGU4IOTQBseFvgxofhrULK/1zxJFcXkLGQRRRjyzjp1Oc12/jDxJ4TsoYLzxBb/aY4eYnuRlVfBAATr684rwfw/8AE2x0nwrDBJYzXOrwgqJHbKyE92PXHtXA+KPEeo+JL43WqTbyOEjThIx6KO1AE3jfVNN1jxJd3mi6dHp9i5AjgQYAx1OPek8CzQweLNOe6YrEZNpbGSMjA/nWBXS+CNDu9Y1u1NsoEcUqM0r8KOemfWgD2r4y6FrXi0+F9M010uyzOFURkeUOPmZvTFXrrTfCnwb8NRreyLe6/PjftUF2B6gA9FrsvEt7q3hHwjJqulaa+oXqxCIJCPMEY/vnHNfIniHU9S1fVri71qWWW+kbL+aCCPbB6CgD6z8KXlvqeh6fexTo+flTzEyDvHGc9MV8uePtB1LRPEd6mpQviWZ2inCnZKM9VJHI7V738Er57/wPHGLVXeAFUAbup+9/Ouw1O20vWll0bXdOF1pUJ8xBKTuXIyWVhyOfSgD47029uNPuUuLOeSCZDkMjYNe1fD7423sLRWOvsrqxx57gbD6bh2+tctF8Kdav9X1AWkQsNMjmdYJLxsF1B4x3PHeu00j4X+GNJeH+17mbUr0HmFTtRmPQbRzQB1/xhuNN8SfCfULtLMM9qUuIZo3ygyduQfT2r5VilkhkWSJ2jcchlOCPxr64n0uKbwVr1lc24Omx2kskcW3YseFBVeOeGr5DOTigCa9upryYzXM0k0jdWkbJre+HN7puneMdOu9a2fYon3PuBIHp0965ogjrSgY60Afat5qOn69dW+teHtahaaKHatooDCUDnqOR3rmvFWheGdZ12DWr/TA94seJy67Y3b1YfxGvn/4a+MZfB2stOY/MtZ18uYD7wX1FfSFnPBrD2erWRuVtVtwoi6ib/b2n+LsMdaAGj7VdXttFayrb6bHFlkVcPJ7L2RQO9QeGdQsdW0/XNJ0W7t54drxgyMdqyEHP4A9DXjnjj4oaybrUNK0+1GlxKzQEum2cL/d/2c/1p3wC1z7B4lksXwY7gbxld2WHXJ9MUAeamCK01YwXuJIoZikpjPUA4ODX0n4W0DwTfeHIry08O2txL5O5QzMWQgffJ9O/PevI/jlo8ek+PrtoFYW92onX9z5agnqFHTFZPgrWvFlk8lr4Ve8Zrj93shj3jJ/Dg0AfUXi3XE0Twp4fumtprhHZYC0YyI2YDBY+lN8T+KpPCK6FbfYbOKTUphGpzvJXuxOOtSaDFLceD9L0fVVNvqMJSSdLlcZK8kYrlfjj4X1vxVqWnz6YYFsdNVZBBIdjt3Yr2IwOlAmrmd+0lqOp6ONEvtKCR2dxGUefaM+YDnA/DvXzxe6re3pJu7mWbP8Aeb+lfT/xr8Man4s8D+GrXRIVnmhbzHBcLxtx+dfOOq+CvEulxSy3+iX0MUZw7mIkL9SKbk3oZwoU4S5oxV+9jAYnNAPGOK9NsPhFqt14DbxGbhI2Kh4rUod0i+gPTNeYkEEgjBpGo9GOetTrcOJEcyMzRkMpY5xVUDjNOwaeq2B67nrHg/x9cXw+wam8W/G1CR8rjuDXaIsdsIYbfTvJ82QsREvBGMkgVxfwKtoWuryWWGJ5FICmRQSOO1adh4g1/wAR+JLhUiVbOxdoQ6YDBjnA65wdp7Y4pY6s6OFlU5rStoz5rDYGGIzX2FOH7uNnJX0fovzJ7jwDpl5qB1HW9Yu3jkbKwuACV9D6Cuf+IeneFtL0NY9MsnW7Ztschc598jv9ag12bxQPFE8dqY42ig80Ry3ESqYRnL/MwGOCT3GOa5mey17XxBdTBH80MYEkuI4y4BOdiMwLDIPQGscPjKfsIupJc1tdT1J5XiljeZTfs09IrRemx1dhb2Fl8J7yW31yCO/nwz2+cs3qgGeDisj4RX0Nh4sjNxKY1kQqOvX8K5KPTb99Ll1JbWT7BGwVpyMLuJxgE9T9OlaHhSK8+3HUbSAtDYgSzycAIvTPJ/TrXN9WpunUp1J3Unq9NL20PSqe0UW4LW2iPUfip411LTLqKx04W6wtmUXHl5fk/d57d68yvfFWtagqJdalO6Rj5VLYA57V1fxNuBquk2FxatF5Me5mdpUTzDwMoGIL++0GuNHhjV2gSRbeOQvALhYkuI2lMZG4N5YbfjHPSnTw+Dw65Ycvrp+phhPrFegnXj7z308ypdahc3IYT3Duv90nj8qoZz1o3DHSmV3JKKsjVJR0SHdKSkoouMWkoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBR1r3/AOHX/JGtU/695v5mvAB1r3L4ReKfCsPhOXQvEV7LbmZWRwBtBDHs1AHh2DijafSvoaX4M+DNZG7w34sMQXhll2ygk9OQQR+Vc3qvwA8WWwDabLp+pK2f9TNtYD1w3agDyOytJr27ht7dN0srbVHqa950O0sPAngoXWoSxi8j3SBS3+tkPRdv9eledaNpmseA/FNld+IdHubeBHKOZU+TBOOCOK9W+PnhyLXPBum+JtCUGOyXbPGnOVb+P3IOPwoA4DQ/jV4k0vUpJ90Ulq7ZFtjaEHoCOa7qL4heAfiBCsHjbSYrS8I/4+VXYw+ki89u9fOmCfxpcjvQB9feAvCGhaLHcXHhXVRe2NywdIpnDGMngbSO2M9av6lqf2e6ltZLdLiLmKOXfjCg4wT2r5V8C6jc2niCxih1CazgmlCyskm1cdz6V7b8QPF1lob6FZx3KTNJIZJypDBVxgMSDwe9AHR33i7w5bP9m1K7W1vI2/eJJLkkdhz2rd0j7Hq2mTahpN1FBbbCz3ckYCMen3hgn864a78B6f4/8RaXq1vNCYY/mvMLuV1HYkdec/hisL46+PVs4F8I+Gka1slj2XI8vYSOwHsR3oA7n4d6hH420XxBYXN1HPegTWwmQEIQRhWxnnsa8/034H29toiX/iXWHtjLKY1WJAMDOOS1Zn7O15eaZrdzegEaZlYpHJ4Vz0x71u/tTavci90fTYblTp0kbXAjQnIOcYPr3oAzLn4Ixm5Y2nia3aD+AyRfNj3wao3/AMD9WWOOTTdV067U53BmMZX+deXrq1+ihY766VFGFUStwPzroPB3iPWE1uxtRqNyYJp1EiM5IIz70Adl4W+EupWPiy3TxLHELNF85PJmB88g8Ad8Dvmu1+KPirW/BmqaOlrpk/2MkSPNtyk2OAqkdCPSsj40x6pLrXhaLQTcfb3icJ5JIPUdfb616R4d1TWdM02ysNbeDVLmT5pl8sbV47Zzn68c0Ac5418PaL8R9Bg1S8STRdeEYYTTQlWlX0de/wBa4Pw/8KfEGjeJ7e7tL20kt4JA3mI5UyIeeBjuO1fRNleWeoQFNKSyNxG214rs7ih7jvj6V5n8VPif4n8DavBZppWn/ZJI90UyZCyeoxjgj0oA6HxjpHhSXS7TxB47hvZIbBPKWKRWEa7uxA65NcBqnx30rQrf7B4D0CC3tlXAd0CAnp0HJ+pNeZeNPif4l8X20lpqd0q2TtuMES4U46Zrh9h9KAPoT4S/EC68UeIr2PxhdmfcuYIwu0R56kEdO1ek6rqb6RcR2Ou25u9JuAUtLxAWHPUHH3GH5V4r+zzaLPfak81uGUhUDlPxwD+FdpP4j0uGVRquswJsmMaQFiwh5wfl7ke/50Adh47lvLX4ZXA8JyNPd2kqSR5wXK5+bjvxVH4Uz+J9f0TUm8UaTPFFcRmGFWBjDqRglgT61oWRijuoFtGH2W7jJDbt53D+PPTJ449q0WuNY1i8it7e8ZZUjZnXcAAQRgN6dxQAzxDc2OgaDptjPPaWdpbR7Z952oABjA9+4FfIHjK50+78S38+jqwspJCULDGT3OOwJycV9F/G3w03jTwcde09pP7Q0sHzrVTlXUHDHHdh696+XCPTpQA5T8vWu70e80vWdBGiJp9tb6jjMdyVGSw9/U1wQ4GK1PDe7+2bTZMsBEgPmN0WssRDmhe9ramlKVpHovwvsNX0nxBPZXtpJao4zukXrj0P9a2lmudL1fXTY2kUxe9gVUc4ym19zDBHQkfnXKePta1HSNet5LHV1uFMQICchSOxrjLvX9Tu5BJPezMwJYEHbyfpXkPBTxknWdrSS013T/4B3rEQoJQitnuen+L7dl8XXEtxNZwCbQ5YU864SMF2VwoG9h1JFcppPk3dtpkOvrolzpsMe03H2wR3MEeSdu0MCxBJwNjdetcff31zfSCS7nkmccAuc4FVa6qWAcKag5a2W3TfbXzOeeJUpXS0On0m1D+HNcEVxaKJjH5KTXcUcjBHJPyswPT257ZrS0LXdKbSrmymtZ7ZItOkQqL1FSeQ7dzAGPO9sccnAGAK4Wit54VVL87637dEu/kZRrONuU9ElvbC80+2e5fS20pNJEJQiL7VHcKmAF/5affwc/dwTnqaYyw/274e1c6lYxWdlZ2bSsLpGkzGi7kEYJfdwRjH1rz6is1gUtpd18n+vn+Bf1i+6/r/ACJ76Zbi9uJo02JJIzqvoCc4qCiiu5KysjmbuFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBRS5FNpV+8O9AE0M81ucwyyRnr8jEc10+k/ELxVpe42msXOGx987unpmvV/Afw98D+L/C0P2ZL0XqfNLOkvzsccgKeMA1l678BLxXP/CM6zbah8pYRyjym+memeaAOx+NE73nwFsLu4bfPNPC7v0ySOTVT9nXxDFrOgXvh7VnSUbDEEfJyhGBn1/8ArVqfGTSr2D4G6fpr20hvoriCNokXcScdsda5T4P/AAq1/Tb6PxBrd0NDtYgSUlA3uv8AtZ4AoA8i8deHbnwr4qv9Ju1AaGQ7GAwGQ8qR+Fc6ete0/tF+ItD1+70tdMlhudTtQ0VxPE2QVHQZ6dc14tQBJEjSOqIhdmOAqjJP4V6/4J+FqLbxax4xuBBbKPM+yOcHHbzG/hHtXP8Awi8UaL4Zv5pdXtXM0uFS7VQxiXuAO2fWvZtZtPCHxL0iCytfFM1tMpJCKw2yP6sh5PFAHFeIvi1aeHw+keD7SA20ZCNLGdsRXuqKOv8AvVsWHibwd8ULOPTvEdmlnqjKI4p1wJYgOmxjww9jXKan8AvFUNyg0+Wxv7ZuTLHLt2jPUg812GmeDvBPwvtPt3iu7j1DWowzRRuDtDADhV7nnrQBfuvDEXgHw3dXEMrXGk2YLxydN7erY75OK+dvFWvXfiPVnv73arMAqIvRFHQCu2+JXxa1Xxas9jbr9k0iQBTDgbmAOQCa8yJzQAlb/ga2e68VaesZA2SCQ5OOByawK1vC+of2Xr1nds7JHHIPMKjJ29xQB9KeNvFNt4Xawkeza8v7qIRW0SfKx55+bsOlGr69J4c8JXGuam6tfSKBFDjaFkI4VR6CuT8Q+K9I1PxDoGs2llqF9pumxMs0y27bYnboffFdZrvg+y+KumadcWF9fW1rbgku0eIjnqcHnNAHz14d1bxC3iIXGiyXMup3EhbbGC28k9xX01daJda1oNhovj2O3a7v0bbICWML4yMehB9O1U706B8HfC803hzSLrUbxxg3vll1LY/ib+ECuR8G+JPEPim1vNf1WRZXWZTD5YCrEF68dqAMu5+BDWeoGG78QweWjfOFgIfb6gE1Mvw48DaY73Op67NdWyjBjaVI+fXI5P4Vu/tFWV5qHhLSPEtjPKET9xcrBwqqw4LkdeePxr5wJOPvE496APobTPGPgTwNp09rpLTXAkVnURuZG3kYBz0GK+fLy4a6upp5WZ5JXLszckknNR9KbtJoA734feOr7SL6xsbu4L6YJPuvyUJ7g+lfRbfb7S7ttf0thdWUiBbmODA8ruHx/ECc5r5I8P6Pd67q1vp9hE0s8zBcKpO0ep9q+ltYltPg74T0uBtUuptRk6xN824HrgHpj09KAOxhnTTbuO9gIbT74iK4DY+YsDngflXzn8dPBcHhTxQJtLRV0jUAZYFU5CH+JPwr6H0p9O8T6VaXejkRN/rTAVwJMjqAeh9K+efj7/aSeM1j1EKkAgVraJWztQ/3h2bOc0AeZE80obA4pp60lO7AlMm45Ykn1NJuFNAzUjW8y26TtDIIHYqshU7WYYyAehIyPzpXSHqxjEEcU3FaC6LqjJcMum3pW35mIgfEfGfm444557UkekanLZG8j068e0AJM6wMY8Dvuxio9rDuh8kuxQPFJUvkS/Z/P8p/I3bPM2nbuxnGemcdqVLaeS3knSGRoIyA8gUlVJ6AnoM1V0KxDRVttOvVsRetZ3AsydonMTeWT6bsYqa+0TVbCHzr7TL62hzjfNA6Ln0yRU+0he10Pll2M6iiirJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApV6jFJUtvK1vcRzJjfGwYZ5GQc0AfRPwb8IT6P4efUbqeVNRnKywW4cmMAcgN2BNd5daHceJ7201iz1iXR7iL5LyJGHlso4OF6A57+lfPd/8XvElzZxwxG2t3C7XkRMlvQ4PArk7nxRrdys6Tapdss+PMAkIDfgKAPtK61ex0jQbjUfP+221goaS7lO5VJOCVA715p470e/+JGnLJoHi/zY3XmycgRP+K8/nmneGYJb79mzULOyRprprQkRr1POT+lZn7LOjPaWmqeILoyJb7dqAgbWC8kg0AeC+JND1Dw3q82matCIbyLG9A4YDPTkVlHrXRePtX/tzxlquoB2dJZ28vcMYUHAFc73oA7T4e+Bp/GMkrLfQ2ttAQJCwLOc/wB1e9eq3Gj+FPhhp8N/dadc3VxMCIrmaIyFjyDg/dXv714HpWq32k3K3Gm3UttMP4o2xn6+tezeD/jWktimk+NLCG/s3wrSOoYf7zKen1FAGLqfxk1OK7RvDtuLK3jbO2Ri5k+o6Ct63+JnhzxfbraeOdMjdwP3bsOAxGCQ45Gc/hVvxH8LfC/iqzfV/AmsW9oxQMbFsvGW9FPVSfQ1P4Q+EGleFdMbX/iTcxKIQJBZLJwvoG9T7UAYWs/BmDU4Hu/BupiUHLR2tzx5gxn92/8AF1A5rxzULC6069mtL6B7e5hbZJHIMMpr3nWvjba3Xi3SotFskg0K0bYJGTa+DxwOwrqPjT4Mt/GmhW/iDSzDHfKuWkI4kwPusR/OgD5VIxSpwc5xSuMHB6imigD6e+BbrffDe4sLW5h+3vHNEkUrfKWbkA+1dTrFv4m1XwS+iwyPpmtCLaqKwVT7Buw46ivMP2eYPtGj6kiLulMhCAHB3bRiu78D/Ei11O8fRPEFtPb6vZOwIIzsweu70oA8m8OfFzxD4buZLDWoxdpCxhlVuHGOCD2b8a9t0FbLVfD0l1YaT/Z325fkt0UI0jtzkr0HqSKpeIfh9ocviceInsZLt5VDM5PmRyOf4mT16DHSuh1C7n8JaCb5LCbUNbePy4bS3A/dKeg9hQBz/irXPD3g7Tv+Ed8ceXf2d3+9SFEJwAQeQOhzXHGy+CmtAXm86cW+UwxzMn47T0ry3xD4b8a63qd5qGoaRqE07kuwxvKL1wB1wK4uaJ4ZGjlRkdThlYYIPoRQB9DDwD8KNaU2+j6/NbTr8xfzw3Hphq4j4s/Cz/hDdPttV0y+e/0qZ/KMjoFKNjgdec/SvLQ2GBx+VfXnga4034g/DFrG8txcQxqMRSDnK9ge31FAHCfs9WjaXYSamsbJc3DYV+CGjH8uc1T8ZfDzxZrPj62u9fmW+0m5kLrcwsWjiQH/AFZGPlY8fWvQLO30jwvarZrOtnDL8igv8qH15788CtPwi13o9tPCdfXWoFO5UljCOwPReOM0AX/D2lRR61YWLRSwrDDvU5wdvRUz6V8tfF3V/wC1viDq8ymXyo5jEiyNkrt4OPbOa+vNI1GO/wBVu71I2zZW2ET+LJGSp/ECvijxd9ok8T6o93bS2txJcO7wyjDISxODQBkdfarOmWT6hew20bojyNtBc4AqvjHBrb8J2DXmsQZjc28bB5GHAUDuTU1JKMHLyLhHmlYf4p8NTeHb2K3luYLlpU3qYj0HvWiZLGPwDpn9o21zOPt1wF8i4WLHyx5zlGz+ldZaWPhvxb4y8qJbmRFT5xuwpxxxWFrfh3w3B4gn02O9uLR4ZAh8wb92emDXmLExq8tOq3zRtJ2T810Ot0XBOcLcr039C9r1pcTy+O3t7ad4/ItQCqFsYaJjyB2UEn2GarCyn1SKGXVLDUNLeHT/AC11OCf/AEYoifKGGMcgYIV+p6VzvjTSNO0bUUg0y7a6RkDsXGChPb3rnQBVUcJz01KEu1nZp7Jd/Lqialblm1Jfj5t9vM6ye21af4eRPPBfSWsN3vjZ0cokWzqCeAufTjNakt5pFz4O1m306e+jsYBBshe1RTv3H5mYSHcWI5OBgAYBxiuAOM9AKAme9bvB828ut/xT/p+Zkq1tl0sejeM7O3u01e7msVt7OCGI6ZfJJIVnXKhYwCxUjaScKBjHPetDxbamO48Y7rC+sorhQ7Xtw2YZijBlRBsXlj05Y8fWvKNvX2ptZLL5Ll9/b1/u+f8Ad9NdjR4lO/u7/wDB8vMKKUUleicgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAKKlhgknlSOGN5JGOFVBkn8KiBwcivev2cDHDYarc+RC06llEjICyjb0B7UAeYab8PfE+oqWt9IuVRXCM0w8sA/j2FdppnwSvWCPq+r2tth8NHEDIdvqDwM1R134v+IpLh47Vbe3Ebsu7bvJwcd64fU/E+t6rJuvtUu5ScjHmEDnrwOKAPovQ9S8NfDvwnqOlf2wbkXcciQl2Bfc3AG1eg96m1byPh98ATANgub2IxACQkMz9SD6jOa+ZdEu4rLV7O5uo/OgilV3jPO4A9K+ivHMsXxT8FWy6PcRxLa4kjjHA3AEYYdh79qAPmYnPWm1amsriFpRJBKBC/lu2w4VvQn1rvfB/wAKdZ1qSGbUo206wkGQzjMjjttT/GgDzoLnpya9r/Z/tdC1S01HT9W0y3uZZODLLGGbB6Kp9eCa6PwxpXg3w/4qstH0uGG+1Rt6zNORIy4Hfsv0q1L4JudG8da3rmmSW62KGMm1VQuJDtyAg42j196AL9heaT8JvC2otaaej3KSblklYbpwWwMHpkD0rP8AG+jQfE7wXFqek3ck2vxgSCLzcRsp5Kkf3umPeu71/QtC8Z6bbwatcgNHKJDG52A44wAOoxW9oHhrT/DtrFb6DptpGy5AcLnHcE4NAHwpcQS21xJBPG0c0bFHjYcqwOCK+vvhja3GkeFNIh1ac3dlqEHlksNuwkfc59q4PxZ8I9W1PxXP4gu7zS4IJbhZWhtVIYjcASqkcmtb9ovxRdeGLPwzpmlXLRXUY89vl+VlHAB/GgDzPxd8HfEtr4u1Cx0LTJ72xVw8Mq4ClG5AyT1HStnSf2ePEcwZ9Vv9P0+MKCCWMhz6EDpWdd/Hnxc9jDb2721uVHzSKmS3+FcRrHjnxNrJb+0NavZQW3FRIVGfoKAPo3wV4I8M/D64kaXxSbi9mCp5OVUF/wDZHWs/4gaxF8P9CjvLbTYZbjUZWI4BV26kyMOfwr5mjuZhcrOJGMwbeHJyd3XNfRvw28Tv458H3mk6/p8NzEoCO0i8MezL/tfSgBvwV8a+KNW+1vdJby6cknyjO3BP8IHcCt/xT8VvC+hXswdn1TVNw89Uyyg55UdsAe9cz8S9fk8BaFaWPh/SzarcxlIrsR/u0XuAe7e5r57uEljmYTpIkh+Yh1IY55zigD6d8FfE658Xa49vYae1pYWyfvJ1ceZy2QMf/rrn/FPwm0fXtXvbzS/ELwXUs5aaG6QNtJ6/dxjn1qL4AaebPQrzU3tsSuzPHKf+WiqOn0zXkiy6nrfiq6bS47sT3dwWaO1ZiQN3tQB1Wo/BTxXbXSR2cdtfwvIUEsEowB6kHkV7f8ONBtvBtrp7WYYW8/7m6Ej/ADGU+3p1FZfj/Vz4A8D6NeWltcSXcp8pXknJ3HHJfvmqPw6+IEnjKxubG8jjjvF+6B82D1BHcdMUAdR8YvCM2r+B7200axa51RrhCip3TOc8/wA68c0D4QfEYo1zB/xL5QdoE11tZh7da9S+KvjTWfCXgexvdPvt9xeS+QuYx+6K8nJ78cV4Nq3xW8ZakUEutTxKnRYQEH1oA+mvBehy+CfA0kOt3kP9qOgE0ocyYyevqa88+M2qabq/gB7jWLKFdYRkFpcoMMSTyCR1yOcGvELbxfriasuoTX811MPvLcOWRh6Yzik8W+K9R8TTxtfsgihz5caLgLn+ZoAwSxzzzXT6P4xutM0C40uG2t2jnBVnYfNg9a5diWOTSA4qKlONVcs1dFRm4axOv8A64+lXsi28CG5lwFmYZ8sDrgV1tktjeeI7u8vrcz32VkkcnAxj+EevFeY6Tci0vEnYM209BXf6ddBrgX8Nr+/kQxBpB2PtXpUsshjcHVVBL2za1629eiOaWLlh68JVL+zXTzOZ+IUVvF4ouhaoY4mCsELZxkVze3GDXqGsxWWovayXlnAtxGu1mjzmX0LVhazaRXNo0cUaKYvu7Rg1rRyPE0cMpV2k0turIqZjSqVfc2ZxYpVBLgDOScUuCCR0PSuq+G+jw6x4iWGd8RpGznPT069vrXk1akaMXUnstzrV3oi5beG7OfwfqV4oP2yzjEuMHLLnBPXt9KyLHwyJ59LjuLz7OLq2kvJ28rd9mhXcQx55yFJxx1HrXoeipbWupXNpMy/YZGltZcOGBjZSp+bofXNReJNIk0TTdY11ksL21vFis7WB5jhLVcAcIytn5E6cfez151zebo1acaeinFSWivrpb7/e19DnwU1OEnPdNr+vyOBm8LyQXPiKCW5AbSI/MyEyJhvVQRzwCGDd6p+HdHj1iS7R76K2eC3knSNkZml2IzkLgYH3eSSOvGeldO/ifSb5Ls3kN1aS3umR2UxtohKqvHIpVhvkBI2IoOTnI71keH7rRNL1W5me71OSBraWCMrZR7iZI3QkjzcDG4EYJz7VwKdXklzJqXTTyX6nY4xuuw3RfD1ne6PbX17qFzbm5vjYxxw2gm+bah3EmRePn6AHpWLq9k2m6reWLyJK1tM8JdD8rFSRkflXU6J4jtNP8PNpkGra3p7LfyXIms4VBljKIoDDzVwflJxlgM9TXPeJdQh1XXby9trcW8Mz5WPj0AyccZOMnHcmqpSqOo+bb+rdP8yZKNtDLooorqICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAUda90/ZxuLd4dRsXl2TO2SNucKRjNeFjrXr/7OQH9v6gxICrGpOT70AeceLLBdN8TapZLKZlhuHUPt27ueuKytuM5GCOte4X/gHxHp3xCudfXSbbU7A3Bm8tJFkJRjwdp7ius+IXw+0zxtoY1bR44bDW4xhoY49que4cD3z81AHzBXXeBPGV94VvAYCZLOQ/voT0I74rnNS0+50y9ltL+F4biI4ZGHT/61VMmgD6z8EeMNB1Ym0sEjvorjM81v5OXib1JI59jWB8Z9M8US6CdU8OX3n6MuTcx2wKzovYvzyo9sVg/sq6XJceJb7UElVUhQIUwcnvkVYHxcGg/EnXY3Jm0J7lgmxc7OxGO4zmgDkfgJaw3fi+eabcZo4sxvuOQScE+9e621jd6xazWdiy/aZZcTSMCQqBuWJ9ccVF4O0Dwzqcd1qvhIQQz6gd8qE/IM9dvdcdcVQ+LPiyPwL4NNhogkmurxjC14WxhsckevSgDkf2h9b0S2s7DQ9MuPP1i0cM08fWEf3cjp9K8x0f4l+K9I8tYdWmkjRt2yb5w3sSea5LdPd3JY+ZPPK2SeWZmP6mu78NfCnX9XKveIum25Gcz/AHyP93qM+9AHofgv46azqmrWOm3mn28txO/l+eDypPQ98Csb9qITHXtCnucCaa1Z2AGNvzYx+n613/hbwjpvg7Qri4tIUlktozLcXkqjewxyB/dHoBXzz4+8V3ni/WTeXjARRgx28Y6Rx54H1oA5k80ldT4E8F6j4z1I2mnPBCF5eWdtqj/GpfF3w98ReFXY6np7tbDOLmA+ZE34jp+OKAOe0nTbzVbxLTTbaW5uH6RxrkmvrDwja/2f4WtbS8soNPuhbmMRRuCYmI+9x1P414J8FFuo/GUd1bQebbQoRcOTjy0PGfc167+0VqUug+HrJdLhjjg1T5fN3HchUc7fQn1oA7OK2nuNEEYhfUbS2QnMmJCzAZBCdCfoK5GC+8OfFPS7jQ9etG03WbYkIXQLPbsOhPAyPavEPBvxC8ReG72M2d3NcxFv+Pd2JDE+h6g/Sve9PvV+INit/L4Mu4Naj+5eFTA3HBPmDr9GBoAyvFemH4f/AAsvrILucJ9nV1cjeWP31P49K0PhJ4et/CfheO8huLWTUL1dzyNJnY3bH4H866fVtHTUNBTRvG1mHsLgfu5Q4Lwt2OR0Pv3r5n+I3h3UfAOunS49WkntHTzrZ4pSuUJ/iXs1AH0J8QNIsfG2j2tjqd20f2d/NMlqwJYgYyVI/WuCtPDOg+AnGp2Wr308khEIhKgK+T1PTgda625Ew+DelyaM1vFr5SKRJXwGZcjdlvQ9653x3reo6hoejadrdhbQ3iSszumHI2j+FuwJ6iunB0PrFeNLuzGvU9nTc+xB8aZ18Q+F9KhsLiGacTec0Kvnb8uD+deHXOi31sCZrWQADOQMj9K66+dUupJWaRQOCFPAqrLrrWyAsJ2QjglOG/GvbnleFppqpNq3XT8jhhi60neMU0zjCm3qCPY0w1sa3qw1JUxbpGR3A5NY5NeDWhTjO1OV13tY9Gm5SjeSsxRj0rR0vSJ9RZvIC4XqSateGdLN9cb5VBhXk56E119qLW3ldbdBHnqV6GvXy3KPrKVSq7Rf3v8AA4sXjvZXhBXl+Bhab4ZeKYG8CyAHhUbrW5dyXEEsf2aFWjztKL94UzVZ7uJEa1iV493zsvJApsTli6hm3MMqe4NfQUaNHC3pULpq2umvlqtTzZ1J1bVKlmuxX1PS2uibi3eW3uyBwT8prnbm81GymeG5GyXGMsO1dGst19kO8Zn6YJx+NGoS232ArqflOQvGOvtjvXHi6EKkXVpScJPV9n+iN6NWUGozSkuncbZeENHufC8WpzeJIIbx3Aa2KgkZ7detdBdaRZeEvhzfTwakrapfFUVTHtLR56Ln2rylX2zB0A+VtwzXU+KvG+qeJ9Ks9PvxB5FqcoUTBLYx/kV+e4jCYidSKc+aHNd3ttultrqe9GSRBBqUB0qK2eQeWAA6Fc5NTaZrMHnrBIC0X3R5hyPoBV7wj4GOpiKe9m2RE5Maj5iPr2rsT8P/AA/Mwito5y4JBfzSP6V6lTiinQqpO14+TZ87iMdgaMpU5Sd/LoeaeJdJNoxuoAPssh6D+E+lc9nA5Fe6TeErC3tZLdtQkmWMbXBgZ0B92AwD/KvJvFuhy6LqDRsB5DH5CDnsDj8iKdbH4HGy9phJaveLTVn5X3RvlmZ08UvZp3a8mr/eYR5pKs/Yrj7SLfy/3xXcFyOmN38qRbSY2/n4VYucFnC7sdcAnJ/CseaPc9bnj3K9WLe1luEd4/LCoQCXkVBk5x1I9DUp066EXmbEI8vzcCRS23Gc7c5x+FNi/wCQTc/9d4v/AEGSk5pr3WS5pr3WH9nzf37b/wACY/8A4qj+z5v79t/4Ex//ABVVK0NO0e+1KC4lsLdrgW4BkWMguAe4XqRx2FKTcVeTS/r1FJuKvKSS/rzIv7Pm/v23/gTH/wDFUf2fN/ftv/AmP/4qqzKVYqwIYHBB7Vqa7pH9lx6fNHN59ve26zo+zbg9GUjJ5B4ocmmk3v5f8EHJpqLau/L/AIJU/s+b+/bf+BMf/wAVR/Z839+2/wDAmP8A+Kq5qejNYabpU7ylrm/RpRbhOUTOFOc87ueMVe8W+Fn8PwWsou1ulkYxTbU2+TKACUPJz16+1Z+2V0uZa3to+m5n7dNqPMru9tH03MX+z5v79t/4Ex//ABVOTTbh3VENuzMcAC4jJJ/76qzf6R9k0DStT8/f9uaZfL2Y2bGA655zn0FVNI/5C1l/13T/ANCFVztxcova/Tt8yuduLlFrS/Tt8ypRRRWxuFFFFABRRRQAUUUUAFWLK8ubKYS2k8kMg/ijYg1XooA7nSPib4o07YFvvPVVxtlGc/j1rt/h/wDF25HiK3Go20EUk5EZmU4Q5P8AED+PNeIZoyelAH1j8T/htH46srObQ7/T4Z4tziSX78pb+AkdB6V5b/wz54yz103/AMCP/rV5jZa1qdhJE9nf3UTRfcCyEBfwrX/4WB4r/wCg9f8A/fygD6J/Z98D674Nv9Xh1u0EauQUlRwyOMdiP618v+JD/wAVDqmDx9ql/wDQzX0j+zv4k1jxb9ri1y/mnS0ACqvG/j+L1r5t8RgL4h1QAYAupf8A0M0Aen/CvxxoWh+HZdP1OW7trrJZJolyOTntXbJ8SvA2o3+ntqFrDLJbZWJ5o2IGfXtz7181ZpKAPsCw17w1qn2caW2mJJ5jGS4jiQNGAOFGOmfWl1f+0prN4tCSBZy4Ek0z42Rk4LJn7zHtmvkGKWSJw8TsjjkMpwRXvn7O+n6vrMGoXN7qlydJiUgxFt+W6k4PNAG3+0LrqaN4G0rQLSYm4usNK4YFmjH9768V82QQvLMkUalpJCFVR1JNfRviLxl4O/tOTRPE+mxXIhygllh5QHkfMORTPDng3wVqOv29/wCFt8zAb/J87egJ44B5GOvNABpENr8OPhy93P5UlyVyuBzJKw+7nvj2qt4J8S+PI9PSbUtLjvrGTBMTOqyrGejFD1X68122peELrWvEVvc3XlSafpYISxYZJk7yP2wAOK8h8c/EySDxeG0FYJbe0YBpmU7pWHX6AdsUAezxW+iW8M8MdjbaLd3e471QBZHI6kZ5x6A0nxF8Mr4l8DWNnOsN5PYzpI0q5BMY++FxyOPWvmPxt431jxjqcN5q0wUwDEKRDaEH+PvXe/D/AOI9tY6EtprN/dG4CtEFCltwP3ee5oA9B1/xV4U+GNhpkFn4Wt5JpUMqEKGO4YwSx5rzrxF8ffFOpI0WnLb6bCRgGMb2x9Tx+laf7QVnFc6BomqrM2V/crHt6gjJJNeFc0Ab2t+Lde1pt2p6rdT85CmQgA+wFY9zcz3cxkuppJpD/FIxY/rUNAoA7aP4i69Fo0enCSAxxKEjkMY3Io7Dt2q5pGt6zrc8Z1SVpoIiShKhcE9a5nw5HaSXpF2u/uqk8V19zcPFMsSwt5W3cmwZyK+hyfBrTFzlZJ2SR5uOruzoxWrF/wBGgnZHkEszksVz0qpPIL37RYy7QSeADx9apJcaXb3PmMrJK3UknJ/Ord15VzKtxGzrIowrDv7GvbddVItLl3d0nuvM4VT5JXd/VrqYVl4dmnuZYpJkjCNjdjORWgNB0qBv394WC9V4GTWpZ3Kfb0Xd++ZfmXPOfWsaLTEPiiUSkmND5nzDrmvP+pUKEY8kFNt21bsuv5HR9YqTbU5Wsr7GxF9h0q1HlJIqM3c9TUnmKCwgiWIbelY3iwXVzcwpFA5to+QyjIz+FaNqnltFli0brgDuPWvQjW/eyoRVoxsk7ffb5nNKn7iqSd2xllqsMsjIpeJgecjjir3mpIu5kG7swqpPMiBnmYJEpyM96wJNfbzH8qMGPtk1lPHrCJKtK79LaFLDOtrSRr67emxgjeNMmQ/LnpmuPu7qW6lMk7lnrfs/L12Qpcs6JEPlUHqT3NVfEVpaWvlpDGUk785BHrXj5j7XExeIi7U+h34VQotUmveMWMF3VRyScAV6d4W8MWkWmPPewJJchSQxOQpx6V51pcAn1KCMkgFxk17notuv2JWQszYHyEfer4nN8TKjGMYu1zhzzFyoQjGDtcr+H7sx2zDOGANa2g3YB3cZPJPrWDrFg2nyGWM7Y5TxHyCPpUehm5efy4zjHr2rwK1KNSDmnufMVqEKsJVIvc6yO7uLXSXtoftMV2hco0cQdZSSSCSVIHXnpWL4r0ltWhvoZ7R2kd42VzCxX/VqCQyjA5FdRZRSRoPMGSvU5rT+1LswcVwUcY8LWVWlFcyd/wAfy8jyaeMeGq+0prX/AIKPB9Z0y0024a7uW8m4jUqqE/eAXbgevaudEsMkFv5rWptUtijq23zA4B6fxdcHjivcfH1hp+o+H5vtUQZo0Lo3dTivnF+tfZYLFRzCnzqPK42X9efmfd5NiFj6PO7prT/hjohLD+5ZjaiI2ixyTCb94vyYIC7uvbpWLF/yCbn/AK7xf+gyVUrQtIJbjTLlIInlYTRHCKWONsnPFdnIqavft+Z7Hs1Tje/b8y9omp6JaWZj1Tw//aM5ckTfbXhwvGBtUY9efeo9F0291C7mutMZLKG3bc1xJP5aQA5xl+ufpzVD+zb7/nyuf+/Tf4Uv9nX+MfY7rH/XJv8AChqOrjLV93f8LiagruMtX3ba+69jpfFOsabc6abV2Gq6qCP+JkIhDgA8jjl+OMt9an8OWDeKfCy6VHzd6feI8Z7iGUhXx7A4Y1yX9m33/Plc/wDfpv8ACrNlDrFjI0llHqFtIy7C0KuhKnsSO3ArJ0oqHLCWqd1/X+RjKjCNPlpys07pvv6drdEddZSWusfESW8mYJo2krvBwSqQwjCdOTlsHHfJq01tpeqaFr1nZa+NUvpnOpRx/Y3hKuuS5BbrlTjFcJFa6rDFNFFBfRxzALIio4DgHIBHf8aLW11W0nWa0gvoJlziSNHVhkYOCPaolQW8Z2ta23Tv137GcsMnZxqWslbbprr133sdLf6bf6j4C8M/2fZXN15b3W/yImfbl1xnA46GuctbO5sdcs4b23mt5hNGdkqFGxuHODVmzufEllAsFnNq9vCuSI4nkRRnk8Dilgj1a71m0udQS+ncSpulnDsQAR1J7VcbwUk2ravz1dzSF6cZRclbV+erbMKiiiuw7wooooAKKKKACiiigAooooAKKKKAF71NbW8l1cxwQIXlkYKqjuT0qEV658CvCxvdQfW7pf3NudkG4cF+7fhQB3dpLD8L/hyZVbF6EwCODJMw/kPyr5suZnuLiWaU7pJGLsfUk5Neg/GbxSuveJPsVo+dPsMxIezv/E35152RzQA2ilwaMUAKPu19afC670mz+HNjp+kXYuLubCzhGGU7tnH5V8lYNek/BLWNU07XHg0jRzqbzkblEmzb+J4oAu+P/B/iDxH8RdTOi6Vc3SOQyOq4RlAHRjwa6f4XfDzxH4Y1K41e7aKD7LHulgD5x3Ksem7HpXqel2vji9S8OqwafpNu/wAkUCT5bYGzyRwB9Ks+N9DudZ0O30z+37bQYsfP5Q3s/rzkUAc18efE+raN4Stbvw+irb6g22a7TrG2OAB7jua+TyWdmZssxJJJ65r6v8ban4U074aah4av/ESX062+xXDKHaVeV6Z718oxDLAdSaaV2A3HNSW+FuI2bgKwJP413elWkFvZxW6xo8kgy2QDis+703SJrl4VcRTA8lG4H4GvbnktRU1OMld9NtThjjoOTi09D2C9n8IePfDNnp9xrTRSQYlURkKwPQhg1cvqnwQ80TyaD4gtLheGijnXYWB7bhkE/hXH6H8OdU1q8RbCWMWhPzXTghFH9foK9VSXQPhbokTXFxJf6gMJtEmZGP8AsqThFHvzXj1aUqcnCW6OyE4yV4u55Rrfwy8UaU0hlsFuUTB32zh92fQdf0rj7q1ns53huoXhlQ4ZXUgg16jf/GrVrm9mmWyhVWPyr5h4Hb8cVwvi3xNfeKb+O51Hyw0a7ECDoM559azKMaHcJUMed2RjFegWbzbEywE2MDnv/hXJ+H7I3F2HYZjj/U1palq/2XU40iwyRff56mvocslHC0nWrO0ZNJf5/wBdjzsYnWmqcFdpXJ5fEBinkg1GzVmQ4OQDV63bT5lSZEmiH8I5A+uKq38mn3Ekd1MEYlcZLdfwrH1PV5SohgR4o8YJYYJ/+tXZUxToOTrSU4p6aa/fpY540VVSVNOL666G9qShb21u0ZmRCEdh3B9azvGSyRXdtcxyMNy447YqxoVwLnTnikckgEE5p2tx3F7pUMUURkYNnCjnFa4h/WMLOcN5Wl53WnTyIpXp1oxfS6+TMa11+7hwGG/jucE109vK91aRXLREDrlecfhXP2nhm+edPNVUj4Jy3OK0dT1M6MyQQ7XfGSM8AVhgqmIw1OVTFtqOm/8AwTXERp1JKNBXl6mH4hvftV4yxsxiU8LjArMUEkALkmuqTX7C7TZf2q5PBbbn9antbLRZZlmtpAjLyFZ8j8RXBUwKxdXnpVVK+/R/idEMR7CHLKDViHR7L7FbRySLiUt830Pas7xbAUvUmG3Y6jG2jXtR33iRW75jiOdwPU1qanbvqOixmHe7qQVUDr9a66ip1qFTDUb+5Z+pjFyhUjWqP4tDlLSdra5jmTG5TnmvR/C3irzEI2sGXkg9PqK4+z8NXs+DMogU/wATn+la1rolrp7+ZPqBGByq8Zrxf7Anjbe3g1Hvt+YZgsNiI8k3d/12Oz1fxE80S7YtxA6nnjvVXSrz7POkp4V+a4vVr90ZV08yuOckoSD9K15biaLw/HOiFpUALKeMDvWy4ay6dOpRpXTir82//Af4HkvL406cYRXxOx6jb67b+QQ74GOa5nWPG1rYFkMjlsfKAOtecS+JpHQIsXfJ5rRuoIdc00zqriZFyhPT6GvCwnCWGqKXLU5pLW1rfmY0cipYealXWjF8S+ObvVLY29tmKI8E9yPSuHNSNwcdxUda0cPTw8eSmrH1WHw1LDQ5KKshKKKK1NwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApQKB1rs/hj4Kk8a6+LP7Qltax4aaRjzjPQe9AFv4W/Dq+8caooB+zaZG3764Pt1C+9exeJdY0DRJ7HwH4NIS+mH2eS7BLCDI5Puxp3xU8R2nwt8LweGvC+nNDJdRFftTL8pHQnd3NeF/C9nk+ImjPIzM5nBLE5JOKAPTvEv7PV9Gwbw7q8N2+0GSC7HluDjOQRwc15Br/AIb1bQNRksNWsZ4LqMjcu3dnPTBHWva/2kPEOq6B440iTSr64tQbJS4ibAb5j2r07wprseseC21rSrK2udRWISsHTdI+0crmk2XBJny5ovw78V6w7iy0K8O1Qx8xNgIPTrjNO8Z/DnxF4QFo+r20SpdsEi8uQMS5/hx1zXojfGjXtY8WW1lb+VaW8swikKD5goOcA9vrXq15aaPLp0HiHxeyHT7FzLAZySXf1Of0oWwVI8kuW+x4tY/BG5j8Kf2prmqCwvZRugtFh8xiO+efp9K7zwX4XTS7GKKwi8lkwJZgPukj1/vH9KxbD4pDxj8QBb+V9n0xUMdryFbr1OfX0q38QPHvib4e6oqWUEc2lXK5gmmXkt/FnHH/AOqmQbHjrwj4w16xtU0DW7eGJDvkiknZZVOMffxyPavGvE3gH4hWjGfU7DUroA7BLE5mB9CNpPFe5fDrx7r/AIi0c6jrdvZxWhYkbhxsA5bBrzXVvjvrlr4nv30pYH00PtgiYEYA4z+PpQB4xdwT21y8V3FJFOp+ZZVKsD7g1oeH7YyXXnEDZH6+te1WHjnQPiNcSW3i+wtll2/u5Gwrx8fwvwSM9q4zxF8O9a0OGa/8OSNq2lfMWkt0JaJRz84+net8NUhTqKU1oiKkXKLUdytbMLW2uLp27Hn1NWPhD4X0jxbrl2+t3P8Aq/mjtt20yk+p6gfSufu2Y+GWLMSTgmuf0+7uNPvI7mzleGeI5V0PINetnFdy5Kcdkr/NnHgafxS63t9x9C/ETxFqvhOWz0XSdMk09SMpdFA0OzHSPsT7nmvHPGN+80XlzOZZ5W8x3bk17v4M8RW/jzwn/Y+uNbi6cAq0iZ8tv7615f458ML4d1P7Br9tgyZ8i8XISZfUHpn2qcHGPsZ0bqM5aa6aDrSftI1N4rseV4PpSY5rrLnwurAGyuN3tJwfzrBvtNurJyLiB1Xs3UH8a4sRl9fD61I6d+h0U8RTqu0XqdL4W2y2PlLC4fJ+cDA/OpJfC9uZ1aSeQKeWzyWNO8P3jXGlmGMsjBSowMkGubXUr61unLyuXUkMG5r3KtXDU6FF148ytp0S9TgpqtKpUVNpfn/wDpyml6cB5Fo0kgOMsMkZqtrltLqEUW10QopYK3G7/wCvUMGu29ymy8QByOG9Pxq1tt7xkB2zJGCCUONuf61y4/EweEqezcbaWSVmv8z0Mswrq4unTcW3re7/ACa2Mextb2yc4T5H4Y5yAK19Wv7qwhjltCOR8+RWfZ3VvDO0CSy7WcAFznvVnxEbmzuoniYOkq7QmM1z4KvXhgKlSLd018k7fmaY3D4ZYyFK/utO/XXVeV9kzLt9Xu7m5VLm5kWNzzs4NLr2nrbhJ4pS8b8HzDlga0ikktsqw6cIrtPmwVwT9Kql21OUW99EYZF/jAwBXhVMXVrS5pydlur3Pfp5dRo0XS5bzlbldmte1/0OfKn6j2pOQeCRWu+lKkxj+2RY3YzVPUrNbOfYJllB7rVRqKTsjzKuDq0ouU1ovNfoUxXQaHrktuotiVAPRjXP4xScg12YbE1MPNTpvU8+tRjVjyzR38l1Na2xupojcJ3x2/CqP/CRW0jKFsN7HoAuTVLw7rJjcQXDjyzwC38jWg+mNYX63tqM28h6L/B/9avpliq2IhGeHldbSTSbXn5o8v2NOnJxqrXprZMryeKpFYhLVEA6K3aqd74knubeSEQogcbWx6VuakNMby21KBI2fhXHf8RVMaJpE/FvdsG643A1jiIY6TlGNZPy2f3Mqm8NZScGn33OTT7wAHJOM12t0TpfhbYSRI67cZ6E1RTwxIlwkiTRSwqwJBOMijxvcAG3tlxtUbvpWOGw9TAUK1WqrO1l8zSrVjialOEHdXu/kcpzim08HrzTK+dbPTEooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFX9L1W90q5W4065lt5h/EjY/OqFFAHvXhD4uWesWh0XxrZwzQT4i3suUx+PKn3Faw+GFhp3i7TvEXhO9i/seKVDLayyEuhPHyH+IcjrXziTXTeFvGuq+HWWO3maazDbjbyH5Sfr1FA1ufQHxk8FTeK/H2nzShhp1vp4EjqcEvk4UcVnfDxtV8EeKhpl7ayyafIgJuYo2aFSe2cVh3P7Ql/Hp0P2G3Zrv+NZlGxR7Ecms2f8AaD8RzQSQS2Vk0UilWUgjINS43ZpGtKNN07KzOo8ReAxovxfstZsrNZ9Hvt1wu5cpHL3B/mK6fxzFpfjqFfDeqarLpV/GRKIY2BB9CU7qPan+AfHFh4i8CObu7htbmBMuGcArjqMHt9a5LxF478GaTq0l95UeoasygGWFN7DAwBuPA+nvVGfdHBXvwn8XaH4kgGn232y2WUNDfROFjIB4Lc/J+Nev+MvD8PivwrZ6ZqsjQX8EyuhVi4A/j9unc157p3xyktb4qulldOYAMnm7m/I8Y9q7aL4h+C5NPudZS7MF3sAFqc5kYcgbf4fXigRznxd8SW3hnw2nhrSSUu5o1RgowIofTjufSvFdB0HVPEF6lro1jPdzHAxGuQvuT2rUs7k+LfH0M2r73W9uMyKGwQv90H0r3Pxr8QbT4aaJZ6T4P0SK1nuYvMWZug5wdw6k/jQBl+H/AIO6H4X03+2PiXqUeYxvNpHJgL7HuT7CqPjn42QPanSPA9ktrZbDE08iYJB4+UfT1rx7xR4l1fxLffa9bvJLmX+ENwqj0ArIVvmB596a3D0Oq1tmTRY0jUYcgHA6Vz0NpcS4McMjgHnaua6CHxHbw26DyXeRRja2MVueFJdW8UaktrpFnGiL/rp34SIepI/lXvYpYOvJVJ1raLRK551F1qacY076vrYhs11WT7MNJhnguQQVIX5v90AetfQ2g6V4r1TTLQa9ZWqIsWFFyyttP98Lzg1xusatoHw4s4DOjXepOMAKcTOPXnhF/WuMfx1rmr211qF7fSQwbT5VtE+FRew9ayqKOY1uWirJLeXZem34l3+qwvN+iXdns2taX4OsooB4lvdNM0aqqCJFDE/zNeRfG/UvBzaXBZeGrOVLveGM4JCFe4I9a860R5dT19rmcGU53Ek9PSofF85k1dkOCI1AFT7FxwbrObd3ypdPmVzp11TUVorvuQeG7v7PeBDyr/pW5caVaz6i07KfLIBKjgZ7/hWRomlvJKlzMNsY5AP8X/1q3Jpra8SSCKUls4+Q45/wrvwFO+GtWinreN+9vyObEStWvTe61sU7nRrC8G7TpCr5IK5ytVo9B1O0dHhVX+bkRt2+lXhLaWCrG5WM45A6/wD1jUT+IbZGYIZmwOCvGfzorYbAzT+sJRl/den3WKo4jEwknS1t3LNzpHnMJVtJI5E+Yuvc/SptTSWXQvN2MLiA7we+R3rO0nWpZ5pBPM/H3QopZfEPmpLDcCRVIK4Ax1rhw+Iy/DQq0oSk7q1mr69Gux62Kp4zGSpYmShF33Ttt3VzGuNXvZplkec7gMDHarFpqtzFn7THvVxwWGPypI9JE0TTW06PGvIDcGta7mmjsInikiuQnBXbXzk3T0ike/h6eLXNWqVGrar7Sf4/lcx9R0wQ2v2pJlKsQRGfvDNZWT1PU1v3MMmtlGtI9sigho84/KsF42SQowwwODWtKXMrN6nnZjSjCfNSj7j69H3NjSNGXULd3NwEkzhRjjPvWbe2c1nOYp1KsDx6H6Vp+H47lZS0ccjQNwWA4Bror+1XUbAxz8SgZR8Zx7V9HRwEMVhr01yzX3NHz88TKjWtPWL/AAOCAwea7DwlNcyo6yNugTjJ9PSsiHw/dMx81oowOhJzmuos7P7PpYtYpV3uCGf0961yjB16Vbnkmkl6XM8dXpyp8sXd3+4zvE8S3Om+bEvETZznoK4/cQeMg+1dxcpZWWkywT3CyFlIA9TXCkjsa5s6Vq0Z7NpXV72NMvfuOPRPQtw6hdQ/6udxj3zUM9xJcSGSV2Zz3NQ5FGRXkurOS5W3Y7lGKd0hcetNpc560lZjEooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAkWQqCAWAIwQDjNNJGemBTaKAHZ4pQRimU4DvQBo+HrqW01yxngfbKky4YjOOcfyr6D8ceDrrxn4fsIbK6to7mAtIHlJxKvQDI6Hk+1fNY4960tP1vVNPKmy1C5h2jACyHAH06U7Ad5cfBTxQsEjwtYzyIM+Uk3zN9M8Vjn4XeLoivmaURuIUfvF5J7da2/htceO/FOvxQaRqNwyJ/rZpRmNF96+gZdW0rwxexaakzap4i8rLNncsPqxHRRSA8Z1f4NWPhfQ7LUvE+uiKQyKZ7RE52EgYDZ4Pviu98RyT+G/AC6j4Nt9Oks7dRujJ+4uOGAH3z+Nee/tA+IXuPselTbnuCftUrsMEZ4GCOoPX2rP+EfxOPh+SLTNZVJtMJwrOoYIPQjuKA3PONRvLzWL+W7vJZLm7nOWc8kmui0ETJaCC8iOx8gBuM16t498D6Ta2j+JvCrRx2U7BprVeTGx7x/7PfHavKNauLuxuoZQd9oTndt7+5r38thChD61e/Rr/M8/FSlUkqSXoWdLgttG8+V3AJ6E8Y9q5dd19qpcxtKHkyyrzxXV3VnZarFDcXU2xFBJIbGapya3p+mIY9LgDNjBY9PzrrxVGPLCE5RjTi7q2rd/Ixo1Hdyim5vR9kadzaC5s/JhzARwUHcDsKqLaQ6Xp7XTgAjjbjrWTpeo319qyASFtx6dgK6HUoI79HsbiTZMPmDA9/euylUp4uLr04+9G6Tffp5fI55RnRkqU3o9XbsZYOjaum0/wCjzn+LOD/9eqOoeGrmBGe1cXEY5+X735VBDoN19sMUy7EDY356/SuhgR7C2K27OzIejN1+vpXl/u60HLGQ5GvtLS/y6nfThUc1Twrc3vbf8Tn9HDWCyXkqkFPlCkd6zr64e6upJpdu58ZxXQ6093caU0shjKO251U8g1zODggYOOnFfNJRc5Sg7pP8D6LGe0o0qdCSaVuZrzY+J3UbUdlB4ODwa24dOeNUaxuysxH3XGM/SufDYUg9a6/QZI7rTSrbPMRSAxGcHtXq5bhqVeUoVFfTQ8bE4ipQSnCTVhSt7JbKqwGG5U8t6jvTntITJHJc2vmIOGB4zUFj4kCqIL3nHBbGRUt9paahGJtKvHZuoR34x7GsamTKreWCnddU9H/wT2qfEEIRUMXT97TXRx0+Wnn3HRGazIhkHlW0hPlBTn8DSeIZZLGzgeMEyMcM/Yisq4vZ9J+yrJbRPcNES5n3kg72HA3YHAHao5PE1xJA0L2tm0bdQQ//AMVXVhs0dLCyoVFLnWl9NLPzZ5uNy2lPEqrSnFRdnZ83VX6Rt1Btdm2bVjjB7k/NzVCXUrqQFTMwX0XikN7D/wBA60/76l/+Lo+2w/8AQOtP++pf/i64J4+vP4m/w/zKjgqEXpOP3S/+RKzMWHJJ+tR1d+2w/wDQOtP++pf/AIuk+2Qf9A20/wC+pf8A4uuZzb6P8P8AM19hD/n5H7pf/IlKitGUwz6ZNKlrDBJHNGoMbOchlcnO5j/dFZ1EZcxFaj7K2qaavpfu11S7BRRRVGIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH0l4U+GvhK/8LaPeXek+ZcXFnDLK/2mYbmZAScB8Dk9q1P+FVeDP+gN/wCTU3/xdavhW7hsPh3o95dPst4NLhlkb0VYlJP5Vzs3xB1WG1tb+bwlcQ6VdTRxQXMt4gYhzgM0YBZfX8ueaALv/CqvBn/QG/8AJqb/AOLo/wCFVeDP+gN/5NTf/F1oeJfDU+rXrXU3iTVtNs44uIbGYQBSMkszc5/+tUfwxvNQvfC4l1O4e6xPKlvcuMNPCGwjn68/UYoA+YvFdpDYeKdYs7RPLt7e8mijTJO1VcgDJ5PA71lVueOv+R28Q/8AYRuP/RjVh0AFFFFABRRRQAUUUUAFSLjHNR09TjFC8wNXT9Cu71d6bEXGQXOM0+fQL23kCbEk91YVPb+IfLjCmDgLtwDxTf8AhIJWmX92FQHHXkCvZVPL+RJydzjc8VzOyVj174IeMLjwzB/ZOpWYjs5GLCZf4s9mp/j/AMK6v4S1O48aeCrh77T5/muUlHmyQZ67s9Vz37V57rd5LZadb3duxIb5SrdCK7j4Z/Ea50qBRqpV7GQbWDDIUHjBHcVWOy2FKThQbbSu0/zIw+LlNc1S1m7fM8Z1rU7vW9QlvtQl8y5mOWIGB9AO1WvC/hvUvEmox2mmQM7MfmkYYRB3LGvdfE3wf0TxDqEOu+HL1bPS5v3l3boN233j9AffpUHi3xbY+BdEg0zwpaxSzL3UBoo8d3I++xrxowcvhVzub5dzc0/V9N+F+h29tq2qS3jeWQkUiBjLx91VxwvbJrxpdTtfEM18pt47eOeRnSEdIwTxiuS1vVr3WtSmvtTnae5kOSSensB2HtUFlcPb3KSREhgee2a7MvxX1ep7+sXo15GOIoqpGydmtmT6lbTWMzW8pYhT8pPQj2qhmus8VIH0u2lcZk3bd3tiuUC0Zhh/q9Z007rp6MMNV9rTUn6HU+CoYxJJOxXf0ANZ2rzXUWsSTtujJOVJ6EVnWk81tIrwsVPt3rpYL+01ay+z3YVJOx759q76VaGJw0cNF8kovTs3/mc1SDpVXWkuZPT0MmfXLmRNoxGSOWHU1Ws4Z7yUKrSYz8zdl962E8P28MjPPOzxLyBjace9LPq1raqlvYxhlJwccD8+9Q8LNy58dOyXTdv5GirxiuXDx17/APBLdjpAtmeSeeUwfwJ3b8KwtZvYruZBFAsZTg4GC1dJfXT2NrHcAfdAH61WkGm67GTnyrnGA3TH1HeujGZbh5v2dCymtfN38ww+ZYiMJRqNuDt8rfkce3ua3vCtyYrho+cHkcd6ik8O3iXvkKodevmD7uPWtmK3sdBRiXFxckcf/WFc+X4WvSrKtNcqju3+QsTVhOm4R1bMLxHbC31ORgrBH+Ybu+aqWd7NaSbreQr6jsa6rUZUmtVmu442Vj/EPu+1Z8dnpd45CMYCThSrZ/Q1WIwUliHKhO3NqtbPUmliIumlUW2/UzfEF0961jcS43vb8/hI4/pWlqOm/bbXTJPttlb4tEXbPLsY9ecY6VR8T20dpPZwQyebGlvw57/O5P61V1W8ju1shGHHkW6xNuHUgnp7c189XhU9rq9U5Xe/Vn1NDEUKVKaqRunCnZXa6R/I3pIvI1bw9F5kcm1FG+NsqfmPQ1LfXGqf6QP7c0zy/mHl703Y9Pu9axk1SBbnSJCsm20QLJwMnBJ45pbl9BlaWRf7T8x8sM+XjJ/pXF7F3XMr/JPqz21mNP2c1Qqct2tOdx05IrpvqmtS/Gq3fh7T7BgPMljkkhP+2rnj8RkflRdBIPDd9ZR7Sbd4vMYd5CTu/LAH4Vi3N8r2WnRwmRJbYNlunJbIIOaWC9RNKvbZw7TTujBuo4Jzk/jWnsJb/wB69v8At7f7jjeaUX7nX2fLzeXs/h9efr6Iji/5A11/18Q/+gyVSq7F/wAga6/6+If/AEGSqVdcd5ev6I+fr/BS/wAP/t0grQ0G3jutd063uF3wy3McbrkjKlgCMj2rPrU8Lf8AIz6R/wBfkP8A6GK3pK84p90ck9Is9i/4QPw3/wBA3/yPL/8AFUf8IH4b/wCgb/5Hl/8Aiqm8bvL/AGXbW8Urwi7u4baR0OG2M2Dg1jeEItMTxPOPDUrLp8duVuImkb5pNwwQrHdwM5PTtX104YeNVU/ZR+5X+StrbqeBGVVwc+d/j/maf/CB+G/+gb/5Hl/+Kqhr/grw/a6FqNxb6fsmhtpJEbzpDhgpIOC3rSeJNMvNMsZtSj8Qak18HHlRFx5UjE8II8c/rXQeIjIfCWpmYBZTYy7wOgPlnNDo0ZKcXSSaV9l5gqlROLU2033Z880UUV8afQhRRRQAUUUUAFFFFABRRRQAUUUUAfWGl6Z/bPwosNND+W11o8USueikwjBPtmuX1S08a6xoun6TdeHraBLOeBpLhb1G84Iw+ZF/h4GSCfp6V3XgX/kSfD3/AGDrf/0WtblAHnfjiPxPfa59lh0A6p4dRVbyY76O2+0P1IkLZJUH+HAB75rq/DF5qd3Zv/a+iDR3jYJHCLlJwy465UAD0xWzRQB8e+Ov+R28Q/8AYRuP/RjVh1ueOv8AkdvEP/YRuP8A0Y1YdABRRRQAUUUUAFFFFABSjpSUoNABTl6g/pTc05O9NAdpqZW68IJK6/MoBXnpUd0kz6LHFbgl3CoQB2p+lTQ3Xhx7acpwuAueh9afcXcWnWimVyzhdqjoT/gK+xk4ziq0nZOCTf5niRUovlitpMuabqWoaDoktt/aN0beQYeJHO3/AHRWFYapLJcSIbZmjfogBP50tt4nkiBDQKwNOm8VM8TLHbqrHvXEsRhYRj7CpypdLav5m/sqzv7SF2+tyS40KC6Jlib7Lj70ZGfxqNbHSrA5mk8xxyNx/oKntJ5LnRLiVzmRlPSuSJPXnPvWOLqUMPy1KdP4le7/AMjSjGpVvGUttLG3rmrx3lulvFHtRG3bj3rCJpSTikFeRiMRPEz9pPc7KdONOPLHY7HTreyu9MSKaNVXbxIo5BrB1PTZ9Ol+b5oyfkkHetbwvN5lvJbluntwKtW+oQ3Dy6fqONgOBuGM+hr3pUaOJoU22oya0fn2f6HnxqVKNSS3XX/gHKz3k8yKkkjsqjgE1HCcSx55O4V0k3hQsxa1u42Q9A3UVW/4Ri/ikDARuqnOQ1ebUyzGKSc4t+e51QxVBr3Wi/4hYf2UAx5YDA/GuVileFw8bEOOh9K7a+02HUIIkmuPKKdRjBzWdJ4WRwPst6jHvvFejmOAxGIre0pR0su1zlwtelSp8s31KMfiK9FuYgVJbjdjmrlhZPxdXJZriRuQ3GBU1n4cNpL5lzIkgH3dp6H3qKXXYUuyvls8ScZz1NEITpqNTHy8knr8xylGTawq9SHxVc7fJt0PQZYZ71zoYg8VPqV0by7eY8bug9qq5rxcZiPb15TW3Q7aFP2dNRZoG6tZYLdLmCdniQpuScKCNzN0Kn+960zfp3/Ptd/+BK//ABuqWaM1w8i/ps9D63Udr20SXwx6aLoXPM07/n1u/wDwJX/43R5mnf8APrd/+BK//G6p54xSUezXn97F9bn2j/4DH/Iu+Zp3/Prd/wDgSv8A8bo8zTv+fW7/APAlf/jdUqKPZrz+9h9bn2j/AOAx/wAi7Nc2/wBie3toJU3yK7NJKH+6GGBhR/eqlRRTjFR2M6taVVpy6aaJL8grU8Lf8jPpH/X5D/6GKy61PC3/ACM+kf8AX5D/AOhitqP8SPqjnqfCz2Px80q6fpzW6K8w1CAxqxwGbdwCfrUdlbatqXiSy1HUdMi02OzSRcCdZXmLDGCV7Drz3ror2yt71YVuo94ilWZOSMOpyDxVmvt5YfmqObemmnp8vyZ84qvLDlS11/E4O2fxKNQN7qHhz7XcqSIf9OiRIVPZV559WJJ+ldFrzyy+D9Re4h8iZrGRni3BtjeWcjI649a2qy/FP/Isav8A9ec3/oBqfYeypy95vR72/RIftOecdEvv/wAz51ooor4Y+lCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACnLnmm0oJFAEill5ViCPSlkkeQ7nJZiepNRbjnOaUsfWq5nawWQvPpR+FNyaVetK4HWeF5WNjKpxhcjpWUdDv3jMq25IJJC55I9cU/RtVisYJEkiZy3TBxTl8QXn2tZFIwONp6EV7TrYWrQpRrSd126fecKhWhUk6aWvcx5YniYiRCrDsaYK6+PV9P1NfK1OBUb+9/9eobnwzHMVfT7kPGT91uoH1rJ5XKoufCtTj+P3blrFqLtVXK/wAPvJfCVkI7eS9nO1McDOOK57VboXWoTTIDtJ4zXT+I5k0/SUsIjh2GOvQVxmSBWuZuOHpwwcfs6y9WZ4NOpKVd9dvQlS7uIxhJpFHXAY1ch1q/j27Z2IHYisvPNGT615UMRVp/DJr5nZKnCXxK5pajqlxfhfOI49OOaqJcTRE+XK6/Q1Bk+tGT60p1pzlzSbbGoRiuVIstdXDqVaZyp7ZqI5OKYGI70mTmplOU/idykkthz9aZSk5xmkqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApV60lFAD6FODnNNop3QDzyas2l7cWrgwSsvt2NU80VUJyg7xdmKUVJWZcvbma7naW4O5zx9Krd+aZk+poolNzbcndsEklZAetJRRUDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this view the alpha chains are shown in white, the beta chains in blue and blue-green, and two of the heme moieties are shown in red. The site of hemoglobin S mutation is also shown in green.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18821=[""].join("\n");
var outline_f18_24_18821=null;
var title_f18_24_18822="Anatomy embryology pancreas div";
var content_f18_24_18822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Anatomy and embryology of pancreas divisum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pancreas develops from two parts whose ducts are in continuity with the common bile duct. One part is ventral and the other dorsal to the intestinal tract before rotation. The rotation brings the two parts together with separate ducts. The duct of the dorsal (larger) part later becomes continuous, enters that of the ventral part which enters the duodenum with the common bile duct. However, in a congenital malformation (pancreas divisum) the other two parts of the pancreas remain distinct, each with its own duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18822=[""].join("\n");
var outline_f18_24_18822=null;
var title_f18_24_18823="Smallpox vaccine: Drug information";
var content_f18_24_18823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Smallpox vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/37/2641?source=see_link\">",
"    see \"Smallpox vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ACAM2000&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Live (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Primary vaccination and revaccination:",
"     </b>",
"     Percutaneous: Not for I.M., I.V., or SubQ injection: Vaccination by scarification (multiple-puncture technique) only:",
"     <b>",
"      Note:",
"     </b>",
"     A trace of blood should appear at vaccination site after 15-20 seconds; if no trace of blood is visible, an additional 3 insertions should be made using the same needle, without reinserting the needle into the vaccine bottle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Use a single drop of vaccine suspension and 15 needle punctures (using the same bifurcated needle) into the superficial skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     According to the manufacturer, revaccination is recommended every 3 years for patients at a continued high risk for smallpox infection. The ACIP recommends routine nonemergency revaccination every 3-10 years, depending on type of exposure. Additional information can be obtained from the Department of Defense and the CDC.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F221470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Primary vaccination and revaccination:",
"     </b>",
"     Children &ge;12 months (in emergency conditions only): Percutaneous: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution [purified monkey cell source]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ACAM2000&reg;: 1-5 x 10",
"     <sup>",
"      8",
"     </sup>",
"     plaque-forming units per mL [contains polymyxin B, neomycin (trace amounts) and human albumin; packed with diluent, tuberculin syringes for reconstitution, and 100 bifurcated needles for administration]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ACAM2000&reg; is deemed to have an approved REMS program. The smallpox vaccine is not available for general public use. All supplies are currently owned by the federal government for inclusion in the Strategic National Stockpile. In October 2002, the FDA approved the licensing of the stockpile of smallpox vaccine. This approval allows the vaccine to be distributed and administered in the event of a smallpox attack. The bulk of current supplies have been designated for use by the U.S. military. Additionally, laboratory workers who may be at risk of exposure may require vaccination. Bioterrorism experts have proposed immunization of first responders (including police, fire, and emergency workers), but these plans may not be implemented until additional stocks of vaccine are licensed.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142576.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142576.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F221447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vaccination should only be performed by healthcare providers trained in the safe and efficacious administration of the smallpox vaccine via the percutaneous route.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A single-use bifurcated needle should be dipped carefully into the reconstituted vaccine (following removal of rubber stopper). Visually confirm that the needle picks up a drop of vaccine solution. Using a bifurcated needle, 1 drop of vaccine is introduced into the superficial layers of the skin using a multiple-puncture technique. The skin over the insertion of the deltoid muscle is the preferred site for vaccination. Deposit the drop of vaccine onto clean, dry skin at the vaccination site. If alcohol is used to clean the skin, allow site to dry completely prior to administration to prevent the inactivation of the vaccine by the alcohol. Holding the bifurcated needle perpendicular to the skin, punctures are to be made rapidly within a diameter of about 5 mm into the superficial skin of the vaccination site. The puncture strokes should be vigorous enough to allow a trace of blood to appear after approximately 15-20 seconds. Wipe off any remaining vaccine with dry sterile gauze. Dispose of all materials in a biohazard waste container; do not reuse the bifurcated needle. All materials must be burned, boiled, or autoclaved. If no evidence of vaccine &ldquo;take&rdquo; (major cutaneous reaction characterized by a pustule at the site of inoculation) is apparent after 6-8 days in patients vaccinated for the first time, the individual may be vaccinated again.  Previously vaccinated patients may not experience a cutaneous response following revaccination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     To prevent transmission of the virus, avoid scratching the vaccination site and cover with gauze (using first aid adhesive tape to keep gauze in place); cover gauze with a semipermeable barrier (eg, semiocclusive dressing) or clothing. Ointment or salves should not be applied to the vaccination site. Good handwashing prevents inadvertent inoculation. Vaccinees should change bandages away from others and launder their own linens separately to prevent transmission.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC,  2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active immunization against smallpox disease in persons determined to be at high risk for smallpox infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Laboratory workers at risk of exposure from cultures or contaminated animals which may be a source of vaccinia or related Orthopoxviruses capable of causing infections in humans (eg, monkeypox, cowpox, variola, vaccinia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Consideration may also be given for vaccination of healthcare workers having contact with clinical specimens, contaminated material, or patients receiving vaccinia or recombinant vaccinia viruses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     In a Pre-Event Vaccination Program, the ACIP recommends vaccination for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Persons designated by authorities to investigate smallpox cases with the likelihood of direct patient contact",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Persons responsible for administering smallpox vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     In the event of an intentional release of smallpox virus, the ACIP recommends vaccination for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Persons exposed to the initial release of the virus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Persons who had close contact with a confirmed or suspected smallpox patient at any time from the onset of the patient's fever until all scabs have separated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Healthcare providers involved in evaluation, care, or transport of confirmed or suspected smallpox patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Laboratory personnel involved in processing specimens of confirmed or suspected smallpox patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Persons likely to have increased contact with infectious materials from smallpox patients",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .  In addition, clinicians may enroll patients with adverse reactions in the CDC Registry at 877-554-4625. Serious adverse reactions to ACAM2000&reg; may also be reported to the manufacturer, Acambis Inc, at 866-440-9440.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (32% to 51%), fatigue (34% to 48%), malaise (28% to 37%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythema (18% to 24%); rash (6% to 11% erythematous, folliculitis, papulovesicular, urticarial, nonspecific)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (10% to 19%), diarrhea (12% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site: Pruritus (82% to 92%), erythema (61% to 74%), pain (37% to 67%), edema (28% to 48%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (27% to 46%), rigors (12% to 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Lymph node pain (19% to 57%), feeling hot (20% to 32%), exercise tolerance decreased (8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (6%), vomiting (3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Lymphadenopathy (6% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined: Abdominal pain, Bell's palsy, blindness, cardiomyopathy (nonischemic/dilated), contact dermatitis, corneal scarring, death, dizziness, eczema vaccinatum, encephalitis, encephalomyelitis, encephalopathy, erythema multiforme, fever, generalized vaccinia, Guillain-Barr&eacute; syndrome, hypersensitivity reactions; inadvertent inoculation at other sites (including autoinoculation to eyelid, face, genitalia, lips, mouth, nose, rectum); ischemic heart disease, keratitis, meningitis, myelitis, myocarditis,  myopericarditis (asymptomatic or symptomatic), ocular vaccinia, paresthesia, pericarditis, photophobia, progressive vaccinia, secondary pyogenic infection, seizure, Stevens-Johnson syndrome, toothache, vaccinial skin infection, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F221450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Manufacturer labeling: Severe immune deficiency (eg, persons undergoing bone marrow transplant, individuals with primary or acquired immunodeficiency requiring isolation). There are very few absolute contraindications regarding vaccination of individuals at high-risk for exposure to smallpox. The decision to vaccinate must be based on a careful analysis of potential benefits and possible risks.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     ACIP contraindications in a pre-event vaccination program: Hypersensitivity to the vaccine or any component of the formulation; history or presence of atopic dermatitis, eczema or other acute, chronic or exfoliative skin conditions (or persons with household contacts with these conditions); immunosuppression (or persons with household contacts who are immunosuppressed); pregnant or breast-feeding women (or household contacts of pregnant women); children &lt;1 year of age",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     According to ACIP, persons exposed to smallpox virus in an emergency situation have no contraindications to vaccination.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F221435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal. Personnel responsible for preparation and administration should observe appropriate contact precautions to avoid inadvertent inoculation (eg, wear surgical or protective gloves and avoid contact of vaccine with skin, eyes or mucous membranes). Dispose of all materials for preparation and administration in a biohazard waste container. All materials must be burned, boiled, or autoclaved. Vaccinees should change bandages away from others and launder their own linens separately to prevent transmission.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Encephalitis:",
"     <b>",
"      [U.S. Boxed Warning]: Following vaccination, encephalitis, encephalomyelitis, and encephalopathy have been observed.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopericarditis:",
"     <b>",
"      [U.S. Boxed Warning]: Following vaccination, acute myocarditis and/or pericarditis have been observed.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular complications: [",
"     <b>",
"      U.S. Boxed Warning]: Patients with eye diseases requiring treatment with steroids may be at increased risk for adverse reactions.",
"     </b>",
"     Following vaccination, accidental infection of the eye may occur (due to touching or rubbing of the eye) resulting in keratitis, corneal scarring, and blindness. Patients using ophthalmic steroids may be at an increased risk for ocular vaccinia. In a nonemergency situation, the ACIP recommends deferring vaccination in persons with an eye condition requiring steroid treatment until the condition resolves and treatment is complete.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin and systemic reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Following vaccination, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, and erythema multiforme major (including Stevens-Johnson syndrome) have been observed.",
"     </b>",
"     Vaccinia immune globulin (VIG) is available for treatment of vaccinia. Cidofovir is also available from the CDC under the Investigational New Drug protocol for treatment of vaccinia post-smallpox vaccination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Patients with or with a history of cardiovascular disease and patients at risk for cardiovascular disease (eg, hypertension, hyperlipidemia, diabetes, and family history) may be at an increased risk for severe adverse reactions.",
"     </b>",
"     Persons with cardiac disease include those with a previous MI, heart failure, cardiomyopathy, chest pain or shortness of breath with activity, stroke, TIA, or those with 3 or more risk factors for ischemic coronary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Eczema:",
"     <b>",
"      [U.S. Boxed Warning]: Following vaccination, eczema vaccinatum has been reported. Patients with eczema, a history of eczema, or other acute or chronic exfoliative skin conditions may be at an increased risk for severe skin infections;",
"     </b>",
"     these patients should not be vaccinated in nonemergency situations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence:",
"     <b>",
"      [U.S. Boxed Warning]: Patients with congenital or acquired immune deficiency disorders (including those on immunosuppressive medications) are at increased risk for severe adverse reactions.",
"     </b>",
"     Use in patients with severe immune deficiency may result in progressive vaccinia and is, therefore, contraindicated by the manufacturer. The ACIP recommends that these patients not be vaccinated in nonemergency situations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established for use in children &lt;16 years of age; recommendations are based on previously available vaccine.",
"     <b>",
"      [U.S. Boxed Warning]: Infants &lt;12 months of age may be at increased risk for severe adverse reactions.",
"     </b>",
"     Per the ACIP, vaccine is contraindicated for use in infants &lt;12 months of age (nonemergency situation) and use is not recommended in pediatric patients &lt;18 years of age (nonemergency situations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Pregnant women are at increased risk for severe adverse reactions  and should not be vaccinated in nonemergency situations.",
"     </b>",
"     <i>",
"      In utero",
"     </i>",
"     transmission of virus has been observed. Pregnant women should be warned about the possibility of inadvertent transmission of vaccinia virus from others who have recently been vaccinated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin: Some dosage forms may contain human albumin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neomycin: Products may contain neomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polymyxin B: Products may contain polymyxin B.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For percutaneous administration only. Vaccination is given by scarification (multiple punctures into superficial layers of the skin) only.",
"     <b>",
"      Not for I.M., I.V., or SubQ injection.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of vaccination complications must be weighed against the risk of experiencing a potentially fatal smallpox infection.",
"     </b>",
"     Patients at greatest risk for adverse reactions from the vaccine are also at increased risk for death from smallpox infection. Recommendations for use in response to bioterrorism are regularly updated by the CDC, and may be found at www.cdc.gov.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood and organ donation: Patients should be advised not to donate blood or organs for 21-30 days following vaccination; contacts who have inadvertently contracted vaccinia should avoid donating blood for 14 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transmission of virus:",
"     <b>",
"      [U.S. Boxed Warning]: Live vaccinia virus may be transmitted to close contacts of the vaccinee; risks for the close contact are the same as those receiving the vaccine.",
"     </b>",
"     Virus may be cultured from vaccination sites until scab separates from lesion; viral shedding ceases once the lesion is re-epithelialized (~14-21 days after vaccination). Individuals should be instructed to avoid contact with patients at high risk of transmission/adverse effects,  including breast-feeding women and patients with eczema or immunodeficiency during this time.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus Vaccine: Smallpox Vaccine may enhance the adverse/toxic effect of Varicella Virus Vaccine. It may be difficult to determine which vaccine caused skin lesions or other adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F221453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Pregnant women are at increased risk for severe adverse reactions.",
"     </b>",
"     Animal reproduction studies have not been conducted with this vaccine. Vaccinia vaccine has not been associated with the development of congenital malformations. On rare occasions, vaccination has been reported to cause fetal infection. Fetal vaccinia infection is associated with stillbirth or neonatal mortality. Vaccination of pregnant women is not recommended in a pre-event setting. Pregnancy should be avoided for at least 4 weeks following vaccination. Healthcare providers may enroll pregnant women who were inadvertently vaccinated during pregnancy (or who were a close contact of a vaccinee within 4 weeks of vaccination) in the CDC pregnancy registry by calling 404-639-8253 or 877-554-4625. Military cases should be reported to the Department of Defense.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F221465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F221454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in a breast-feeding woman in a nonemergency situation. Breast-feeding should be interrupted if the vaccine is administered in an emergency situation. Breast-feeding women should take precautions to avoid inadvertent contact with a vaccinee. One case of tertiary transfer to an infant has been reported following secondary transfer to a breast-feeding woman.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F221442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primary vaccines: Monitor vaccination site; inspect after 6-8 days. Evidence of a major reaction (vesicular or pustular lesion or an area of palpable induration surrounding a central lesion) confirms success of vaccination. An equivocal reaction (all responses other than a major reaction) requires revaccination in patients undergoing primary vaccination only (preferably with another vial or vaccine lot, if available). Consult CDC or state or local health department if response to a second vaccination from a different vial or lot is equivocal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Revaccination: Successful vaccination is confirmed when a major cutaneous reaction is observed 6-8 days postvaccination. Prior vaccinations may reduce the cutaneous response and does not necessarily indicate a vaccination failure. A revaccinated individual without a cutaneous response does not require revaccination.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F221434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vaccinia virus is similar to the variola (smallpox) virus. By inducing a localized infection with vaccinia virus, immunity to both vaccinia and variola is achieved. Vaccination results in viral replication, production of neutralizing antibodies, immunity, and cellular hypersensitivity; revaccination is recommended every 3-10 years (depending on type of anticipated exposure) to maintain immunity in patients eligible for pre-event vaccination.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F221449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Neutralizing antibodies appear 15-20 days after vaccination; time to appearance of neutralizing antibodies may be shorter (~7 days) following revaccination (CDC, 2001).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Blendon RJ, DesRoches CM, Benson JM, et al, &ldquo;The Public and the Smallpox Threat,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(5):426-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/24/18823/abstract-text/12496352/pubmed\" id=\"12496352\" target=\"_blank\">",
"        12496352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bozzette SA, Boer R, Bhatnagar V, et al, &ldquo;A Model for a Smallpox-Vaccination Policy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(5):416-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/24/18823/abstract-text/12496353/pubmed\" id=\"12496353\" target=\"_blank\">",
"        12496353",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/24/18823/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Recommendations for Using Smallpox Vaccine in a Pre-Event Vaccination Program. Supplemental Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC),&rdquo;",
"      <i>",
"       MMWR",
"      </i>",
"      , 2003, 52(Dispatch):1-16. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/m2d226.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/m2d226.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Secondary and Tertiary Transfer of Vaccinia Virus Among U.S. Military Personnel, United States and Worldwide, 2002-2004,&rdquo;",
"      <i>",
"       MMWR",
"      </i>",
"      , 2004, 53(5):103-5. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5305a3.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5305a3.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/24/18823/abstract-text/14961003/pubmed\" id=\"14961003\" target=\"_blank\">",
"        14961003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cono J, Casey CG, Bell DM, et al, &ldquo;Smallpox Vaccination and Adverse Reactions. Guidance for Clinicians,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR-4):1-28.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eckart RE, Love SS, Atwood JE, et al, &ldquo;Incidence and Follow-up of Inflammatory Cardiac Complications After Smallpox Vaccination,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2004, 44(1):201-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/24/18823/abstract-text/15234435/pubmed\" id=\"15234435\" target=\"_blank\">",
"        15234435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parrino J and Graham BS, &ldquo;Smallpox Vaccines: Past, Present , and Future,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2006, 118(6):1320-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/24/18823/abstract-text/17157663/pubmed\" id=\"17157663\" target=\"_blank\">",
"        17157663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/24/18823/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rotz LD, Dotson DA, Damon IK, et al, &ldquo;Vaccinia (Smallpox) Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2001, Jun 50(RR-10):1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/24/18823/abstract-text/15580803/pubmed\" id=\"15580803\" target=\"_blank\">",
"        15580803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sepkowitz KA, &ldquo;How Contagious is Vaccinia?&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(5):439-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/24/18823/abstract-text/12496351/pubmed\" id=\"12496351\" target=\"_blank\">",
"        12496351",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Smallpox Vaccine,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2003, 45(1147):1-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/24/18823/abstract-text/12515951/pubmed\" id=\"12515951\" target=\"_blank\">",
"        12515951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/24/18823/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10175 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18823=[""].join("\n");
var outline_f18_24_18823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709414\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221461\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221473\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221463\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221470\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062221\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221445\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221432\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234330\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874989\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221447\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221446\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221471\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221450\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221435\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300047\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221439\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221441\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221453\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221465\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221454\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221442\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221434\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221449\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10175\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10175|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/37/2641?source=related_link\">",
"      Smallpox vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_24_18824="Motion sickness";
var content_f18_24_18824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Motion sickness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/24/18824/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/24/18824/contributors\">",
"     Adrian J Priesol, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/24/18824/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/24/18824/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/24/18824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/24/18824/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/24/18824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motion sickness is a syndrome that occurs in response to real or perceived motion, which can include gastrointestinal, central nervous system, and autonomic symptoms.",
"   </p>",
"   <p>",
"    Motion sickness is considered a physiologic form of dizziness, since it is not indicative of a disease process and can be induced in nearly all normal human subjects. There is enormous variability in susceptibility to motion sickness, as it may be produced with minimal provocation in some individuals but can be very difficult to elicit in others.",
"   </p>",
"   <p>",
"    The symptoms of motion sickness were first described by Hippocrates. They frequently occur during boat travel, and the principal symptom (nausea) is derived from the Greek word for ship (naus).",
"   </p>",
"   <p>",
"    This topic discusses the pathogenesis, clinical presentation, treatment and prevention of motion sickness. A possibly related disorder, disembarkment syndrome, and other causes of vertigo and dizziness are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=see_link\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The brain receives numerous inputs that are used to estimate the motion and spatial orientation of the head. The principal sensory signals that contribute to this process are vestibular cues from the labyrinth, visual information, and somatosensory cues. Afferent information derived from the labyrinth encodes both angular motion (sensed by the semicircular canals) and linear acceleration and gravitational force (sensed by the otolith organs).",
"   </p>",
"   <p>",
"    During active movements such as locomotion, the motor command generated by the brain (sometimes referred to as a corollary discharge or efference copy) is also used to estimate the motion of the head and body. During self-generated movements in normal subjects, the motor command and sensory feedback are congruent, and the brain can generate a stable and accurate estimate of head motion and orientation.",
"   </p>",
"   <p>",
"    In the absence of active movements, the brain's estimate of motion is primarily based upon vestibular, visual, and somatosensory information. When these three sensory cues are not congruent, a sensory conflict is generated in the brain, and it is hypothesized that this conflict underlies the symptoms of motion sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, if the visual system indicates that a person is stationary (eg, viewing the interior of a cabin on a ship), but the vestibular system senses ongoing head movements (eg, due to motion of the ship), the vestibular and visual cues conflict and engender symptoms of motion sickness. Furthermore, if the semicircular canals and otolith organs produce sensory cues that are incongruous, motion sickness can be evoked that is independent of vision.",
"   </p>",
"   <p>",
"    Similarly, if the visual system indicates movement (eg, moving a microscope slide, engaging in virtual reality games or rides, watching a point-of-view movie) but the vestibular system does not, an illusory sense of motion, referred to as vection, can be evoked. This can sometimes result in motion sickness in the absence of physical movement.",
"   </p>",
"   <p>",
"    Labyrinthine inputs are clearly crucial to the development of motion sickness, since experimental animals with inactivated semicircular canals or otolith organs do not develop the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], nor did a group of deaf subjects who were presumed to lack peripheral vestibular function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/6\">",
"     6",
"    </a>",
"    ]. Conversely, blind subjects have a predilection to motion sickness similar to those with normal vision, suggesting that the contribution of visual information to this syndrome is less critical [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/7\">",
"     7",
"    </a>",
"    ]. Movements that are most likely to elicit motion sickness include low frequency rotations and translations and novel motion patterns, particularly those involving head rotations about two axes simultaneously (resulting in cross-coupled, or Coriolis forces) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anatomic basis for motion sickness is not well understood. It is presumed to depend upon connections between the central vestibular system in the brainstem and cerebellum and the autonomic and emetic centers in the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/9\">",
"     9",
"    </a>",
"    ]. Projections from the nodulus and uvula of the cerebellum to the brainstem that modulate a central vestibular process referred to as \"velocity storage\" may be critical for the development of motion sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Histamine, acetylcholine, and norepinephrine appear to be the critical neurotransmitters involved in the production of motion sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/12\">",
"     12",
"    </a>",
"    ]. GABA also plays a role in motion sickness through effects on the velocity storage integrator [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motion sickness can be induced in almost all people with sufficient provocation. Individuals vary in their susceptibility to motion sickness, and certain characteristics show some correlation with this susceptibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sex &mdash; Women are generally more susceptible to motion sickness than men, but the incidence varies substantially with age [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age &mdash; Children less than two years old are typically resistant to motion sickness; the incidence peaks at approximately 12 years of age, and then decreases throughout adulthood.",
"     </li>",
"     <li>",
"      Hormonal factors &mdash; Pregnant women are particularly susceptible to motion sickness; susceptibility may also be affected by the menstrual cycle and by use of oral contraceptives [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other sensory illness &mdash; Diseases that alter vestibular or visual sensory cues (eg, labyrinthitis) may make subjects more sensitive to head motion and visual stimulation than the normal population. In addition, disorders that increase the sensitivity of the brain to sensory stimuli (eg, migraine) are associated with more prominent symptoms of motion sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Migraine &mdash; Migraine sufferers are more susceptible to motion sickness. In one study, 50 percent of migraine sufferers reported a history of motion sickness versus 20 percent of persons with tension headache [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/18\">",
"       18",
"      </a>",
"      ]. Symptoms of motion sickness in migraineurs may be movement or visually induced [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/19\">",
"       19",
"      </a>",
"      ]. A relationship between the trigeminal system and the vestibular nuclei may play a role in both migraine and motion sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reduced brain serotonin may be important in both motion sickness and migraine. In one study, migraine sufferers and control subjects were given an amino acid drink that contained or omitted L-tryptophan (required for the synthesis of serotonin) after which motion sickness was induced by the visual illusion of movement. Tryptophan depletion (reduced brain serotonin) resulted in increased symptoms of motion sickness in the control group to levels similar to that of the migraineurs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/22\">",
"     22",
"    </a>",
"    ]. In a small randomized pilot study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/14/29925?source=see_link\">",
"     rizatriptan",
"    </a>",
"    , a triptan serotonin agonist, prevented the development of motion sickness symptoms in patients with migrainous vertigo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychosocial &mdash; Expectations and other psychological factors may affect the risk of motion sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/24\">",
"       24",
"      </a>",
"      ]. A controlled trial found that naval cadets who were told they were unlikely to experience seasickness were at decreased risk of developing motion sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type of motion &mdash; As discussed above, low frequency motion and certain directions of motion are more likely to induce motion sickness. In a study of air travelers, the magnitude of low frequency lateral and vertical motion was associated with motion sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Body position &mdash; Lying supine, at least on a ship, may decrease susceptibility to motion sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Food &mdash; There are conflicting data on whether eating and drinking (and the type of food or drink) affect the risk of motion sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/26,28-30\">",
"       26,28-30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motion sickness can be induced in nearly all adults, so the incidence of motion sickness depends upon the specific conditions encountered. The following observations illustrate the findings in different settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 20,029 passengers on 114 voyages at sea (six ships, two hovercraft, and one jet foil), 7 percent experienced vomiting, 21 percent felt \"slightly unwell,\" 4 percent felt \"quite ill,\" and 4 percent felt \"absolutely dreadful\" [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 923 passengers on 38 commercial airline flights, 0.5 percent reported vomiting, 8.4 percent reported nausea, and 16.2 percent reported illness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of motion sickness is easily recognized, since it includes stereotypic symptoms in the setting of passive motion or in the setting of visual perception of motion without actual movement (vection).",
"   </p>",
"   <p>",
"    The principal symptoms are a nonvertiginous sense of dizziness, nausea, belching, increased salivation, warmth, and diaphoresis, and a general feeling of malaise [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/15,31\">",
"     15,31",
"    </a>",
"    ]. The initial symptoms may be reported as a sense of being aware of one's stomach. Hyperventilation is a common associated feature and can induce dyspnea, paresthesias, and feelings of impending doom.",
"   </p>",
"   <p>",
"    Physical signs usually cannot be detected, although pallor may be present. Subtle autonomic changes can be quantified with appropriate testing, and include increased perspiration, slowing of gastric emptying, and postural hypotension.",
"   </p>",
"   <p>",
"    Motion sickness tends to improve or resolve with repeated exposure to the inciting stimulus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/32\">",
"     32",
"    </a>",
"    ]. In a study of pilots undergoing flight simulator training, 47 percent of pilots reported motion sickness during their first flight and 24 percent during their last flight [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms typically subside after 36 to 72 hours of continuous exposure to a stimulus, but they can recur on returning to the pre-exposure environment (ie, returning to land after a sea voyage) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of interventions can be used to prevent or alleviate motion sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/34\">",
"     34",
"    </a>",
"    ]. Treatments may be more effective when used for prevention rather than after symptoms have developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Environmental modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since conflicting sensory cues are believed to induce the symptoms of motion sickness, a straightforward treatment approach is to minimize the discrepancy between these cues. If visual and vestibular information are congruent, motion sickness is less likely to occur.",
"   </p>",
"   <p>",
"    Labyrinthine cues cannot be readily manipulated, so this approach is based on providing visual information that contains equivalent motion information to that sensed by the vestibular system. Since the labyrinth senses motion in an inertial (earth-fixed) reference frame, this can be accomplished by viewing an earth-fixed environment during motion rather than a head-fixed environment. As an example, motion sickness on a ship is reduced if passengers view the horizon or land masses from the deck rather than their cabin. Similarly, passengers in a car should sit in the front seat and look through the window rather than sitting in the rear and focusing on an object moving with the interior of the car (such as a book).",
"   </p>",
"   <p>",
"    Motion sickness does not occur during self-generated movements under normal conditions, so a second way to reduce the susceptibility to these symptoms is to control the motion of the vehicle. The driver of a car is less prone to motion sickness than a passenger, presumably because the driver's brain can utilize the motor commands related to controlling the car to predict in an approximate manner the motion of the head.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug therapies can be used to suppress conflicting sensory cues in the brain regions that process afferent signals or to treat nausea. In general, the effectiveness of medications depends upon inhibition of activity in the vestibular nuclei, where labyrinthine and visual sensory cues are combined and synthesized. Drugs that reduce activity in the vestibular nuclei include antihistamines, anticholinergics, and benzodiazepines; other medications that reduce motion sickness include antidopaminergics and sympathomimetics (",
"    <a class=\"graphic graphic_table graphicRef67413 \" href=\"UTD.htm?14/19/14651\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/15,35\">",
"     15,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, medications should be taken before passive motion begins, since they are less effective in relieving symptoms that have already developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of antihistamines can be used to treat motion sickness, and their effect is probably related to their anticholinergic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/15\">",
"     15",
"    </a>",
"    ]. Medications include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/46/12006?source=see_link\">",
"     dimenhydrinate",
"    </a>",
"    (Dramamine),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/36\">",
"     36",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"     meclizine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/54/32612?source=see_link\">",
"     cyclizine",
"    </a>",
"    , and cinnarizine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/37\">",
"     37",
"    </a>",
"    ]. Dimenhydrinate is available as a chewable tablet. Cinnarizine is not available in the United States, but is widely used in other countries.",
"   </p>",
"   <p>",
"    Side effects are mainly related to anticholinergic effects and can include sedation, blurred vision, mouth dryness, and, in the elderly, confusion and urinary retention. One small study suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/54/32612?source=see_link\">",
"     cyclizine",
"    </a>",
"    may be less sedating than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/46/12006?source=see_link\">",
"     dimenhydrinate",
"    </a>",
"    at a dose that is equally effective for symptoms of motion sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonsedating antihistamines do not appear to be effective for the treatment of motion sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Anticholinergics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     Scopolamine",
"    </a>",
"    is commonly used for the management of motion sickness. A systematic review of randomized trials concluded that scopolamine is effective for prevention of motion sickness, but that no trials had examined its effectiveness in treating established motion sickness, and that the evidence comparing scopolamine with other treatments was inadequate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least three randomized trials were performed after the systematic review:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of experimentally induced motion sickness in 75 patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"       scopolamine",
"      </a>",
"      was more effective in preventing motion sickness than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"       promethazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"       meclizine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of the prevention of seasickness in 76 naval crew members,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"       scopolamine",
"      </a>",
"      was more effective than cinnarizine, an antihistamine [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/42\">",
"       42",
"      </a>",
"      ]. Although differences were marginally significant, scopolamine was associated with fewer adverse effects than cinnarizine.",
"     </li>",
"     <li>",
"      In a trial of preventing motion sickness in 64 helicopter passengers, the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"       promethazine",
"      </a>",
"      and caffeine appeared to be more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"       scopolamine",
"      </a>",
"      alone [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     Scopolamine",
"    </a>",
"    is most commonly administered as a transdermal patch applied every 72 hours. Side effects include those discussed above (sedation, blurred vision, mouth dryness, and, in older adults, confusion and urinary retention), and scopolamine is contraindicated in people at risk for angle closure glaucoma. Some instances of poor clinical response to scopolamine patches may be due to inadequate transdermal absorption leading to inappropriately low scopolamine levels in the blood [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Antidopaminergics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     Promethazine",
"    </a>",
"    can be used both for prevention and treatment of motion sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/15,45\">",
"     15,45",
"    </a>",
"    ]. In two trials of the prevention of motion sickness cited above, promethazine appeared to be less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    but more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"     meclizine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/41\">",
"     41",
"    </a>",
"    ], and promethazine and caffeine appeared to be more effective than scopolamine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    has also been used for motion sickness, but there is somewhat less evidence for its efficacy than that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects of antidopaminergics include sedation and extrapyramidal effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Sympathomimetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ephedrine and amphetamines have been used both to treat motion sickness and to counteract the sedating effects of other medications [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Effect on performance'",
"    </a>",
"    below.) Ephedrine may have some benefit even after symptoms have developed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/47\">",
"     47",
"    </a>",
"    ]. Amphetamines are controlled substances with potentially significant side effects and the potential for addiction. Although less studied, pseudoephedrine is readily available in the United States including in combination medications with sedating antihistamines.",
"   </p>",
"   <p>",
"    Caffeine may also be of benefit when used in combination with other medications. A randomized trial in 64 patients examined the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    25 mg plus caffeine 200 mg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"     meclizine",
"    </a>",
"    25 mg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    patch 1.5 mg, and an acustimulation wristband [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/43\">",
"     43",
"    </a>",
"    ]. Only the combination of promethazine and caffeine produced a significant decrease in symptoms; the combination also improved reaction times.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other medications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benzodiazepines may be of some benefit for motion sickness, but they are sedating [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Standard antiemetics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      can relieve nausea, which is usually the most prominent symptom of motion sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/49\">",
"       49",
"      </a>",
"      ]. However, in two studies in highly susceptible subjects, one in a laboratory model of simulated rotation and one at sea, ondansetron was ineffective in preventing motion sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15496?source=see_link&amp;anchor=H10#H10\">",
"       \"Migrainous vertigo\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      GABA agonists such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      inhibit the \"velocity storage\" mechanism in the central vestibular system that may be specifically responsible for producing motion sickness. The utility of these drugs has not been extensively studied to date and their potential usefulness is currently based on results from experiments that use complex movements to induce motion sickness and on case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Effect on performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treating motion sickness can be a particular problem in patients who need to perform tasks such as flying a plane or acting as crew on a ship, since most of the medications used are sedating [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/46/12006?source=see_link\">",
"     Dimenhydrinate",
"    </a>",
"    may have particularly negative effects on performance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/54\">",
"     54",
"    </a>",
"    ]. A controlled trial of medications for experimental motion sickness in 67 adults suggested that, at clinically useful doses, the drugs had the following order from best to worst for cognitive side effects:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"     meclizine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One trial found that administering amphetamine, but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    , with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    appeared to prevent the sleepiness and impairment of psychomotor performance seen with promethazine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/56\">",
"     56",
"    </a>",
"    ]. Another trial found that ephedrine decreased sleepiness and improved performance in patients administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    , although it did not add to the effectiveness of chlorpheniramine in treating motion sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, pregnant women may be particularly susceptible to motion sickness. Medications that are felt to be safe for the treatment of morning sickness can also be used for motion sickness. These include the antihistamines (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"     meclizine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/46/12006?source=see_link\">",
"     dimenhydrinate",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    , which is listed as category C in pregnancy by the US Food and Drug Administration (FDA) (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=see_link\">",
"     \"Clinical features and evaluation of nausea and vomiting of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the vestibular response to head motion can decline over time (habituate), if a given motion pattern is presented repetitively. For this reason, physical therapy approaches that utilize recurrent head movements and associated visual cues can sometimes reduce the sensitivity to motion sickness in subjects who are particularly prone to this problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Ginger",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ginger has been used as an alternative medicine to prevent motion sickness. Randomized trials both in experimental motion sickness and in naval cadets at sea have found benefit with pretreatment with one to two grams of ginger [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The mechanism of benefit with ginger appears to be related to its effects on gastric motility rather than the vestibular system [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Acupressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure at the P6 acupressure point on the anterior wrist (three fingerbreadths proximal to the proximal wrist fold, between the palmaris longus and flexor carpi radialis tendons) (",
"    <a class=\"graphic graphic_picture graphicRef82211 \" href=\"UTD.htm?21/28/21956\">",
"     picture 1",
"    </a>",
"    ) either by manual pressure or with a wrist band has been reported to be effective for motion sickness in some [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/62-64\">",
"     62-64",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/65-67\">",
"     65-67",
"    </a>",
"    ], controlled trials. A randomized trial with a device that applies electrical stimulation to the P6 point found no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While these results raise the possibility that acupressure may be of benefit for motion sickness, trials of this sort can be difficult to perform with adequate blinding and allocation concealment. It remains uncertain whether acupressure is effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Magnets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although sometimes promoted for this use, we know of no studies evaluating the efficacy of magnets in the treatment of motion sickness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14313209\">",
"    <span class=\"h3\">",
"     Nicotine deprivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One small observational study found that overnight nicotine deprivation in smokers resulted in a reduction in motion sickness susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18824/abstract/68\">",
"     68",
"    </a>",
"    ]. The effect was most pronounced in subjects who were heavy smokers and with mild to moderate susceptibility to motion sickness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/42/30370?source=see_link\">",
"       \"Patient information: Motion sickness (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Motion sickness is believed to be caused by conflicts between sensory cues regarding perceived motion.",
"     </li>",
"     <li>",
"      Nearly everyone will develop motion sickness with a sufficient stimulus; however, individual susceptibility to motion sickness is variable.",
"     </li>",
"     <li>",
"      Symptoms include a nonvertiginous sense of dizziness, nausea, belching, increased salivation, warmth, diaphoresis, and a general feeling of malaise. With continuous exposure to a stimulus, symptoms typically subside over 36 to 72 hours.",
"     </li>",
"     <li>",
"      Individuals can prevent or treat motion sickness by keeping visual cues congruous with vestibular cues. This can be achieved by looking at the outside world's frame of reference (ie, sit in the front seat and look out the front window in a car or view the horizon from the deck of a ship). Activities that maintain vision within a local frame of reference are particularly provocative for motion sickness (eg, reading a book or watching a video or movie). Self-generated movements do not induce motion sickness, and controlling the motion of a vehicle (eg, driving) reduces the likelihood of motion sickness. Lying supine can decrease motion sickness.",
"     </li>",
"     <li>",
"      Medications with anticholinergic effects (including sedating antihistamines) are most commonly used for treatment of motion sickness; nonsedating antihistamines are not effective.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"       Meclizine",
"      </a>",
"      is probably less sedating than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/46/12006?source=see_link\">",
"       dimenhydrinate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      at an equally effective dose; as a result, the choice of antihistamine can be based in part on whether or not sedation is desired. Transdermal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"       scopolamine",
"      </a>",
"      is effective, and a patch can be worn continuously for 72 hours. Caution must be taken when using medications with anticholinergic effects in the elderly or in patients at risk for angle closure glaucoma. Other medications can also be used (",
"      <a class=\"graphic graphic_table graphicRef67413 \" href=\"UTD.htm?14/19/14651\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Alternative treatments are often considered for motion sickness. Randomized trials suggest that one to two grams of ginger may help prevent motion sickness. There is conflicting evidence on acupressure, but acupressure is safer than many other treatments, and some patients report finding it helpful.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/1\">",
"      Oman CM. Motion sickness: a synthesis and evaluation of the sensory conflict theory. Can J Physiol Pharmacol 1990; 68:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/2\">",
"      Flanagan MB, May JG, Dobie TG. The role of vection, eye movements and postural instability in the etiology of motion sickness. J Vestib Res 2004; 14:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/3\">",
"      Shupak A, Gordon CR. Motion sickness: advances in pathogenesis, prediction, prevention, and treatment. Aviat Space Environ Med 2006; 77:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/4\">",
"      Miller EF 2nd, Graybiel A. Semicircular canals as a primary etiological factor in motion sickness. Aerosp Med 1972; 43:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/5\">",
"      Brizzee KR, Igarashi M. Effect of macular ablation on frequency and latency of motion-induced emesis in the squirrel monkey. Aviat Space Environ Med 1986; 57:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/6\">",
"      James W. The sense of dizziness in deaf-mutes. Am J Otol 1882; 4:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/7\">",
"      Graybiel A. Susceptibility to acute motion sickness in blind persons. Aerosp Med 1970; 41:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/8\">",
"      Woodman PD, Griffin MJ. Effect of direction of head movement on motion sickness caused by Coriolis stimulation. Aviat Space Environ Med 1997; 68:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/9\">",
"      Balaban CD, Porter JD. Neuroanatomic substrates for vestibulo-autonomic interactions. J Vestib Res 1998; 8:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/10\">",
"      Dai M, Kunin M, Raphan T, Cohen B. The relation of motion sickness to the spatial-temporal properties of velocity storage. Exp Brain Res 2003; 151:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/11\">",
"      Cohen B, Dai M, Raphan T. The critical role of velocity storage in production of motion sickness. Ann N Y Acad Sci 2003; 1004:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/12\">",
"      Takeda N, Morita M, Hasegawa S, et al. Neuropharmacology of motion sickness and emesis. A review. Acta Otolaryngol Suppl 1993; 501:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/13\">",
"      Cohen B, Dai M, Yakushin SB, Raphan T. Baclofen, motion sickness susceptibility and the neural basis for velocity storage. Prog Brain Res 2008; 171:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/14\">",
"      Cooper C, Dunbar N, Mira M. Sex and seasickness on the Coral Sea. Lancet 1997; 350:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/15\">",
"      Gahlinger PM. Motion sickness. How to help your patients avoid travel travail. Postgrad Med 1999; 106:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/16\">",
"      Grunfeld E, Gresty MA. Relationship between motion sickness, migraine and menstruation in crew members of a \"round the world\" yacht race. Brain Res Bull 1998; 47:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/17\">",
"      Barabas G, Matthews WS, Ferrari M. Childhood migraine and motion sickness. Pediatrics 1983; 72:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/18\">",
"      Kayan A, Hood JD. Neuro-otological manifestations of migraine. Brain 1984; 107 ( Pt 4):1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/19\">",
"      Drummond PD. Triggers of motion sickness in migraine sufferers. Headache 2005; 45:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/20\">",
"      Marcus DA, Furman JM, Balaban CD. Motion sickness in migraine sufferers. Expert Opin Pharmacother 2005; 6:2691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/21\">",
"      Drummond PD, Granston A. Facial pain increases nausea and headache during motion sickness in migraine sufferers. Brain 2004; 127:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/22\">",
"      Drummond PD. Effect of tryptophan depletion on symptoms of motion sickness in migraineurs. Neurology 2005; 65:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/23\">",
"      Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med Sci Monit 2006; 12:PI1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/24\">",
"      Murray JB. Psychophysiological aspects of motion sickness. Percept Mot Skills 1997; 85:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/25\">",
"      Eden D, Zuk Y. Seasickness as a self-fulfilling prophecy: raising self-efficacy to boost performance at sea. J Appl Psychol 1995; 80:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/26\">",
"      Turner M, Griffin MJ, Holland I. Airsickness and aircraft motion during short-haul flights. Aviat Space Environ Med 2000; 71:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/27\">",
"      Gahlinger PM. Cabin location and the likelihood of motion sickness in cruise ship passengers. J Travel Med 2000; 7:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/28\">",
"      Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat Space Environ Med 1988; 59:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/29\">",
"      Lindseth G, Lindseth PD. The relationship of diet to airsickness. Aviat Space Environ Med 1995; 66:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/30\">",
"      Hu S, Lagomarsino JJ, Luo YJ. Drinking milk or water has no effect on the severity of optokinetic rotation-induced symptoms of motion sickness. Aviat Space Environ Med 1998; 69:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/31\">",
"      Money KE. Motion sickness. Physiol Rev 1970; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/32\">",
"      Spinks AB, Wasiak J, Villanueva EV, Bernath V. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev 2007; :CD002851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/33\">",
"      Ungs TJ. Simulator induced syndrome in Coast Guard aviators. Aviat Space Environ Med 1988; 59:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/34\">",
"      Murdin L, Golding J, Bronstein A. Managing motion sickness. BMJ 2011; 343:d7430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/35\">",
"      Brandt T, Dichgans J, Wagner W. Drug effectiveness on experimental optokinetic and vestibular motion sickness. Aerosp Med 1974; 45:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/36\">",
"      Buckey JC, Alvarenga D, Cole B, Rigas JR. Chlorpheniramine for motion sickness. J Vestib Res 2004; 14:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/37\">",
"      Lucertini M, Mirante N, Casagrande M, et al. The effect of cinnarizine and cocculus indicus on simulator sickness. Physiol Behav 2007; 91:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/38\">",
"      Weinstein SE, Stern RM. Comparison of marezine and dramamine in preventing symptoms of motion sickness. Aviat Space Environ Med 1997; 68:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/39\">",
"      Kohl RL, Homick JL, Cintron N, Calkins DS. Lack of effects of astemizole on vestibular ocular reflex, motion sickness, and cognitive performance in man. Aviat Space Environ Med 1987; 58:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/40\">",
"      Cheung BS, Heskin R, Hofer KD. Failure of cetirizine and fexofenadine to prevent motion sickness. Ann Pharmacother 2003; 37:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/41\">",
"      Dornhoffer J, Chelonis JJ, Blake D. Stimulation of the semicircular canals via the rotary chair as a means to test pharmacologic countermeasures for space motion sickness. Otol Neurotol 2004; 25:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/42\">",
"      Gil A, Nachum Z, Tal D, Shupak A. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study. Clin Neuropharmacol 2012; 35:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/43\">",
"      Estrada A, LeDuc PA, Curry IP, et al. Airsickness prevention in helicopter passengers. Aviat Space Environ Med 2007; 78:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/44\">",
"      Gil A, Nachum Z, Dachir S, et al. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors. Aviat Space Environ Med 2005; 76:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/45\">",
"      Davis JR, Jennings RT, Beck BG, Bagian JP. Treatment efficacy of intramuscular promethazine for space motion sickness. Aviat Space Environ Med 1993; 64:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/46\">",
"      Kohl RL. Failure of metoclopramide to control emesis or nausea due to stressful angular or linear acceleration. Aviat Space Environ Med 1987; 58:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/47\">",
"      Wood CD, Stewart JJ, Wood MJ, et al. Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness. Aviat Space Environ Med 1990; 61:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/48\">",
"      McClure JA, Lycett P, Baskerville JC. Diazepam as an anti-motion sickness drug. J Otolaryngol 1982; 11:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/49\">",
"      Benline TA, French J, Poole E. Anti-emetic drug effects on pilot performance: granisetron vs. ondansetron. Aviat Space Environ Med 1997; 68:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/50\">",
"      Muth ER, Elkins AN. High dose ondansetron for reducing motion sickness in highly susceptible subjects. Aviat Space Environ Med 2007; 78:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/51\">",
"      Hershkovitz D, Asna N, Shupak A, et al. Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea. Aviat Space Environ Med 2009; 80:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/52\">",
"      Nicholson AN, Stone BM, Turner C, Mills SL. Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med 2002; 73:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/53\">",
"      Cowings PS, Toscano WB, DeRoshia C, Miller NE. Promethazine as a motion sickness treatment: impact on human performance and mood states. Aviat Space Environ Med 2000; 71:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/54\">",
"      Gordon CR, Gonen A, Nachum Z, et al. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. J Psychopharmacol 2001; 15:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/55\">",
"      Paule MG, Chelonis JJ, Blake DJ, Dornhoffer JL. Effects of drug countermeasures for space motion sickness on working memory in humans. Neurotoxicol Teratol 2004; 26:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/56\">",
"      Paul MA, MacLellan M, Gray G. Motion-sickness medications for aircrew: impact on psychomotor performance. Aviat Space Environ Med 2005; 76:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/57\">",
"      Buckey JC Jr, Alvarenga DL, MacKenzie TA. Chlorpheniramine and ephedrine in combination for motion sickness. J Vestib Res 2007; 17:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/58\">",
"      Gr&oslash;ntved A, Brask T, Kambskard J, Hentzer E. Ginger root against seasickness. A controlled trial on the open sea. Acta Otolaryngol 1988; 105:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/59\">",
"      Lien HC, Sun WM, Chen YH, et al. Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. Am J Physiol Gastrointest Liver Physiol 2003; 284:G481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/60\">",
"      Holtmann S, Clarke AH, Scherer H, H&ouml;hn M. The anti-motion sickness mechanism of ginger. A comparative study with placebo and dimenhydrinate. Acta Otolaryngol 1989; 108:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/61\">",
"      Ghayur MN, Gilani AH. Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders. Dig Dis Sci 2005; 50:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/62\">",
"      Hu S, Stritzel R, Chandler A, Stern RM. P6 acupressure reduces symptoms of vection-induced motion sickness. Aviat Space Environ Med 1995; 66:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/63\">",
"      Stern RM, Jokerst MD, Muth ER, Hollis C. Acupressure relieves the symptoms of motion sickness and reduces abnormal gastric activity. Altern Ther Health Med 2001; 7:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/64\">",
"      Bertalanffy P, Hoerauf K, Fleischhackl R, et al. Korean hand acupressure for motion sickness in prehospital trauma care: a prospective, randomized, double-blinded trial in a geriatric population. Anesth Analg 2004; 98:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/65\">",
"      Bruce DG, Golding JF, Hockenhull N, Pethybridge RJ. Acupressure and motion sickness. Aviat Space Environ Med 1990; 61:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/66\">",
"      Warwick-Evans LA, Masters IJ, Redstone SB. A double-blind placebo controlled evaluation of acupressure in the treatment of motion sickness. Aviat Space Environ Med 1991; 62:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/67\">",
"      Miller KE, Muth ER. Efficacy of acupressure and acustimulation bands for the prevention of motion sickness. Aviat Space Environ Med 2004; 75:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18824/abstract/68\">",
"      Golding JF, Prosyanikova O, Flynn M, Gresty MA. The effect of smoking nicotine tobacco versus smoking deprivation on motion sickness. Auton Neurosci 2011; 160:53.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6853 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18824=[""].join("\n");
var outline_f18_24_18824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Environmental modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Anticholinergics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Antidopaminergics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Sympathomimetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Effect on performance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Ginger",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Acupressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Magnets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14313209\">",
"      - Nicotine deprivation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6853\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6853|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/28/21956\" title=\"picture 1\">",
"      P6 acupressure point",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6853|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/19/14651\" title=\"table 1\">",
"      Motion sickness pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 2\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=related_link\">",
"      Clinical features and evaluation of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15496?source=related_link\">",
"      Migrainous vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=related_link\">",
"      Pathophysiology, etiology, and differential diagnosis of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/42/30370?source=related_link\">",
"      Patient information: Motion sickness (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_24_18825="Antiretroviral medications in pregnancy: Protease inhibitors";
var content_f18_24_18825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiretroviral medications in pregnancy: Protease inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/24/18825/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/24/18825/contributors\">",
"     Elaine J Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/24/18825/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/24/18825/contributors\">",
"     Lynne M Mofenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/24/18825/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/24/18825/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/24/18825/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy should not preclude the use of an optimal antiretroviral therapy regimen for the control of HIV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. An additional goal is to decrease the risk of perinatal transmission of HIV infection. Thus, all pregnant women, regardless of immunologic or virologic parameters, are treated with antiretroviral therapy to prevent perinatal transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, certain medications are favored over others due to better safety profiles. Pharmacokinetic data are also an important consideration; physiologic changes during pregnancy lead to alterations in drug serum concentrations, which sometimes lead to changes in drug dosing.",
"   </p>",
"   <p>",
"    This topic will address the animal and human clinical data on the safety of the HIV protease inhibitors. Information on breastfeeding, counseling of pregnant women, and perinatal transmission of HIV are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=see_link\">",
"     \"Prevention of HIV transmission during breastfeeding in resource-limited settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS OF PROTEASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several side effects that appear to be PI class effects, whereas others are agent specific. Some of the class side effects are insulin resistance, hyperglycemia, diabetes, hyperlipidemia, lipodystrophy, hepatotoxicity, and side effects caused by interactions with other hepatically-metabolized drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear if pregnancy increases the risk of diabetes related to protease inhibitor use. The majority of data to date have not shown an increased risk of glucose intolerance with protease inhibitor therapy during pregnancy. A recent prospective study including detailed evaluations for glucose intolerance and insulin resistance among HIV-infected pregnant women did not find differences between women on PI or non-PI regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the rate of impaired glucose tolerance was high (38 percent) in both groups, possibly related to high body weights and ethnic composition of the study group. It is recommended that all HIV-infected women have standard testing of glucose tolerance between 24 and 48 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical information on the safety of protease inhibitors in pregnancy varies by the specific agent, as discussed below. Health professionals are encouraged to contact the Antiretroviral Pregnancy Registry to prospectively report antiretroviral exposures in pregnancy to assist in monitoring pregnancy outcomes of pregnant women exposed to antiretroviral medications (1-800-258-4263 or",
"    <a class=\"external\" href=\"file://www.apregistry.com/\">",
"     www.APRegistry.com",
"    </a>",
"    ). The registry is anonymous. Information is compiled from case reports and updated every six months for public review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AVAILABLE PROTEASE INHIBITOR AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available protease inhibitor agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       Atazanavir",
"      </a>",
"      (Reyataz)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       Darunavir",
"      </a>",
"      (Prezista)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"       Fosamprenavir",
"      </a>",
"      (Lexiva)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       Indinavir",
"      </a>",
"      (Crixivan)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      (Kaletra)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"       Nelfinavir",
"      </a>",
"      (Viracept)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       Ritonavir",
"      </a>",
"      (Norvir)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"       Saquinavir",
"      </a>",
"      (Invirase)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"       Tipranavir",
"      </a>",
"      (Aptivus)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ATAZANAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    (Reyataz) is classified as a FDA pregnancy category B drug (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?8/51/9013?source=see_link\">",
"     \"Atazanavir: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Carcinogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two-year carcinogenicity studies in mice and rats have demonstrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In female mice, the incidence of benign hepatocellular adenomas was increased at systemic exposures sevenfold higher than those in humans at the recommended therapeutic dose. There were no increases in the incidence of tumors in male mice at any dose.",
"     </li>",
"     <li>",
"      In rats, no significant positive trends in the incidence of neoplasms occurred at systemic exposures up to sixfold higher than those in humans at the recommended therapeutic dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Reproduction/fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effect has been seen on reproductive performance, fertility, or embryo survival in rats at",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    exposures up to twice those of human therapeutic exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    did not produce teratogenic effects in rabbits or rats at systemic drug exposure achieved in humans at the recommended therapeutic dose. Maternal dosing in rats, which produced drug exposure similar to therapeutic doses in humans, did not affect offspring. In the Antiretroviral Pregnancy Registry, no increase in the risk of birth defects over the general population has been observed with first trimester exposure to atazanavir [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    crosses the placenta, as shown by maternal and umbilical cord blood sampling at delivery, but levels are low (10 percent of maternal serum levels) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    is excreted in the milk of lactating rats; it is not known if it is excreted in human milk. In a small study in three women, the median ratio of breast milk to maternal plasma atazanavir was 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Human studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    in pregnancy. Elevation in indirect (unconjugated) bilirubin occurs frequently in adults and children. This is attributable to atazanavir-related inhibition of hepatic UDP glucuronsyl transferase enzyme. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few data as to whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    therapy would exacerbate physiologic hyperbilirubinemia in the neonate. One study examined atazanavir pharmacokinetics in 17 women during the third trimester of pregnancy and demonstrated that therapeutic drug concentrations were above the 90 percent inhibitory concentration (IC) for wild-type HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/4\">",
"     4",
"    </a>",
"    ]. None of the infants required phototherapy for hyperbilirubinemia, and all were uninfected.",
"   </p>",
"   <p>",
"    There have been no pharmacokinetic studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    in neonates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DARUNAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     Darunavir",
"    </a>",
"    (Prezista) is classified as a FDA pregnancy category B drug (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Carcinogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic adenomas and carcinomas in male mice and thyroid neoplasms have occurred in mice and rats, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     Darunavir",
"    </a>",
"    was not mutagenic or genotoxic in a battery of in vitro and in vivo assays.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reproduction/fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies to date in animals have not demonstrated any adverse consequences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;No embryotoxicity or teratogenicity has been seen in mice or rats at drug levels approximately 50 percent of that achieved in humans, nor in rabbits at drug levels 5 percent of that achieved in humans at the recommended therapeutic dose. Bioavailability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    in animals is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unknown",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     Darunavir",
"    </a>",
"    is excreted in the milk of lactating rats; it is not known if it is excreted in human milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Human data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    during pregnancy are limited to several case reports that have described successful maternal viral suppression and prevention of transmission with typical dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The infants in these reports had no congenital or major metabolic anomalies. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FOSAMPRENAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     Fosamprenavir",
"    </a>",
"    (Lexiva) is classified as a FDA pregnancy category C drug (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?32/5/32853?source=see_link\">",
"     \"Fosamprenavir: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Carcinogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     Fosamprenavir",
"    </a>",
"    was not mutagenic or genotoxic in a battery of in vitro and in vivo assays.",
"   </p>",
"   <p>",
"    Studies in mice and rats demonstrate an increase in the incidence of benign hepatocellular adenomas, hepatocellular carcinoma and thyroid follicular cell adenomas. In rats only, there was an increase in uterine endometrial adenocarcinoma. The relevance of these findings for humans is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Reproduction/fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;No impairment of fertility or mating was seen in rats at doses providing three to four times the human exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    alone or exposure similar to that with fosamprenavir and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    dosing in humans. No affect was seen on the development or maturation of sperm in rats at these doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;No embryo-fetal effects were demonstrated in rabbits or rats, although the incidence of abortion was increased in rabbits.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     Fosamprenavir",
"    </a>",
"    was associated with a reduction in pup survival and reduced body weights in rats.",
"   </p>",
"   <p>",
"    Female rats had an increased time to successful mating, an increased length of gestation, a reduced number of uterine implantation sites per litter, and reduced gestational body weights compared to controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     Fosamprenavir",
"    </a>",
"    is excreted in the milk of lactating rats; it is not known if it is excreted in human milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Human studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are very limited data on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    use in pregnant women and no data on use by neonates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     INDINAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     Indinavir",
"    </a>",
"    (Crixivan) is classified as a FDA pregnancy category C drug (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Carcinogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro screening tests have been negative. No increased incidence of any types of tumors occurred in long-term studies in mice. At the highest dose studied in rats (1.3-fold higher than systemic exposure at human therapeutic doses), thyroid adenomas were seen in male rats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Reproduction/fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effect has been seen on reproductive performance, fertility, or embryo survival in rats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been no evidence of teratogenicity in rats, rabbits, or dogs.",
"   </p>",
"   <p>",
"    Developmental toxicity, manifested by an increase in supernumerary and cervical ribs, was observed in rats at doses comparable to those administered to humans.",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    was administered to neonatal Rhesus monkeys, indinavir caused an exacerbation of the transient physiologic hyperbilirubinemia seen in this species after birth; serum bilirubin values were approximately fourfold above controls. A similar exacerbation did not occur in neonates after in utero exposure to indinavir during the third trimester of pregnancy.",
"   </p>",
"   <p>",
"    In the Antiretroviral Pregnancy Registry, no increase in the risk of birth defects over the general population has been observed with first trimester exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Rhesus monkeys, fetal plasma drug levels were approximately 1 to 2 percent of maternal plasma drug levels approximately one hour after maternal dosing. Minimal to no transplacental passage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    occurred in 21 pregnant women in the PACT 316 study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     Indinavir",
"    </a>",
"    is excreted in the milk of lactating rats at concentrations slightly above maternal levels (milk-to-plasma ratio 1.26 to 1.45). In one report, the breast milk concentration was between 90 and 540 percent for indinavir compared with the plasma concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Human studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    safety and pharmacokinetic study (PACTG 358) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    (800 mg tid) in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    was conducted in 16 pregnant HIV-infected women who received treatment from 14 to 28 weeks of gestation to 12 weeks postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    plasma area under the curve concentration was significantly lower than that observed six weeks postpartum; 55 percent had drug levels below levels of detection. At six weeks postpartum, the pharmacokinetics of indinavir in these patients was generally similar to those observed in nonpregnant patients.",
"   </p>",
"   <p>",
"    Other studies have also shown a marked difference between the AUC",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    exposure and peak concentrations between the third trimester and postpartum evaluations in the same women, suggesting increased CYP3A activity during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Therefore, given the substantially lower antepartum exposures observed in these studies and the generally limited data in this patient population, use of indinavir as a sole protease inhibitor is not recommended in HIV-infected pregnant patients.",
"   </p>",
"   <p>",
"    Few data are available regarding the use of boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    . In two pregnant women receiving a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -\"boosted\" combination of indinavir (800 mg every 12 hours) and ritonavir (200 mg every 12 hours), indinavir AUC values were significantly higher than in women receiving indinavir alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    side effects seen in adults (hyperbilirubinemia, renal stones) could be problematic for the newborn if placental passage occurs in humans and the drug is administered near to delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .) It is unknown if administration of indinavir to the mother during the perinatal period will exacerbate physiologic hyperbilirubinemia in neonates. Because the half-life of indinavir in adults is short, these concerns may only be relevant if the drug is administered near the time of delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     LOPINAVIR-RITONAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"     Lopinavir-ritonavir",
"    </a>",
"    (Kaletra) is classified as a FDA pregnancy category C drug (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Carcinogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro mutagenicity and clastogenicity screening tests are negative for both lopinavir and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In animals studied for up to 104 weeks,",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    was associated with an increase in benign hepatocellular adenomas in mice and an increase in the combined incidence of hepatocellular adenomas plus carcinoma in rats at two times and 0.5 times the recommended therapeutic doses,",
"    <span class=\"nowrap\">",
"     respectively.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Reproduction/fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lopinavir/",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    produced no effects on fertility in male and female rats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of teratogenicity with administration of",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    to pregnant rats or rabbits.",
"   </p>",
"   <p>",
"    In the Antiretroviral Pregnancy Registry, sufficient data on first trimester exposures to",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    are available to exclude a twofold or more increase in birth defects; the prevalence of birth defects with first trimester",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    exposures in the Registry is 1.7 percent (95% CI 0.8-3.2), which is comparable to the prevalence of birth defects in the US population based on CDC surveillance (2.7 per 100 live births) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lopinavir crosses the human placenta, with an average lopinavir ratio in cord",
"    <span class=\"nowrap\">",
"     blood/maternal",
"    </span>",
"    plasma of 0.20",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    0.13; there is minimal transplacental passage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lopinavir and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    are secreted in the breast milk of lactating rats; it is not known if either drug is excreted in human milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Human studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been ongoing concern about achieving adequate serum drug concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    during the third trimester of pregnancy.",
"   </p>",
"   <p>",
"    In a study of 17 pregnant women receiving",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    (three capsules twice daily) during the third trimester of pregnancy, lopinavir exposure was lower during late pregnancy than postpartum; 14 of 17 women did not meet the target area under the curve AUC concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent trial (PACTG 1026) was designed to determine if a higher dose in the third trimester of pregnancy of",
"    <span class=\"nowrap\">",
"     533/133",
"    </span>",
"    mg of",
"    <span class=\"nowrap\">",
"     LPV/r",
"    </span>",
"    twice daily may improve serum concentrations compared to",
"    <span class=\"nowrap\">",
"     400/100",
"    </span>",
"    mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/15\">",
"     15",
"    </a>",
"    ]. Preliminary results from 23 subjects determined that the higher dose achieved adequate levels during the third trimester, but resulted in excessive levels by two weeks postpartum. The authors concluded that higher dosing in the third trimester is indicated, but dosing must be reduced two weeks postpartum. The capsule formulation that was used in this study is no longer produced now that a heat-stable tablet formulation (containing 200 mg lopinavir plus 50 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ) is available.",
"   </p>",
"   <p>",
"    A subsequent prospective study of 33 HIV-infected women evaluated the pharmacokinetics of 2",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    tablets (400",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    mg) twice daily during the second trimester, 3 tablets (600",
"    <span class=\"nowrap\">",
"     mg/150",
"    </span>",
"    mg) twice daily during the third trimester, and 2 tablets (400",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    mg) twice daily post-delivery through two weeks postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/16\">",
"     16",
"    </a>",
"    ]. Drug serum levels were stable throughout and comparable to those levels seen in nonpregnant adults taking standard dosing of",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    (eg, two tablets twice daily).",
"   </p>",
"   <p>",
"    The authors concluded that the dose of",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    should be increased to 600",
"    <span class=\"nowrap\">",
"     mg/150",
"    </span>",
"    mg twice daily, during the third trimester only, to maintain adequate serum drug levels. Once-daily dosing, as studied in adults, is not recommended during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     NELFINAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     Nelfinavir",
"    </a>",
"    (Viracept) is classified as a FDA pregnancy category B drug (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link&amp;anchor=H14#H14\">",
"     \"HIV protease inhibitors\", section on 'Nelfinavir'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Carcinogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro screening tests have been negative. However, an increased incidence of thyroid follicular cell adenomas and carcinomas were seen in association with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    use in male rats (with similar systemic exposure as humans at therapeutic doses) and female rats (with a threefold higher exposure than that in humans).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Reproduction/fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effect has been seen on reproductive performance, fertility, or embryo survival in rats at exposures comparable to human therapeutic exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;No teratogenicity or effect on fetal development has been demonstrated in rodent or rabbit studies at exposures comparable to human therapeutic exposure.",
"   </p>",
"   <p>",
"    Furthermore, no increase in the risk of birth defects has been observed with first trimester exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    in any of the cases reported to the Antiretroviral Pregnancy Registry; the rate of birth defects with first trimester exposure was 3.4 percent (95% CI 2.4-4.7) compared to an overall rate of birth defects in the United States population of 2.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental passage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    appears to be minimal.",
"   </p>",
"   <p>",
"    In a phase I study in pregnant women and their infants (see below),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    was not detectable in cord blood from four infants, and in one additional infant, the cord blood nelfinavir concentration was only 12 percent of that detected in maternal blood at delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/17\">",
"     17",
"    </a>",
"    ]. In another study of 38 women, the cord blood nelfinavir concentration was below the assay limit of detection in 24 (63 percent), and was low in the remaining 14 women (median, 0.35",
"    <span class=\"nowrap\">",
"     microgram/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     Nelfinavir",
"    </a>",
"    is excreted in the milk of lactating rats. In a study of women receiving combination antiretroviral therapy with nelfinavir, the breast milk concentration of was between 6 to 24 percent of that in maternal plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Human studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    safety and pharmacokinetic study (PACTG 353) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    in combination with ZDV and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    was conducted in 33 pregnant HIV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/17\">",
"     17",
"    </a>",
"    ]. This study showed that thrice daily dosing with 750 mg produced inadequate serum levels; however, serum levels were adequate when nelfinavir dosing was modified to twice daily at 1250 mg. Thus, nelfinavir should always be dosed at 1250 mg twice daily during pregnancy.",
"   </p>",
"   <p>",
"    In two other studies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    levels have been noted to be highly variable during pregnancy (even among pregnant women receiving 1250 mg twice daily) and lower than observed in the post-partum state or in nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/13,18\">",
"     13,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Warnings were issued from the US manufacturer, Pfizer, against the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    in September 2007 regarding the presence of ethyl methanesulfonate (EMS), a manufacturing process-related impurity. However, as of March 31, 2008, all nelfinavir manufactured and released by Pfizer now meets the new final EMS limits established by the FDA for prescribing to all patient populations, including pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     RITONAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    (Norvir) is classified as a FDA pregnancy category B drug (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Carcinogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dose-dependent increase in liver adenomas and combined adenomas and carcinomas was observed in male mice at exposures fourfold greater than that in male humans at the therapeutic dose. However, no carcinogenic effects were observed in female mice or rats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Reproduction/fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effect has been seen on reproductive performance or fertility in rats at drug exposures 40 percent (male) and 60 percent (female) of that achieved with human therapeutic dosing in males and females, respectively. Testing of higher doses was not feasible due to hepatic toxicity in the rodents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;No drug-related teratogenicity has been observed in rats or rabbits. In the Antiretroviral Pregnancy Registry, sufficient data on first trimester exposures to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    are available to exclude a twofold or more increase in birth defects; the prevalence of birth defects with first trimester",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    exposures in the Registry is 2.5 percent (95% CI 1.4-3.3), which is comparable with the prevalence of birth defects in the U.S population based on CDC surveillance (2.7 per 100 live births) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a human placental perfusion model, the clearance index of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    was very low, with little accumulation in the fetal compartment and no accumulation in placental tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/19\">",
"     19",
"    </a>",
"    ]. Additionally, in a study of cord blood samples from six women treated with ritonavir during pregnancy, the cord blood concentration was below the assay limit of detection in 83 percent and was minimal (0.38",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    in the remaining women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    is excreted in the milk of lactating rats; it is unknown if it is excreted in human milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    safety and pharmacokinetic study (PACTG 354) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    in combination with ZDV and 3TC in pregnant HIV-infected women and their infants showed lower levels of ritonavir during late pregnancy compared to postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h1\">",
"     SAQUINAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     Saquinavir",
"    </a>",
"    is classified as a FDA pregnancy category B drug (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). The soft-gel formulation of saquinavir (Fortovase) was discontinued and only the hard capsule formulation (Invirase) is available. Most of the information on saquinavir in treatment studies is based on Fortovase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Carcinogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro screening tests have been negative. Carcinogenicity studies found no indication of carcinogenic activity in rats and mice administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    for approximately two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Reproduction/fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effect has been seen on reproductive performance, fertility, or embryo survival in rats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;No evidence for embryotoxicity or teratogenicity has been found in animal studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental transfer in the rat and rabbit was minimal. In a phase I study in pregnant women and their infants, transplacental passage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    was minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/21\">",
"     21",
"    </a>",
"    ]. Additionally, in a study of cord blood samples from eight women treated with saquinavir during pregnancy, the cord blood concentration of saquinavir was below the assay limit of detection in samples from all women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     Saquinavir",
"    </a>",
"    is excreted in the milk of lactating rats; it is not known if it is excreted in human milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Human studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies demonstrated that standard dosing with unboosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    (eg, 1200 mg three times a day with the soft gel capsule) did not achieve adequate drug levels during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these preliminary results, the PACTG 386 study was modified to evaluate the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    (800 mg) as the soft-gel capsule Fortovase plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    (100 mg), both administered twice daily, in 13 pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/23\">",
"     23",
"    </a>",
"    ]. This regimen was well tolerated and achieved adequate saquinavir levels, but this formulation is no longer available.",
"   </p>",
"   <p>",
"    Three studies evaluated the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    hard-gel capsule (Invirase) combined with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    (saquinavir 1000",
"    <span class=\"nowrap\">",
"     mg/",
"    </span>",
"    ritonavir 100 mg given twice daily). In a total of 19 pregnant women, trough levels were above the target in all but one woman [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Thus, the limited available data suggest that 1000 mg",
"    <span class=\"nowrap\">",
"     saquinavir/100",
"    </span>",
"    mg ritonavir given twice daily should achieve adequate trough levels in HIV-infected pregnant women; data are too limited to recommend once-daily dosing.",
"   </p>",
"   <p>",
"    The pharmacokinetics of the new 500 mg tablet formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    boosted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    (SQV 1000",
"    <span class=\"nowrap\">",
"     mg/RTV",
"    </span>",
"    100 mg twice daily) was studied in 14 HIV-infected pregnant women at 33 weeks gestation and parameters were comparable to those observed in non-pregnant individuals; none of the women had a subtherapeutic trough level [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"      saquinavir",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"     -based",
"    </span>",
"    treatment in pregnancy reported mild abnormal transaminase levels in 31 percent within two to four weeks of treatment initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h1\">",
"     TIPRANAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     Tipranavir",
"    </a>",
"    (Aptivus) is categorized as a FDA pregnancy category C drug (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h2\">",
"     Carcinogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     Tipranavir",
"    </a>",
"    showed no evidence of mutagenicity or clastogenicity in a battery of five tests.",
"   </p>",
"   <p>",
"    Long-term carcinogenicity studies in mice found an increased incidence of benign hepatocellular adenomas and combined",
"    <span class=\"nowrap\">",
"     adenomas/carcinomas",
"    </span>",
"    in females in all doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    studied except the lowest dose exposure; these tumors were also increased in males at high doses. Systemic exposures of tipranavir in the mice at all doses tested were below those in humans receiving therapeutic dosing.",
"   </p>",
"   <p>",
"    An increased incidence of benign thyroid follicular cell adenomas was observed in female rats at dose levels equivalent to therapeutic dosing in humans. The clinical relevance of these findings in rodents to humans is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h2\">",
"     Reproduction/fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     Tipranavir",
"    </a>",
"    had no effect on fertility or early embryonic development in rats at dose levels similar to human exposures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;No teratogenicity was detected in studies in pregnant rats and rabbits at exposure levels approximately 1.1-fold and 0.1-fold human exposure.",
"   </p>",
"   <p>",
"    In rats exposed to 400",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (approximately 0.8-fold human exposure) and above, decreased ossification and body weights were observed.",
"   </p>",
"   <p>",
"    Fetal or developmental toxicity was not seen in rats or rabbits; however, growth inhibition in pups and maternal toxicity were seen at 400",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (approximately 0.8-fold human exposure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown if placental passage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    occurs in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown if breast milk passage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    occurs in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66\">",
"    <span class=\"h2\">",
"     Human studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No data are available on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    in pregnant women or neonates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67\">",
"    <span class=\"h1\">",
"     AGENTS TO USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The USPHS guidelines have ordered the above PIs into categories of recommended and alternative agents based on safety and pharmacokinetic parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/1\">",
"     1",
"    </a>",
"    ]. Those drugs with insufficient data for which to make recommendations are also listed below. The selection of combination ART in the pregnant woman is discussed elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68\">",
"    <span class=\"h2\">",
"     Recommended PIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the safety and pharmacokinetic data cited above, the USPHS guidelines recommend",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    as the preferred PI for use in combination therapy during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69\">",
"    <span class=\"h2\">",
"     Alternative PIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative PIs include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18825/abstract/1\">",
"     1",
"    </a>",
"    ]. Atazanavir, indinavir, and saquinavir must be prescribed with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    for pharmacokinetic boosting.",
"   </p>",
"   <p>",
"    Full-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is difficult to tolerate in full dosing of 600 mg twice daily due to gastrointestinal symptoms and is also associated with significant metabolic disturbances. Full dose ritonavir is thus not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70\">",
"    <span class=\"h2\">",
"     Insufficient data",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are insufficient data on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    to recommend their use in pregnancy. The exception to this would be a woman for whom there is no alternative drug (eg, multi-drug resistant virus); in such cases, the benefit to the woman's health outweighs potential risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"       \"Patient information: HIV and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy should not preclude the use of an optimal antiretroviral therapy regimen for the control of HIV disease. An additional goal is to decrease the risk of perinatal transmission of HIV infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Health professionals are encouraged to contact the Antiretroviral Pregnancy Registry to prospectively report antiretroviral exposures in pregnancy to assist in monitoring pregnancy outcomes of pregnant women exposed to antiretroviral medications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Adverse effects of protease inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected pregnant women should undergo routine glucose screening between 24 to 48 weeks of gestation.",
"     </li>",
"     <li>",
"      The USPHS guidelines have ordered the protease inhibitors (PIs) into categories of recommended and alternative agents based on drug safety and pharmacokinetic parameters. We agree with the USPHS guidelines committee and recommend",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      as the preferred PI for use in combination therapy during pregnancy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Once-daily dosing is not recommended due to potential underdosing during pregnancy. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Lopinavir-ritonavir'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H67\">",
"       'Agents to use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternative PIs include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"       nelfinavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"       saquinavir",
"      </a>",
"      . Atazanavir, indinavir, and saquinavir are prescribed with low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      for pharmacokinetic boosting. Full-dose ritonavir is often associated with gastrointestinal intolerance and is not recommended. (See the appropriate section above for the specific drug of interest).",
"     </li>",
"     <li>",
"      There are insufficient data on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"       fosamprenavir",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"       tipranavir",
"      </a>",
"      to recommend their use in pregnancy. The exception to this would be a woman for whom there is no alternative drug; in such cases, the benefit to the woman's health outweighs potential risks. (See the appropriate section above for the specific drug of interest).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Public Health Service Task Force Recommendations for use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. September 14, 2011. www.AIDSInfo.nih.gov (Accessed on March 16, 2012).",
"    </li>",
"    <li>",
"     Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 Jan 1989 - 31 January 2010. Wilmington, NC: Registry Coordinating Center; 2010. file://www.APRegistry.com (Accessed on August 26, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/3\">",
"      Hitti J, Andersen J, McComsey G, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007; 196:331.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/4\">",
"      Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007; 21:2409.",
"     </a>",
"    </li>",
"    <li>",
"     Spencer L, Neely M, Mordwinkin N, et al. Intensive pharmacokinetics of zidovudine, lamivudine and atazanavir and HIV-1 viral load in breast milk and plasma of HIV+ women receiving HAART. 16th Conference on Retroviruses and Opportunistic Infections; February 2009; Montreal, Canada. file://www.retroconference.org/2009/PDFs/942.pdf (Accessed on August 26, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/6\">",
"      Furco A, Gosrani B, Nicholas S, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS 2009; 23:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/7\">",
"      Ivanovic J, Bellagamba R, Nicastri E, et al. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS 2010; 24:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/8\">",
"      Jaworsky D, Thompson C, Yudin MH, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther 2010; 15:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/9\">",
"      Mirochnick M, Dorenbaum A, Holland D, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002; 21:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/10\">",
"      Colebunders R, Hodossy B, Burger D, et al. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS 2005; 19:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/11\">",
"      Unadkat JD, Wara DW, Hughes MD, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2007; 51:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/12\">",
"      Hayashi S, Beckerman K, Homma M, et al. Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS 2000; 14:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/13\">",
"      Kosel BW, Beckerman KP, Hayashi S, et al. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003; 17:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/14\">",
"      Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/15\">",
"      Mirochnick M, Best BM, Stek AM, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2008; 49:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/16\">",
"      Best BM, Stek AM, Mirochnick M, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2010; 54:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/17\">",
"      Bryson YJ, Mirochnick M, Stek A, et al. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials 2008; 9:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/18\">",
"      Nellen JF, Schillevoort I, Wit FW, et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis 2004; 39:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/19\">",
"      Casey BM, Bawdon RE. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol 1998; 179:758.",
"     </a>",
"    </li>",
"    <li>",
"     Scott GB, Rodman JH, Scott WA, et al, for the PACTG 354 Protocol Team. Pharmacokinetic and virologic response to ritonavir (RTV) in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-10-infected pregnant women and their infants. 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, WA. Abstract 794-W.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/21\">",
"      Acosta EP, Zorrilla C, Van Dyke R, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2001; 2:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/22\">",
"      Vithayasai V, Moyle GJ, Supajatura V, et al. Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission. J Acquir Immune Defic Syndr 2002; 30:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/23\">",
"      Acosta EP, Bardeguez A, Zorrilla CD, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48:430.",
"     </a>",
"    </li>",
"    <li>",
"     Hanlon M, O'Dea S, Woods S, et al. Evaluation of saquinavir/ritonavir based regimen for prevention of MTCT of HIV. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Abstract 721.",
"    </li>",
"    <li>",
"     Khan W, Hawkins DA, Moyle G, et al. Pharmacokinetics (PK), safety, tolerability and efficacy of saquinavir hard-gel capsules/ritonavir (SQV/r) plus 2 nucleosides in HIV-infected pregnant women. XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract ThPeB 7064.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18825/abstract/26\">",
"      L&oacute;pez-Cort&eacute;s LF, Ruiz-Valderas R, Pascual R, et al. Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy. HIV Clin Trials 2003; 4:227.",
"     </a>",
"    </li>",
"    <li>",
"     Burger D, Eggink A, van der Ende I, et al. The pharmacokinetics of saquinavir in the new tablet formulation + ritonavir (1000/100 mg twice daily) in HIV-1-infected pregnant women. 14th Conference on Retoviruses and Opportunistic Infections, February 25-28, 2007, Los Angeles, CA (abstract 741).",
"    </li>",
"    <li>",
"     Hanlon M, O'Dea S, Clarke S, Mulcahy F. Maternal hepatotoxicity with boosted saquinavir as part of combination ART in pregnancy. 14th Conference on Retoviruses and Opportunistic Infections, February 25-28, 2007, Los Angeles, CA. Abstract 753.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3781 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18825=[""].join("\n");
var outline_f18_24_18825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H72\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADVERSE EFFECTS OF PROTEASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AVAILABLE PROTEASE INHIBITOR AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ATAZANAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Carcinogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Reproduction/fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Human studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DARUNAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Carcinogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reproduction/fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Human data",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FOSAMPRENAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Carcinogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Reproduction/fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Human studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      INDINAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Carcinogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Reproduction/fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Human studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      LOPINAVIR-RITONAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Carcinogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Reproduction/fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Human studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      NELFINAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Carcinogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Reproduction/fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Human studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      RITONAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Carcinogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Reproduction/fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      SAQUINAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Carcinogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Reproduction/fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Human studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      TIPRANAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      Carcinogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      Reproduction/fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66\">",
"      Human studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H67\">",
"      AGENTS TO USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68\">",
"      Recommended PIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69\">",
"      Alternative PIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70\">",
"      Insufficient data",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H72\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3781\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3781|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/51/9013?source=related_link\">",
"      Atazanavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/5/32853?source=related_link\">",
"      Fosamprenavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=related_link\">",
"      Patient information: HIV and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=related_link\">",
"      Prevention of HIV transmission during breastfeeding in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_24_18826="Pathogenesis of graft-versus-host disease";
var content_f18_24_18826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of graft-versus-host disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/24/18826/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/24/18826/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/24/18826/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/24/18826/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/24/18826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/24/18826/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/24/18826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graft-versus-host disease (GVHD) is a direct result of one of the principal functions of the immune system: the distinction of self from non-self. In an attempt to treat patients with severe and life-threatening illnesses (eg, malignancies treated with allogeneic hematopoietic cell transplantation), immune cells may be transplanted from a non-identical donor to the patient. These donor (eg, graft) cells may recognize patient (eg, host) cells as foreign, thereby initiating a graft-versus-host reaction which may lead to GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An understanding of the pathogenesis of this reaction has been obtained via the study of animal models of GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The basic requirements for the development of this disorder were recognized as early as the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/4\">",
"     4",
"    </a>",
"    ]. These include the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The graft must contain immunologically competent cells.",
"     </li>",
"     <li>",
"      The host must possess transplantation antigens that are lacking in the graft, thereby appearing foreign to the graft; host cells subsequently stimulate donor cells via these specific antigenic determinants.",
"     </li>",
"     <li>",
"      The host must be incapable of mounting a reaction against the graft for a period of time sufficient to allow graft cells to attack the host.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since GVHD is primarily a T cell mediated disease, this discussion of the pathogenesis of the disorder consists of an overview of the more important properties and interactions of a transplanted T cell which may lead to the disease. Although the contributions from other cells are not discussed here (other than antigen presenting cells), it is important to realize that additional hematopoietic cells, such as natural killer cells, also underlie the development of GVHD.",
"   </p>",
"   <p>",
"    The pathogenesis of GVHD will be reviewed here. The prevention, diagnosis, and treatment of GVHD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=see_link\">",
"     \"Treatment of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MAJOR HISTOCOMPATIBILITY CLASSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to discussing those aspects of T cell function relevant to the pathogenesis of GVHD, it is helpful to first briefly review the Major Histocompatibility Complex (MHC) or HLA (for Human Leukocyte Antigens) in humans since these molecules underlie the recognition of antigen by T cells. The MHC is highly polymorphic from individual to individual, and segregates in families in a Mendelian codominant fashion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The genes of the HLA locus encode two distinct classes of cell surface molecules, classes I and II. Class I molecules are expressed on the surfaces of virtually all nucleated cells at varying densities, while class II molecules are more restricted to cells of the immune system, primarily B lymphocytes and monocytes. However, cytokines secreted by lymphocytes and monocytes during immune activation may cause dramatic increases in class II HLA antigen expression, even on cell types which normally have little or no surface expression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are three different class I (HLA-A, -B, -C) and class II (HLA-DQ, -DR, -DP) antigens. HLA-A, -B and -DR antigens appear to be the most important loci determining whether transplanted cells initiate a graft versus host reaction (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the principal task of the immune system is to distinguish self from non-self, HLA molecules provide the crucial surface upon which the antigen receptors on T lymphocytes (T cell receptors or TCR) recognize foreign (non-self) antigens. On antigen presenting cells such as macrophages, class II molecules present antigenic fragments (in the form of linear peptides) to the CD4 positive inducer (or helper) T cells, while class I molecules function at the effector phase of immunity by presenting antigens to CD8 positive T cells, which generally have",
"    <span class=\"nowrap\">",
"     cytotoxic/suppressor",
"    </span>",
"    function. This process of antigen presentation consists of the binding of a single T cell receptor to a complex on the surface of an antigen-presenting cell, consisting of the MHC molecule and a peptide fragment derived from the foreign antigen.",
"   </p>",
"   <p>",
"    In hematopoietic cell transplantation, the principal antigenic targets of the T cells of the graft are the host MHC molecules if the patient and donor MHC molecules differ. However, for grafts matched at the MHC, mismatching of other antigens, termed minor histocompatibility antigens, appear to underlie the development of GVHD (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients undergoing hematopoietic cell transplantation, the following principal factors determine whether graft versus host disease occurs and the strength of the reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Types and properties of the transplanted T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Histocompatibility antigen mismatching",
"     </li>",
"     <li>",
"      Trafficking of T cells to involved tissue",
"     </li>",
"     <li>",
"      Interactions between T cells and endothelial cells",
"     </li>",
"     <li>",
"      Signaling events occurring between immune cells",
"     </li>",
"     <li>",
"      Induction of proinflammatory cytokines [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dose of B lineage-specific progenitor cells [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, one study has suggested that the presence of certain HLA alleles, even if fully matched, may be associated with a stronger (ie, HLA -A10, HLA-B7) or weaker (HLA-B27) GVHD response [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/12\">",
"     12",
"    </a>",
"    ]. Initial observations have suggested that the risk of developing GVHD may be less in certain island populations (eg, Japan), due to limited overall genetic diversity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Innate Immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even before T cells are activated, the innate immune system is an important component of the induction of GVHD. Much of the model for cytokine-driven effects is likely due to stimulation of innate immunity through the preparatory regimen and the gut mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/14\">",
"     14",
"    </a>",
"    ]. Experimental models and clinical experience point to the importance of gastrointestinal damage. The conditioning regimen damages the intestinal epithelium and leads to bacterial translocation or enhanced stimulation of toll-like receptors (TLRs) which results in an increased cytokine release by",
"    <span class=\"nowrap\">",
"     macrophages/monocytes",
"    </span>",
"    and T-cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TLRs are a large family of proteins involved in pathogen recognition through unique patterns such as nucleic acids or sugars. Clinically, gastrointestinal GVHD is one of the most severe manifestations of acute GVHD and frequently precedes progression to liver GVHD.",
"   </p>",
"   <p>",
"    The earliest example of the importance of TLRs is the data on the importance of the",
"    <span class=\"nowrap\">",
"     NOD2/CARD15",
"    </span>",
"    protein in Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/16\">",
"     16",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     NOD2/CARD15",
"    </span>",
"    is an intracellular sensor of muramyl dipeptide (a component of the bacterial cell wall) and mediates nuclear factor kappa B activation.",
"    <span class=\"nowrap\">",
"     NOD2/CARD15",
"    </span>",
"    expression is found in intestinal epithelial cells (IECs) and cells of",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    lineage. Within the single nucleotide polymorphisms in the",
"    <span class=\"nowrap\">",
"     NOD2/CARD15",
"    </span>",
"    gene, high-risk alleles in SNPs 8, 12, and 13 have been identified which confer an increased risk for Crohn disease. Patients heterozygous for these mutated forms have a two- to fourfold increased risk to develop Crohn disease; the risk increases to 20- to 40-fold in homozygous patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=see_link&amp;anchor=H8#H8\">",
"     \"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease\", section on 'Genetic susceptibility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the homologies in the pathophysiology of GVHD and inflammatory bowel disease,",
"    <span class=\"nowrap\">",
"     NOD2/CARD15",
"    </span>",
"    polymorphisms also have an impact on the pathophysiology of GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/17\">",
"     17",
"    </a>",
"    ]. This was shown in a study of retrospectively-typed DNA from",
"    <span class=\"nowrap\">",
"     donor/recipient",
"    </span>",
"    pairs in 169 consecutive patients receiving transplants from related or unrelated donors. Mutated alleles were observed in 21 percent of patients and in 14 percent of donors. The cumulative incidence of one-year transplant-related mortality rose from 20 percent in",
"    <span class=\"nowrap\">",
"     donor/recipient",
"    </span>",
"    pairs without mutated SNPs to 49 percent in pairs with recipient mutations and 59 percent in pairs with donor mutations, and was highest in 12 pairs with mutated alleles in both donor and recipients (83 percent).",
"   </p>",
"   <p>",
"    Similar associations were observed for severe overall and severe gastrointestinal GVHD. These data suggest that differences in TLRs may be an independent risk factor for complications and clearly demonstrate an important role of the innate immunity in GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/18\">",
"     18",
"    </a>",
"    ]. However, others have not found this association [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/19\">",
"     19",
"    </a>",
"    ]. It is unclear if these differences are due to patient populations, preparatory regimens, other factors, or a lack of statistical power to observe differences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     T cell heterogeneity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The particular phenotypic T cell variants transplanted from the graft, and their state of activation or level of maturity are important factors underlying GVHD. The population of T cells harvested from bone marrow or peripheral blood is heterogeneous, with most T cells expressing CD3 and T cell receptors. Within this population, both CD4 and CD8 positive cells are found, as well as T cells negative for both CD4 and CD8 (double negatives). These last cells suppress and dampen the immune response (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Besides these phenotypic differences, T cells also exist in various states of activation or maturity. Altered T cell states can be detected via the varied expression of the different isoforms of the antigen CD45, although these changes are not exclusive in that these isoforms may revert back (ie, CD45RO memory cells may revert back to be CD45RA+) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CD45RO positive cells are usually mature memory T cells",
"     </li>",
"     <li>",
"      CD45RA positive cells are usually naive and nonactivated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The elimination of activated mature T cells, via the use of specific monoclonal antibodies or of different harvesting techniques, may dampen the immune response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The depletion of CD45RO and CD45RB cells significantly decreases the intensity of mixed lymphocyte reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of memory cells alone prevented GVHD in two murine models [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data also exist suggesting that there may be functionally different T cells which arise or differentiate at distinct sites [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/27\">",
"     27",
"    </a>",
"    ]. A prevailing hypothesis concerning T cell differentiation is that a naive T cell is solely educated in the thymus of the host, the location where it acquires its life-long immune repertoire. In the thymus, cells which are highly reactive to self-antigens are deleted, and cells which are weakly reactive or non-reactive also die if they fail to receive the proper stimulatory signals by the thymic epithelium.",
"   </p>",
"   <p>",
"    However, there may be other anatomic areas where T cells may arise and be endowed with different immune functions. The bone marrow, for example, appears to be an area where T cells mature [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. These cells lack certain phenotypic markers and functionally behave as suppressor cells. Another possibility is how T cells traffic to lymphoid organs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/30\">",
"     30",
"    </a>",
"    ]. For example, T cells that home to the Peyer's patches in the gastrointestinal tract may be particularly important in the generation of GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Histocompatibility antigen mismatch",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned previously, CD4 positive cells interact with the MHC class II molecules of antigen presenting cells (APCs), and CD8 positive cells interact with MHC class I antigens. In most centers, a complete match at the HLA-A, -B (both class I) and -DR loci (class II) is required for that individual to be used as a transplant donor, since mismatches at these loci are associated with a higher risk of severe GVHD and death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/32\">",
"     32",
"    </a>",
"    ]. However, in some cases, donors and recipients are mismatched at a single HLA locus. The outcome for these patients with a single antigen mismatch is similar to a fully matched donor-recipient pair.",
"   </p>",
"   <p>",
"    When related donors are serologically matched at class I loci, the match is likely to be genotypic (ie, genetically identical), whereas unrelated donors with the same serotype may have different alleles, leading to potential clinical incompatibility. This was illustrated in a study of transplant-related mortality (TRM, primarily due to acute GVHD) in 100 unrelated donor-recipient pairs, in which amino acid substitutions of the HLA class I heavy chain were evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/33\">",
"     33",
"    </a>",
"    ]. In multivariate analysis, the only variable predictive of severe acute GVHD was substitution at position 116 of the class I heavy chain. Substitutions at other sites did not affect TRM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Extended haplotype matching",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of a matched sibling",
"    <span class=\"nowrap\">",
"     donor/recipient",
"    </span>",
"    pair, the entire chromosome and its accompanying Major Histocompatibility Complex (MHC) is matched, since identical ones are inherited from the mother and the father. However, in the case of an HLA-matched unrelated donor, it is not known whether other genes in the MHC area are matched as well.",
"   </p>",
"   <p>",
"    The genome in the MHC area is organized into blocks of genes that are closely linked (ie, haplotypes) so that matching is based mainly on only three of these genes, HLA-A, B and DRB1. However, the 7.6 million base pairs within the MHC region contain more than 400 genes that have immune-related functions. The total number of transplantation antigens encoded in this region is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The current method used for HLA haplotype matching interrogates only about 18,000 base pairs and therefore cannot define these extended HLA haplotypes. A novel DNA microarray method to isolate DNA strands extending across 2 million base pairs of the MHC has been devised for the purpose of identifying genes that influence transplantation outcomes when the extended haplotypes of the donor and recipient cannot be defined [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two hundred forty-six HCT recipients and their donors who had been HLA matched by current techniques were restudied using this novel approach. The authors found that 22 percent of the donor-recipient pairs were in fact haplotype mismatched. Regression analysis, which included disease risk, age, year of transplantation, patient and donor gender, and presence of mismatching at HLA-DPB1, demonstrated that mismatching at the haplotype level was associated with a fourfold greater risk of grade III-IV acute GVHD. A lower risk of disease recurrence due to a greater chance of a graft-versus-leukemia effect was also seen, such that overall survival remained the same.",
"   </p>",
"   <p>",
"    These data suggest that this novel method of haplotype matching could be useful in selecting the \"best\" donor when several are available. This approach could also be used for discovery of genes that predispose patients to autoimmune phenomena, cancer, or infections in cases where susceptibility to these diseases has been strongly linked to specific HLA alleles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     High and low risk antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thus far, no consistent relationship has been shown between any one particular HLA antigen and the risk for development of GVHD. Preliminary studies may shed some light on this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 167 patients with myeloid malignancies undergoing a first HLA-matched allogeneic HCT, the incidence of acute GVHD of grades II to IV was significantly lower in subjects carrying the DR15 allele than in those with other HLA DRB1 alleles (23 versus 42 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/35\">",
"       35",
"      </a>",
"      ]. The presence or absence of the DR15 allele did not affect the incidence of chronic GVHD, overall survival, or progression-free survival.",
"     </li>",
"     <li>",
"      In a Japanese study involving 5210 donor-recipient pairs, 15 significant high-risk HLA allele mismatch combinations and one HLA-DRB1-DQB1-linked mismatch combination for severe acute GVHD were identified [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/36\">",
"       36",
"      </a>",
"      ]. Six specific amino acid substitution positions in HLA class I were identified as those responsible for acute GVHD. Whether these observations pertain to non-Asian populations is not clear.",
"     </li>",
"     <li>",
"      In a study of 161 HCT recipients matched at the allelic level for HLA-A, -B, -C, -DRB1, and -DQB1, mismatching at the HLA-DPB1 locus was associated with an increased risk of acute GVHD and treatment- related mortality and worse overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/38\">",
"       38",
"      </a>",
"      ]. Mismatching at distinct amino acid positions, especially position 69 of the DPB chain, was of particular negative impact in this study. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link&amp;anchor=H18#H18\">",
"       \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\", section on 'Possible separation of GVT from GVHD'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Minor antigen mismatch",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the recipient and donor are matched for the MHC antigens mentioned above, GVHD is initiated and propagated via recognition by the T cell and its receptor (TCR) of differences in",
"    <strong>",
"     minor",
"    </strong>",
"    histocompatibility antigens (miH), which are presented in the context of MHC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, for example, five miH antigens (HA-1, 2, 3, 4, 5) recognized by T cells in association with HLA-A1 and A2 were studied in recipients of bone marrow transplants (BMT) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/39\">",
"       39",
"      </a>",
"      ]. Mismatching of only HA-1 was significantly correlated with acute GVHD (&gt; grade II), and mismatching at HA-1, 2, 4, 5 was also significantly associated with GVHD. Acute GVHD developed in",
"      <strong>",
"       all cases",
"      </strong>",
"      where a HA-1 positive patient received a HA-1 negative graft. Mismatching at HA-3 was equally distributed between those with and without GVHD.",
"     </li>",
"     <li>",
"      In a second study, mismatching at the HA-1 locus in HLA-A*0201 individuals was associated with an increased risk of acute GVHD (relative risk 2.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because the manner in which a particular protein is processed is dependent upon genes outside of the MHC, two siblings, despite having identical MHC molecules, will have many different peptides in the MHC groove [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The identification of the particular peptides responsible for GVHD has been an area of intense research. One such antigen, the HA-2 peptide mentioned above, has been found to be a member of the class I myosin family [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/43\">",
"     43",
"    </a>",
"    ]. Two other miH candidates associated with acute GVHD may be one of the human platelet antigens (HPA), especially HPA-3, and an amino acid polymorphism of CD31, also known as platelet endothelial cell adhesion molecule (PECAM) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains unclear how many such peptides behave as miH antigens. Although up to 50 such antigens are estimated to exist in mice, the precise number in humans is unclear. Many potential miH antigens exist in humans, but the actual number that may cause GVHD is probably limited.",
"   </p>",
"   <p>",
"    Minor differences in these peptide sequences as compared with the native peptide (such as substitution of one amino acid) can also have profound consequences on the outcome of TCR-peptide-MHC interactions, possibly resulting in partial activation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. TCR interactions therefore do not simply activate or disable a T cell; rather, in response to subtle variations of peptide sequences, this engagement may cause a multitude of responses, ranging from profoundly helpful to deleterious. As an example, small changes in peptides may shift a vigorous proliferative response to the induction of an anergic state (or vice versa). These changes have been referred to as altered peptide ligands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vascular interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a mature donor T cell is placed into the host, the systemic vasculature (including the capillary beds) is the first potential extensive area of contact with new host antigens. Data suggest that some, but not all, such antigens may be important in the pathogenesis of GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/45,50,51\">",
"     45,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Adhesion and activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;To become activated, a circulating transplanted T cell must adhere to endothelium for a sufficient period of time. The current prevailing view is that T cells roll along the surface of endothelial cells, thereby contacting various different antigens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The on and off rates of TCR binding to MHC molecules have been estimated. Data suggest that this binding is relatively weak, raising the probability that the TCR engages a large number of MHC molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/52\">",
"     52",
"    </a>",
"    ]. If the receptor recognizes an antigen while the T cell is rolling, the binding of adhesion molecules on the T cell to their endothelial cell ligand is significantly strengthened; this step firmly anchors the T cell, preventing further rolling and initiating conditions necessary for its activation.",
"   </p>",
"   <p>",
"    These adhesion molecules, named integrins and selectins, are therefore critically important for initial tethering and subsequent activation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/53\">",
"     53",
"    </a>",
"    ]. This adhesion also permits T cells to eventually move from the circulation into lymph nodes, spleen, other reticuloendothelial organs, and target organs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This association also strengthens the interaction between the TCR and the MHC molecule. Interference with adhesion therefore weakens the interaction between the TCR and the MHC, leading to a lower binding affinity and perhaps a weaker immune response. The administration of monoclonal antibodies to adhesion molecules may also physically prevent the dimerization of the TCR and MHC molecules (a process important for the proper signaling events); in addition, this event may be altered by the administration of a polymer which binds to the MHC molecule or a peptide modeled after the D1-CD4 domain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/42,55\">",
"     42,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8474935\">",
"    <span class=\"h3\">",
"     Chemokines and chemokine receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoattractant cytokines, commonly referred to as chemokines, attract leukocytes to sites of tissue injury, infection, or allotransplantation and are essential for the induction of the acute inflammatory response. Initial studies suggest that some chemokines promote the development of GVHD by attracting donor T cells to potential sites of involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link&amp;anchor=H23#H23\">",
"     \"Transplantation immunobiology\", section on 'Chemokines and chemokine receptors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemokines provide the signals that convert the low affinity selectin-mediated leukocyte rolling into the integrin-mediated leukocyte-endothelial adhesion that presages transmigration. The local production of chemokines also results in a chemoattractant gradient, thereby directing leukocyte trafficking through the tissues, blood, and lymph nodes. This process brings naive lymphocytes into contact with antigen, and so enhances the effecter and memory functions of the immune response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of chemokines in GVHD is supported by a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study of the chemokine (C-C motif) receptor 5 (CCR5) small molecule inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    in addition to standard GVHD prophylaxis in 38 patients undergoing reduced intensity allogeneic hematopoietic cell transplantation (HCT) who were at high risk for developing GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/56\">",
"     56",
"    </a>",
"    ]. All patients received oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in addition to a 33-day course of maraviroc. At day 100, the cumulative incidence of grade II-IV GVHD was 15 percent and there were no cases of GVHD involving the liver or gut. At six months, the cumulative incidence of grade II-IV GVHD was 24 percent, with liver and gut involvement in only 3 and 9 percent, respectively. Rates of GVHD were approximately half of what was expected for this population, while relapse rates were not increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Signaling events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two cellular signaling events are required for T cell activation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first is provided by the TCR-peptide-MHC interaction [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. For a transplanted donor T cell, this consists of binding of the TCR to an allopeptide presented with the host or donor MHC.",
"     </li>",
"     <li>",
"      The second or costimulatory signal is delivered by antigen-presenting cells and requires cell-to-cell contact [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The second signal determines the outcome of the first signal, thereby leading to one of three possibilities: complete activation, partial activation, or anergy. The last condition is a long-lasting state of antigen-specific unresponsiveness. Signaling through the TCR complex in the absence of costimulation is a down-regulatory signal for human T cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several ligands have been characterized as candidate molecules for potent costimulation of resting T cells, antigen-primed T-lymphocytes, or T-helper cell clones. The best-characterized are the B7 antigens (B7-1 [CD80] and B7-2 [CD86]); these antigens bind to two T cell surface receptors, CD28 and CTLA-4, resulting in potent costimulation of T cell activation initiated through the",
"    <span class=\"nowrap\">",
"     CD3/T",
"    </span>",
"    cell receptor complex. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In normal animals, the outcome of T cell activation is dependent upon signals from the TCR, a costimulatory signal from CD28, and an inhibitory signal from CTLA-4. These characteristics have been elegantly demonstrated in knockout mice with the loss of either CD28 or CTLA-4 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The absence of the CD28 signal results in a decrease in T cell responses; by comparison, genetic deletion of CTLA-4 causes a loss of the inhibitory signal, resulting in enhanced and uncontrolled cytokine production and lymphocytic proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Costimulatory requirements for T cells differ depending upon their state of activation-induced maturation. For resting (unprimed) CD4 positive T cells, VCAM-1 and ICAM-1 (both adhesion molecules) and possibly others provide the co-stimulatory signal(s). As a result, T cell activation in vivo is complex, depending upon the state of activation of the T cell (resting versus activated, naive versus mature), and on the nature of the antigen-presenting cell (professional versus non-professional APCs and resting versus activated B cells).",
"   </p>",
"   <p>",
"    Interactions between CD40 and CD40 ligand (CD40L) have also been found to be important in costimulatory signals for T cell activation. The interaction between the CD40 molecule on endothelium and the CD40L on the T cell induces endothelial cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/59,64,65\">",
"     59,64,65",
"    </a>",
"    ]. This activation may lead to increased endothelium expression of ICAM-1, E-selectin, and VCAM-1. The CD40-CD40L interaction is therefore a mechanism in which activated CD4 positive T cells may increase the immune response by upregulating the expression of endothelial cell surface adhesion molecules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a T cell is activated and begins to proliferate, it releases a variety of pro-inflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/66\">",
"     66",
"    </a>",
"    ]. Cytokines may be very important in various steps of the graft-versus-host reaction. These include the initial stimulation of T cells, the maintenance of stimulation, the afferent phase, and the efferent phase, a period when toxicity is manifest.",
"   </p>",
"   <p>",
"    Most cytokine studies have used murine models, either across major or minor histocompatibility barriers. When a MHC mismatched hematopoietic cell transplantation is performed in a mouse, both CD4 positive and CD8 positive cells release cytokines such as IL-1, IL-3, IL-7 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], GM-CSF, TNF-alpha and gamma-interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. CD4 positive cells secrete larger quantities of cytokines compared with CD8 positive cells, suggesting that CD4 positive cells may be more efficient in inducing GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to T cell derived factors, macrophage colony stimulating factor also appears to be increased in the serum of mice with graft-versus-host reaction. This finding suggests that once T cells are primed, a cytokine storm is unleashed. These cytokines may subsequently activate other T cells or other cell types, such as monocytes, NK cells or NK-like cells. Some of these factors, such as IL-2, IL-4, IL-6 and IL-9, simulate growth in a paracrine and autocrine fashion.",
"   </p>",
"   <p>",
"    IL-18, a novel cytokine produced by macrophages, induces the production of gamma-interferon from Th1 cells, T-cells, B-cells, and NK-cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/73\">",
"     73",
"    </a>",
"    ]. Patients with acute GVHD have been shown to have high levels of IL-18 that strongly correlate with the severity of acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/74\">",
"     74",
"    </a>",
"    ], while the infiltration of large numbers of macrophages in skin lesions of patients with acute GVHD has been shown in one study to strongly predict for the development of refractory acute GVHD and reduced overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic polymorphisms at a number of cytokine sites may influence the incidence and severity of acute and chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/40,76-80\">",
"     40,76-80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, an allele associated with increased production of IL-1 receptor antagonist (IL-1Ra), the naturally-occurring antagonist of IL-1alpha and IL-1beta, in the transplant donor was significantly more frequent in patients with milder acute GVHD (ie, grades 0-II, 49 percent) than severe acute GVHD (grades III-IV, 11 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study performed in HLA-matched sibling transplantation, severe acute GVHD was associated with the recipient genotype at Interferon-gamma Intron 1, IL-10(-1064), and the d3 locus of TNF-alpha, while chronic GVHD was associated with recipient IL-6(-174) genotype [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In similar studies, the severity of acute GVHD was independently associated with IL-10 gene polymorphisms of the recipient [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/40,81-83\">",
"       40,81-83",
"      </a>",
"      ] as well as the donor [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/40,82\">",
"       40,82",
"      </a>",
"      ], while chronic GVHD was associated with IL-6 gene polymorphisms from the recipient (relative risk 4.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/40,83\">",
"       40,83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     TNF-alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;One cytokine frequently implicated in the evolution of GVHD is TNF-alpha (TNFa). Interest in the role of TNFa is derived from studies of gut flora in GVHD, and the connection between endotoxin, the release of TNFa, and the development of GVHD. Gnotobiotic mice, defined as animals free of pathogens, are protected from GVHD following BMT. Any recolonization by gram-negative bacteria subsequently leads to GVHD in these animals. In addition, gut decontamination of patients and the use of laminar flow rooms may decrease the severity of GVHD in selected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is therefore probable that damage to the gastrointestinal tract from radiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy allows flora and endotoxins to enter the circulation. Endotoxin is a well-known stimulus for cytokine production and release. The connection between endotoxin, TNFalpha, and GVHD is suggested by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mice are protected from GVHD by the administration of a monoclonal antibody against endotoxin [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/86\">",
"       86",
"      </a>",
"      ], or a competitive antagonist of endotoxin [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/87\">",
"       87",
"      </a>",
"      ], a potent stimulus for the release of TNFalpha [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In mice, the incidence of GVHD is reduced by the administration of keratinocyte growth factor, a cytokine that inhibits TNFalpha generation and the translocation of endotoxin across the gastrointestinal tract [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/89\">",
"       89",
"      </a>",
"      ]. GVHD in mice can also be ameliorated by the administration of a monoclonal antibody directed against OX40 ligand (OX40L, also called CD134 ligand) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      OX40L is a member of the TNF family and OX40 is a member of the TNF receptor family that is expressed on recently activated CD4 positive T cells. Serial measurement of OX40+ T-cells may prove useful for predicting the onset of chronic GVHD as well as monitoring therapeutic response of chronic GVHD [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In humans, the administration of a polyclonal neutralizing antibody against TNF-alpha results in a 70 percent reduction in GVHD associated mortality and diminished lesions in the skin and the intestines [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/92\">",
"       92",
"      </a>",
"      ]. Similar findings have been found in mice [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Higher TNFalpha levels have also been described in some, but not all, studies of patients who develop GVHD [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A polymorphism of the TNFalpha gene is associated with severe acute GVHD and early mortality following BMT [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/77,95\">",
"       77,95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increases in TNF receptor 1 levels &ge;2.5 times baseline following BMT have been correlated with the incidence and severity of GVHD and treatment-related mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cytokines and MHC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another important effect of selected cytokines is the ability to induce the expression of MHC class I and class II antigens. A transplanted T cell may therefore interact with significantly more antigens if there is, first, a cytokine-induced increase in the number of class II MHC molecules. Since the triggering of the TCR-dependent signal is dependent upon the affinity, avidity, and the number of contacts it has with a potential antigenic peptide, cytokine-induced upregulation of MHC molecules is more likely to result in a TCR-dependent signal.",
"   </p>",
"   <p>",
"    A T cell may therefore be \"primed\" for response by being bathed in a milieu of cytokines. This may be a specific consequence of the ligation of the TCR-peptide-MHC or may result from non specific interactions. These non specific sources of cytokines include the toxicity from the preparatory regimen such as total body irradiation (either directly injuring the cells containing the cytokines or secondarily through damage to the endothelial surfaces of the gastrointestinal tract), or by concurrent viral or bacterial infections. In addition, with injury to the intact gut mucosa, there is the possibility of the introduction of superantigens (which are antigens that are able to bypass the TCR and directly stimulate a T cell, resulting in the production of inflammatory cytokines).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CELL MEDIATED CYTOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perforin-dependent cytolysis and Fas-mediated apoptosis are two important mechanisms for T cell mediated cytotoxicity in GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. An understanding of these pathways is derived via studies of mice which have received donor T cells defective in FasL",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deficient in perforin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mice that received FasL defective T cells develop severe cachexia, but only minimal GVHD-associated changes in liver or skin [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mice that received perforin deficient T cells develop all the signs of GVHD, but only after a significant delay in onset.",
"     </li>",
"     <li>",
"      In a major histocompatibility complex class I-mismatched lethally irradiated murine model, wild type and either perforin deficient or FasL deficient CD8+ T cells expanded early after transplantation, followed by a contraction phase in which the majority of expanded CD8+ T cells were eliminated [",
"      <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/99\">",
"       99",
"      </a>",
"      ]. In contrast, doubly deficient CD8+ T cells exhibited prolonged expansion, causing lethal GVHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that perforin plays a role in the kinetics of GVHD; it is possibly not critical in the effector phase but may be important in the afferent phase. By comparison, FasL plays a significant role in the expression of the disease in GVHD target tissues. Results in the doubly deficient animals suggest that both perforin and FasL play an important role in the regulation (ie, contraction) of expanded alloreactive CD8+ T cells. Thus, these molecules appear to have a dual role in GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     REGULATORY T CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional regulatory cells appear to be important in controlling the ultimate response of GVHD. Double negative T cells (which are usually NK1.1 positive) may prevent GVHD in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/63,100,101\">",
"     63,100,101",
"    </a>",
"    ]. Presumably, these regulatory cells arise following antigen sensitization to control the overall response of activated T cells.",
"   </p>",
"   <p>",
"    Regulatory T cells (Treg), defined as",
"    <span class=\"nowrap\">",
"     CD4+/CD25high,",
"    </span>",
"    but also described as being CD3+, L-Selectin-high, FoxP3+, and CD103+, have been described as being useful in the prevention of GVHD in model systems [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/102-109\">",
"     102-109",
"    </a>",
"    ]. &nbsp;Naturally arising Treg cells can influence most immune responses including autoimmunity, transplantation tolerance, antitumor immunity, and anti-infectious responses. These cells appear to be central control elements of immunoregulation, and understanding their biology and interactions with other immunoregulatory cells will be important for efforts aimed at therapeutically manipulating post-transplant immune responses (eg, both GVHD and graft-versus-tumor effects) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/108,110-122\">",
"     108,110-122",
"    </a>",
"    ]. Efforts to utilize these cells in clinical trials are beginning [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/123,124\">",
"     123,124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variations in the balance between reactive and suppressor T cells may result in either the development or absence of GVHD. The generation and the maintenance of these cells remain poorly understood, although some effects may be related to differences in the cytokine milieu related to these cells (eg, IL-6) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     B CELL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although GVHD is thought to be primarily a T cell mediated disease, alterations in B cell populations and activity have been noted in patients who develop GVHD, and may play a role in GVHD pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interest in the role of B cells in GVHD was initially supported by observations that changes seen in the skin and other organs in patients with chronic GVHD (eg, fibrosis, Sjogren-like symptoms, polymyositis) resemble those seen in autoimmune diseases, such as systemic sclerosis (SS, scleroderma). Initial studies identified stimulatory autoantibodies to platelet derived growth factor receptor (PDGFR) in both SS and chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/126\">",
"     126",
"    </a>",
"    ]. The presence of these autoantibodies, which act through tyrosine kinase-dependent signaling, is consistent with early observations in man and experimental animals that some of these manifestations may be ameliorated via the use of anti-B cell antibodies (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) or tyrosine kinase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/125,127-130\">",
"     125,127-130",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\", section on 'Autoantibodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link&amp;anchor=H6225514#H6225514\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\", section on 'Autoantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further investigation of B cell reconstitution following hematopoietic cell transplantation has revealed that chronic GVHD is associated with increased levels of B cell activation factor (BAFF), delayed recovery of na&iuml;ve memory B cells, and increased numbers of activated memory B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/24/18826/abstract/131-134\">",
"     131-134",
"    </a>",
"    ]. Stimulation of these B cells provides a hypothetical mechanism for the generation of autoantibodies that may play a role in the development of GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25784855\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Graft-versus-host disease (GVHD) occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient.",
"     </li>",
"     <li>",
"      The pathogenesis of GVHD is a complex, multistep process. While some steps in this pathway have been elucidated from animal models, many remain unknown. It is clear that the following three factors are necessary for the development of GVHD:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The graft must contain immunologically competent cells.",
"     </li>",
"     <li>",
"      The host must possess transplantation antigens that are lacking in the graft, thereby appearing foreign to the graft; host cells subsequently stimulate donor cells via these specific antigenic determinants.",
"     </li>",
"     <li>",
"      The host must be incapable of mounting a reaction against the graft for a period of time sufficient to allow graft cells to attack the host.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GVHD is primarily a T cell mediated disease. In hematopoietic cell transplantation, the principal antigenic targets of the T cells of the graft are the host Major Histocompatibility Complex (MHC) molecules if the patient and donor MHC molecules differ. However, for grafts matched at the MHC, mismatching of other antigens, termed minor histocompatibility antigens, appear to underlie the development of GVHD. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Histocompatibility antigen mismatch'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Damage of the gastrointestinal system by the conditioning regimen appears to play a role in the initial development of GVHD. The damage is thought to allow bacterial translocation or the enhanced stimulation of toll-like receptors (TLRs), which results in an increased cytokine release by",
"      <span class=\"nowrap\">",
"       macrophages/monocytes",
"      </span>",
"      and T-cell activation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Innate Immunity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Circulating transplanted T cells are activated through interaction with the vascular endothelium, TCR-peptide-MHC interactions, and through a second or costimulatory signal delivered by antigen-presenting cells. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Adhesion and activation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Signaling events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once a circulating transplanted T cell is activated and begins to proliferate, it releases a variety of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNFa) which is a potent proinflammatory and immunoregulatory mediator known to play a role in many rheumatologic disorders. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cytokines'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=see_link&amp;anchor=H6#H6\">",
"       \"Role of cytokines in rheumatic diseases\", section on 'Tumor necrosis factor-alpha'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Circulating activated transplanted T cells damage the host cells through perforin-dependent cytolysis and Fas-mediated apoptosis. In addition, regulatory cells appear to be important in controlling the ultimate response of GVHD. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cell mediated cytotoxicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Regulatory T cells'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/1\">",
"      Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/2\">",
"      Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/3\">",
"      Soci&eacute; G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009; 114:4327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/4\">",
"      Billingham R. The biology of graft-versus-host reaction. Harvey Lect 1966; :21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/5\">",
"      Prasad VK, Kernan NA, Heller G, et al. DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Blood 1999; 93:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/6\">",
"      Morris ES, Hill GR. Advances in the understanding of acute graft-versus-host disease. Br J Haematol 2007; 137:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/7\">",
"      Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplant 2010; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/8\">",
"      Coghill JM, Sarantopoulos S, Moran TP, et al. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood 2011; 117:3268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/9\">",
"      Ranganathan P, Heaphy CE, Costinean S, et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood 2012; 119:4786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/10\">",
"      Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood 2005; 105:4191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/11\">",
"      Michonneau D, Peffault de Latour R, Porcher R, et al. Influence of bone marrow graft B lymphocyte subsets on outcome after HLA-identical sibling transplants. Br J Haematol 2009; 145:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/12\">",
"      Remberger M, Persson U, Hauzenberger D, Ringd&eacute;n O. An association between human leucocyte antigen alleles and acute and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2002; 119:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/13\">",
"      Oh H, Loberiza FR Jr, Zhang MJ, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood 2005; 105:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/14\">",
"      Cooke KR, Olkiewicz K, Erickson N, Ferrara JL. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res 2002; 8:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/15\">",
"      Calcaterra C, Sfondrini L, Rossini A, et al. Critical role of TLR9 in acute graft-versus-host disease. J Immunol 2008; 181:6132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/16\">",
"      Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003; 278:5509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/17\">",
"      Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004; 104:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/18\">",
"      Penack O, Holler E, van den Brink MR. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood 2010; 115:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/19\">",
"      Nguyen Y, Al-Lehibi A, Gorbe E, et al. Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease-associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation. Blood 2010; 115:3625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/20\">",
"      Palathumpat V, Dejbakhsh-Jones S, Holm B, Strober S. Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease. J Immunol 1992; 149:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/21\">",
"      Strober S, Hertel-Wulff B, Schwadron RB. Role of natural suppressor cells in bone marrow transplantation. Transplant Proc 1987; 19:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/22\">",
"      Aversa G, Waugh JA, Hall BM. A monoclonal antibody (A6) recognizing a unique epitope restricted to CD45RO and RB isoforms of the leukocyte common antigen family identifies functional T cell subsets. Cell Immunol 1994; 158:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/23\">",
"      Conlon K, Osborne J, Morimoto C, et al. Comparison of lymphokine secretion and mRNA expression in the CD45RA+ and CD45RO+ subsets of human peripheral blood CD4+ and CD8+ lymphocytes. Eur J Immunol 1995; 25:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/24\">",
"      Pihlgren M, Lightstone L, Mamalaki C, et al. Expression in vivo of CD45RA, CD45RB and CD44 on T cell receptor-transgenic CD8+ T cells following immunization. Eur J Immunol 1995; 25:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/25\">",
"      Chen BJ, Cui X, Sempowski GD, et al. Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood 2004; 103:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/26\">",
"      Anderson BE, McNiff J, Yan J, et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 2003; 112:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/27\">",
"      Rangarajan H, Yassai M, Subramanian H, et al. Emergence of T cells that recognize nonpolymorphic antigens during graft-versus- host disease. Blood 2012; 119:6354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/28\">",
"      Dejbakhsh-Jones S, Jerabek L, Weissman IL, Strober S. Extrathymic maturation of alpha beta T cells from hemopoietic stem cells. J Immunol 1995; 155:3338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/29\">",
"      Cheng L, Dejbakhsh-Jones S, Liblau R, et al. Different patterns of TCR transgene expression in single-positive and double-negative T cells. Evidence for separate pathways of T cell maturation. J Immunol 1996; 156:3591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/30\">",
"      Beilhack A, Schulz S, Baker J, et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood 2008; 111:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/31\">",
"      Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005; 106:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/32\">",
"      van Heeckeren WJ, Fanning LR, Meyerson HJ, et al. Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults. Br J Haematol 2007; 139:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/33\">",
"      Ferrara GB, Bacigalupo A, Lamparelli T, et al. Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood 2001; 98:3150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/34\">",
"      Petersdorf EW, Malkki M, Gooley TA, et al. MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med 2007; 4:e8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/35\">",
"      Battiwalla M, Hahn T, Radovic M, et al. Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. Blood 2006; 107:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/36\">",
"      Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 2007; 110:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/37\">",
"      La Nasa G, Littera R, Locatelli F, et al. The human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-host disease in unrelated bone marrow transplantation for thalassaemia. Br J Haematol 2007; 139:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/38\">",
"      Ludajic K, Balavarca Y, Bickeb&ouml;ller H, et al. Impact of HLA-DPB1 allelic and single amino acid mismatches on HSCT. Br J Haematol 2008; 142:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/39\">",
"      Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/40\">",
"      Soci&eacute; G, Loiseau P, Tamouza R, et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001; 72:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/41\">",
"      Schlegel PG, Aharoni R, Smilek DE, et al. Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. Blood 1994; 84:2802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/42\">",
"      Jameson BA, McDonnell JM, Marini JC, Korngold R. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature 1994; 368:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/43\">",
"      den Haan JM, Sherman NE, Blokland E, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995; 268:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/44\">",
"      Balduini CL, Noris P, Giorgiani G, et al. Incompatibility for CD31 and human platelet antigens and acute graft-versus-host disease after bone marrow transplantation. Br J Haematol 1999; 106:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/45\">",
"      Behar E, Chao NJ, Hiraki DD, et al. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med 1996; 334:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/46\">",
"      Balduini CL, Frassoni F, Noris P, et al. Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor. Br J Haematol 2001; 114:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/47\">",
"      Sloan-Lancaster J, Allen PM. Significance of T-cell stimulation by altered peptide ligands in T cell biology. Curr Opin Immunol 1995; 7:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/48\">",
"      Pfeiffer C, Stein J, Southwood S, et al. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995; 181:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/49\">",
"      Vidal K, Hsu BL, Williams CB, Allen PM. Endogenous altered peptide ligands can affect peripheral T cell responses. J Exp Med 1996; 183:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/50\">",
"      Nichols WC, Antin JH, Lunetta KL, et al. Polymorphism of adhesion molecule CD31 is not a significant risk factor for graft-versus-host disease. Blood 1996; 88:4429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/51\">",
"      Maruya E, Saji H, Seki S, et al. Evidence that CD31, CD49b, and CD62L are immunodominant minor histocompatibility antigens in HLA identical sibling bone marrow transplants. Blood 1998; 92:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/52\">",
"      Matsui K, Boniface JJ, Steffner P, et al. Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness. Proc Natl Acad Sci U S A 1994; 91:12862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/53\">",
"      Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/54\">",
"      Liang Y, Liu C, Djeu JY, et al. Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. Blood 2008; 111:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/55\">",
"      Schlegel PG, Aharoni R, Chen Y, et al. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc Natl Acad Sci U S A 1996; 93:5061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/56\">",
"      Reshef R, Luger SM, Hexner EO, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012; 367:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/57\">",
"      Sette A, Alexander J, Grey HM. Interaction of antigenic peptides with MHC and TCR molecules. Clin Immunol Immunopathol 1995; 76:S168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/58\">",
"      Sakihama T, Smolyar A, Reinherz EL. Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Immunol Today 1995; 16:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/59\">",
"      Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 1996; 273:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/60\">",
"      June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994; 15:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/61\">",
"      Green JM, Noel PJ, Sperling AI, et al. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994; 1:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/62\">",
"      Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993; 262:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/63\">",
"      Linsley PS, Golstein P. Lymphocyte activation: T-cell regulation by CTLA-4. Curr Biol 1996; 6:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/64\">",
"      Durie FH, Foy TM, Masters SR, et al. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994; 15:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/65\">",
"      Grewal IS, Foellmer HG, Grewal KD, et al. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 1996; 273:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/66\">",
"      Jadus MR, Wepsic HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant 1992; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/67\">",
"      Chung B, Dudl E, Toyama A, et al. Importance of interleukin-7 in the development of experimental graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/68\">",
"      Dean RM, Fry T, Mackall C, et al. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol 2008; 26:5735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/69\">",
"      Korngold R, Sprent J. T cell subsets and graft-versus-host disease. Transplantation 1987; 44:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/70\">",
"      Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/71\">",
"      Mason DW. Subsets of T cells in the rat mediating lethal graft versus-host disease. Transplantation 1981; 32:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/72\">",
"      Fong TA, Mosmann TR. Alloreactive murine CD8+ T cell clones secrete the Th1 pattern of cytokines. J Immunol 1990; 144:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/73\">",
"      Okamura H, Kashiwamura S, Tsutsui H, et al. Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol 1998; 10:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/74\">",
"      Fujimori Y, Takatsuka H, Takemoto Y, et al. Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2000; 109:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/75\">",
"      Nishiwaki S, Terakura S, Ito M, et al. Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease. Blood 2009; 114:3113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/76\">",
"      Cullup H, Dickinson AM, Jackson GH, et al. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 2001; 113:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/77\">",
"      Cavet J, Dickinson AM, Norden J, et al. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001; 98:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/78\">",
"      Cullup H, Dickinson AM, Cavet J, et al. Polymorphisms of interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2003; 122:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/79\">",
"      Dickinson AM, Middleton PG, Rocha V, et al. Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol 2004; 127:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/80\">",
"      Elmaagacli AH, Koldehoff M, Landt O, Beelen DW. Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation. Bone Marrow Transplant 2008; 41:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/81\">",
"      Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003; 349:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/82\">",
"      Lin MT, Storer B, Martin PJ, et al. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. Blood 2005; 106:3995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/83\">",
"      Chien JW, Zhang XC, Fan W, et al. Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood 2012; 119:5311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/84\">",
"      Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983; 308:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/85\">",
"      Holler E, Rogler G, Brenmoehl J, et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006; 107:4189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/86\">",
"      Bayston K, Baumgartner JD, Clark P, Cohen J. Anti-endotoxin antibody for prevention of acute GVHD. Bone Marrow Transplant 1991; 8:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/87\">",
"      Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/88\">",
"      Moore RH, Lampert IA, Chia Y, et al. Effect of immunization with Escherichia coli J5 on graft-versus-host disease induced by minor histocompatibility antigens in mice. Transplantation 1987; 44:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/89\">",
"      Krijanovski OI, Hill GR, Cooke KR, et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999; 94:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/90\">",
"      Tsukada N, Akiba H, Kobata T, et al. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 2000; 95:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/91\">",
"      Kotani A, Ishikawa T, Matsumura Y, et al. Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation. Blood 2001; 98:3162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/92\">",
"      Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987; 166:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/93\">",
"      Shalaby MR, Fendly B, Sheehan KC, et al. Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. Transplantation 1989; 47:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/94\">",
"      Holler E, Kolb HJ, M&ouml;ller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/95\">",
"      Cavet J, Middleton PG, Segall M, et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999; 94:3941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/96\">",
"      Choi SW, Kitko CL, Braun T, et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008; 112:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/97\">",
"      Baker M, Podack ER, Levy RB. Fas and perforin cytotoxic pathways are not the major effector mechanisms in allogeneic resistance to bone marrow. Ann N Y Acad Sci 1995; 770:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/98\">",
"      Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996; 183:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/99\">",
"      Maeda Y, Levy RB, Reddy P, et al. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood 2005; 105:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/100\">",
"      Chaidos A, Patterson S, Szydlo R, et al. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood 2012; 119:5030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/101\">",
"      Rubio MT, Moreira-Teixeira L, Bachy E, et al. Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. Blood 2012; 120:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/102\">",
"      Taylor PA, Panoskaltsis-Mortari A, Swedin JM, et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004; 104:3804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/103\">",
"      Godfrey WR, Spoden DJ, Ge YG, et al. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 2005; 105:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/104\">",
"      Hanash AM, Levy RB. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 2005; 105:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/105\">",
"      Mutis T, van Rijn RS, Simonetti ER, et al. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice. Clin Cancer Res 2006; 12:5520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/106\">",
"      Hoffmann P, Ermann J, Edinger M, et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/107\">",
"      Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/108\">",
"      Nguyen VH, Shashidhar S, Chang DS, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 2008; 111:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/109\">",
"      Zhao D, Zhang C, Yi T, et al. In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 2008; 112:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/110\">",
"      Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005; 106:2903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/111\">",
"      Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/112\">",
"      Zhang C, Todorov I, Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006; 107:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/113\">",
"      Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/114\">",
"      Wei S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and trafficking. Blood 2006; 108:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/115\">",
"      Le NT, Chao N. Regulating regulatory T cells. Bone Marrow Transplant 2007; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/116\">",
"      Chen X, Vodanovic-Jankovic S, Johnson B, et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007; 110:3804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/117\">",
"      Fujita S, Sato Y, Sato K, et al. Regulatory dendritic cells protect against cutaneous chronic graft-versus-host disease mediated through CD4+CD25+Foxp3+ regulatory T cells. Blood 2007; 110:3793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/118\">",
"      Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009; 114:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/119\">",
"      Becker C, Taube C, Bopp T, et al. Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD4+CD25+ regulatory T cells. Blood 2009; 114:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/120\">",
"      Cai SF, Cao X, Hassan A, et al. Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. Blood 2010; 115:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/121\">",
"      Matsuoka K, Kim HT, McDonough S, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 2010; 120:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/122\">",
"      Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117:3921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/123\">",
"      Trzonkowski P, Bieniaszewska M, Ju��ci��ska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol 2009; 133:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/124\">",
"      Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/125\">",
"      Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009; 114:4919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/126\">",
"      Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007; 110:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/127\">",
"      Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004; 104:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/128\">",
"      Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/129\">",
"      Distler JH, J&uuml;ngel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/130\">",
"      Moreno-Romero JA, Fern&aacute;ndez-Avil&eacute;s F, Carreras E, et al. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease. Arch Dermatol 2008; 144:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/131\">",
"      Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009; 113:3865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/132\">",
"      Greinix HT, Pohlreich D, Kouba M, et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/133\">",
"      Sarantopoulos S, Stevenson KE, Kim HT, et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood 2011; 117:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/24/18826/abstract/134\">",
"      Kuzmina Z, Greinix HT, Weigl R, et al. Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia. Blood 2011; 117:2265.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3545 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-02B1BD5894-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18826=[""].join("\n");
var outline_f18_24_18826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25784855\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MAJOR HISTOCOMPATIBILITY CLASSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Innate Immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      T cell heterogeneity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Histocompatibility antigen mismatch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Extended haplotype matching",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - High and low risk antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Minor antigen mismatch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vascular interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Adhesion and activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8474935\">",
"      - Chemokines and chemokine receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Signaling events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - TNF-alpha",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cytokines and MHC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CELL MEDIATED CYTOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      REGULATORY T CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      B CELL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25784855\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=related_link\">",
"      Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=related_link\">",
"      Pathogenesis of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=related_link\">",
"      Treatment of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_24_18827="RR vs absolute risk fx";
var content_f18_24_18827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative risk versus absolute risk estimates of fracture",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hip T-score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        10-year fracture probability, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        -2.5",
"       </td>",
"       <td>",
"        17.6",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        -2.5",
"       </td>",
"       <td>",
"        17.6",
"       </td>",
"       <td>",
"        11.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Relative risk compared to age-matched women with normal BMD.",
"    <br>",
"     (RR per SD change in BMD)",
"     <sup>",
"      T-score Difference",
"     </sup>",
"     = (2.6)",
"     <sup>",
"      2.5",
"     </sup>",
"     = 17.6.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      10-year fracture probability from Swedish National Bureau of Statistics.",
"      <br>",
"       Data from: Marshall, D, Johnell, O, Wedel, H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254 and Kanis, JA, Johnell, O, Oden, A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporosis International 2001; 12:989.",
"      </br>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18827=[""].join("\n");
var outline_f18_24_18827=null;
var title_f18_24_18828="Giemsa stain method";
var content_f18_24_18828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Giemsa stain method",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Equipment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Staining tray constructed so that slides may be stained face downwards in a small volume of solution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; 20 mL syringe",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; 19 g needle (5 cm in length, with point removed)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Giemsa stain solution (BDH, R66; Product 35086)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Absolute methanol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       &bull; Phosphate-buffered distilled water, pH 7.2:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - KH",
"       <sub>",
"        2",
"       </sub>",
"       PO",
"       <sub>",
"        4",
"       </sub>",
"       0.7 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Na",
"       <sub>",
"        2",
"       </sub>",
"       HPO",
"       <sub>",
"        4",
"       </sub>",
"       1.0 g",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Distilled water 1.0 liter",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Method",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Prepare thin blood film, ensuring the film has a good 'tail' and does not reach the edges of the slide laterally. Allow the film to air dry.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Fix film with methanol for 30 to 60 seconds. Tip off excess methanol and place face down on a staining tray.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Using the syringe and blunt needle, dilute the stock Giemsa 1:10 with buffered distilled water. Mix well and expell air.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Use the syringe and needle to infiltrate the stain under the slide, taking care not to trap large air bubbles. Stain for 40 to 45 minutes.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Rinse the slide briefly with tap water and allow to drain in a vertical position. Do not blot.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Notes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; The syringe method for dilution of Giemsa is recommended because once the stain is diluted with water, precipitation of the stain begins, which is hastened by exposure to air. Staining face downwards allows any precipitation to fall away from the smear.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Alkaline pH is needed for proper differentiation of parasite nuclear and cytoplasmic material, as well as staining of cytoplasmic membrane changes in the infected red blood cell.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Warhurst, DC, Williams, JE. Laboratory diagnosis of malaria. J Clin Pathol 1996; 49:533.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18828=[""].join("\n");
var outline_f18_24_18828=null;
var title_f18_24_18829="Antihypertensive dose-response to thiazide therapy";
var content_f18_24_18829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F61248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F61248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Antihypertensive dose-response to thiazide therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 244px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Antihypertensive response to bendrofluazide in relation to daily dose (in mg, multiply by 10 to get approximate equivalent doses of hydrochlorothiazide). The initial dose of 1.25 mg/day lowers the blood pressure in comparison to placebo; however, higher doses produced little further antihypertensive response. Each treatment group contained approximately 52 patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Carlsen JE, Kober L, Torp-Pedersen C, Johannsen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18829=[""].join("\n");
var outline_f18_24_18829=null;
var title_f18_24_18830="Approach to bradycardia";
var content_f18_24_18830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F85685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F85685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Approach to bradycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 336px; background-image: url(data:image/gif;base64,R0lGODlhDAJQAcQAAP///wAAAIiIiLu7u0RERCIiImZmZpmZmd3d3TMzMxEREe7u7szMzFVVVXd3d5+fn9/f3z8/P8/Pz6qqql9fX39/f+/v7w8PD7+/vwAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAMAlABAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4g5AYuMjY6PkJGSk5SVlouJmZqbJQF7npyhooSgeaWjqKmmn6qtrnOnd7GvtLVls3W4tru8WrqwvcHCWLEEjAJpBMidw83OT8UGAAMBDGjKJr/P29w90SIKByMODSQCCQAFiwUMBuUABA4ADYsJCwcKi8siBAmL0gKUBUBAL4A9Bv4ClBOwzprBRQcOMBI3Qlu3ixhnfJOIYMQEBQAMEJi3L50DaggY/ww8twBAgoDyTBAop5KBgAIDALB0KeDcCAYKrJEDEADZTXglRVjMyLRpimITSSwIMCEePgYLDDCSpsyBNK1bB/gjYG0ENqIHAooA+4+gwYiNChDNeUDuWRJLnerV++1Eg3BAQUpsmUAaPgU5d5ZoIM0ssgkrR+q0Z+Im0LJK6dqNiXev58/MSBBoXFkBYWkIEhZoXEDyvInGArATfUyn64IB0kZl+G8ugLq/IXYGTXxvXiJ3ixwvzrzXciHJiTxvTv3VdDXXq2sflR1N9+3gM303Mz68eVKszqt3VZ5M+/Xw9VyaT7++fUvx84d/r7+//6f/BSigIgMWaCAM/B2o4P9+CzboIFEPRmhgghJW6BSFFmZ4EYYaSnjfhyCGKOKIJJZo4omXdMgHhyoGwWKLW7wIozcz4iFjjTrciCMVOu5oQ48+QgFkkDIMSSQTRh7pQpJKEgGBBEqJIAEETS7xZJQATFmlGRYEEMEDATwQQQAWbJlEl1+GOWaZZpJBgSMUtJnEm43EKecYEjgC5Z1G5NnInnyGMeYiEQR6xKBeGioGmIs8oGgRjIb5aBgXBHDBpEVUeimmX1QQQAWcDuEpqKF2AUEAVJYKxKmpqroFBq4GAWustNZq6624niBirhWFyCsQ3zHZYbC//kDsr8cWy0OyuTKrLIE0CKuhs8/eAIr/A+gAUBML0mZ4CkPvFJBUaNVCu4C4LnGmQrcWfqtAOOmMO1y5OJQygAIOFLBAar3how+WvH4rrmno8pYAZhDSWy8JWuXEGAAIBBUPuc2ao68CBoi7rUjzKlzDKdSIoM5EYgVAFsAVj3AUbwIAN41cFXlsLQkhz0MaCQ8nHLDFIhe1bQOu6SyzRjSDwu8iCMQ2m9C4CiyCREbVgzC7mFJrq9VDL/lxsVhnze3WyILtdQxdx1r22CicraraaHfiK7Jvtw2t3BTTDazddeNNo94o872s30wDPrfeVCtcuJmHF3tlwlranfivaIIpJpl4P/4rnYzY6bjgOvjJCKAzoij6/+j15YpooTtaboXqBUbqaOqJsF6gpkHKPoXtAo5ae+y8sro7IrgLOKuPwQvJ+X+Lg9L4H8lL2erx6kWuJuWASD85mxWSrj0l4GG+iOaAeB8A+B5iB57ni4D+B/oBqB9h8QiGd3oh809rPniuF5K//WnADwjthgAg/7xjHt0ZwoADPIP/mIeqQ/huWJVhRAM6QractCA6vFGITGrTse0MzxAf9FYJ8mWNpFkQQSdcAQblggB0iUYa1Jga9LYUCwVMoAT3CgC8+tEbhCyCMYxAACPsQQ1/BEUiwhHBUWxWgtGAgyJ9m+HvKkLBESgAGfhYAAFGghKfVCSFQpwANXLixP8VaiscSLSLYQbSwU1s742lcxsc50hHTAyjhlCEGBuJkjRkCBEBbkmAOAKQEwbEJjc1MwBXkpLBm/EjKm3UxAJnljdJNiMW+cqJCa+oE9Ng448qkwtVQoKOqRwgkVxRl05gdgIn6goVk/xRNmB5SROwxQAIyOEO/biSqIDFX+o4JSgUGZzchDIFrpwld+gwi1hKwZlggCaAlgmMSoqnlv2jZTUjec073k8U3YmOE2r2Smu6CIzqWIZaVBCydSJBml6AZznBWQIfvgUpMpEXDllEyJqRU5ncVMFUWEnIfOoqhQ7goifcmY0BtDNojsnM3oQhT4CGIhYJiIkAHCkafR7/wZ+/aKYMzoEYiS4phQ0oCUNP8NBWenRh3swmNUeQAIhiI4OGRIYBElBFfxWlnQVQhz2EqBkAOIARmPkICVQylQGMDCcPCUreriMuYrJFiHURCTKe6pATIjE3Cy1APohISLA6dKEjYQtcIFLQ2BCgJQ8xZvxiSsCZiqAdiziZMlRyQmVwTDScASoCFhAOov5GlDcswVQYUBcECKAc/QTFGOHhSJHCgBoLuBdcLahBfI6gAPIoaESBuoBzCYAay4isbRiGjrMQ8ialfQlRjMJKrd2xjnDU5gl2ihSX8eNdVRRBycjS0nQcwLDAuUkADNASmp7jAO5AhmqnMczKWrQF/2wxpmhFq4ysbMU3o0UrPwxATtWqRQD5kI1nCUlMnUijoL61rX8qGgeMUoRjexUtPLxSgOCOgDHFLcAgxUGA2sJLZRgDwLu6ilnqrsW65jwBYRPrk1GCVxmDccl7U4iNlkZMmF98aBiNupnMwNa0volvC+gLCBa/AZND7MhNkYqNjGFGaQwIsDgMdrF6NPeuBc1XZhbgD6g+eKowwMcIhIjXgXBXAEdbDXj5gYx2StDBmWmp0uSCRImQMa+bPSzZAuRiN5R5BZal53/OzAY2TzOgwCNzddyctuu6Uc7UofM8Y2ZX/ei5rk34J5pTKF8+F4nQaUN0FcT55v78WYFPEP90Q006VzirbCSuVfSkhyDpKSPzpRE+z6PJE2mLbFfT67KzCjK9YlTvoNMuYHSdY4TbWtv61rhmVyyOZpj0IqMgIOEqURKy44aYQyASMSJjTTOZq8aVwCMrsA79m2YALJYENgzIV5OdRBFocREgaSuYlfqTAPzYHfxwAK9XKdRzrWOMZn3NtOFrl60aOzdSNnQWRu0MXS8GNRLjzE38a5LZdvIyRn2HEnFCXTJKQ8DGBW9RVgmPkXg5XkgmwUtaeACgrNa1tC3aj1+rLyILYLGNfWzRUjKQh0XMJv0lLIipm9oBDFwEyK03CUBLFIXrmxic8vfOG3HKsbSDNN7tTUH/qfFV9V5auNW1zQRgdmoxdxgU0al2wg0wdZWrhdUqPion2duYjfJEkNFtogC8kg6ir1PAIP1ie/VY1O7e0tNRXF3QmxCLnP375sE5jW9IKNXKSAaV1laAbImSWHrjs2ZZvy5Q5PIXo2A6Jo43gUqIeuKCJXjBJTiMw272dmG2pLw2729FoN1bc2sY74HTe9X4XoKjDQTH8AB3lN/7bp189+lYbq8DmB0SpDn+6lTOOLYfw0a1dDnzUFf6l03WEr6S+AStwXlCIiOyAxBZNqjPvQ59b5B67x72/uM3NpdAIf3aQNZEC7Uh0r93JC3L1S6AzI9haun5Y6F5WfI8WwKA/8tjBOoXOAc4UVVgPWtyJwxIPUdwgFp3Z1ggPuRjJhaoBBKoat10BezjPlvygRrITBzIO1lQP4GCgu9EgvJXCMWzP4ECg++Ua7hVgjkQEAzhWA1hT5BFbNOQDzuUENLAg+S3NHejBQJkKEnIDTdyE4UkVeTgRUphFCDBSVm0RdTlWNlyRkLhcz4APwhkKGHIhEKwTk3XX/QgSL6BEnt0e7wESGm4VusgBPDzQIpih93QhJKBcCVwFEEmF5yEXlr0hqHEh0PgPyFkKIm4DXqoMluRQYPUe7pEYG8IieS3XHQoRerxOO63b5ooas+Ef88UBbsSOnHDCwn4N8YTLTXCNv+6dVGkKDYt4op9RoHQIIsqQotqtotOoIsK4ouckIo7kDjf0lkuNGswci3Zsi1oRlE0+IwgEosIBi/HuGe56G3oklEr9onSYTGCWDBS038PYi/4oi/r5lOpxY2HaDGElTECsDFBI4wuyDAF5XIB14LqKIsrow8u41Ti6CAgAwojAxHDVRbyeCdO03bvWA3zEI+tWDQi4Hc40xgHKScJCTXkdzD/2CABqX1BhHuxl485gosQxIoiaSwkmUBjdpJfmJIiZJIsqYrxl4wuGZM1+TWhc5M2WSSnmIs9uZMuUn9A2YtCOZT2N3tGSXtImZTsV5RMuYJL+ZROsifKI4AWKZX/RvCA2MMnFXkrGagoXWkrItgG0FiWZnmWaCkJGaKCazBq8piKYZkHMtiW9WUjdhCXebCEdAkHb3mXGjKGe/lidpkLGoKHbVaXsuCXGrKI32Rmg8mCJ0mAVjkGkgkHldkGl8mNWpkGm/kGnckGn5kRaYkiRfCVaWCab4CabKCaGPFoQDKWaQCbbyCbbECbrcmXRsCWaKCbbsCba+CbeYibkMIIr7MGc/kGx8kGybkhwpkplvIGegkH0dkG08mcgmkEgJkG2fkG28kG3RmcfCeKLSBoRmKYamCeltlAc4Cet4kXDCkRhyiK8Ad1+KgDjJkG9/kG+ckG+0mGeBFUwRGf/ywwn1j2c1iJZxWBXi3jCUcjDzfRbpeYY0BIYEIIMds3APAZEgBxDCQzMuLgVIxQnwdqHrGQGwzBEPNAE4gxcDJnfeCARZ6kUAQhGYSUoYrkop4FL0rFSeS5JGeJIKNJIroSpCeyLkSKH7aoFN43MhEHD2khGQLmW6DER580EBA3FzZqAPFVpY0ASj26jdJYaI1poIfZaNEUjJ0gDkiUotryWlDacfoViJ70hg1AE5EFSIWBoxOjYHkUiCUqpkoJqIC2kWOgDfKEly9QohShDha6CA76phE6ifj0RwwgVOKmeBu6CIxFkE9VTP6Aj5xYaYFJqGJgqO6BpteJk6soqP+QZoOD6qqemKRlqqq3mKiOCaukZqZfgKis+qq6elmLIJ7HJqLfAWsvYKwpiSEEGgMrJaq4egW8Cqa3SquXuBAxVgKy1awqsFLPARX/ckheiKzrkhPiOpMdlEFFsawdZQ5XlkE8hQLrpK29GpIrQA36EhIQtU/1kEuMwHDmaoJNUKcoKa0LBzHiskTaiG3C2ocQ1a1NBEPV4EQRk1j0qRHkyiG4EAtLRAPJcRQt1BMwk7CGp0T5aqu/ygL2+hUlOwIoAQ8N0LLYApMdiAOHtAyQQRr2hC4l1ZIES3E2cxQoNgJgIS4E0ELygC0LwBuzkUEN66yuFA5OxIz0uW48hIn/8lYUahVV1gCixlS1vfYv1tg3G4sU1HBDhSFvlIEbKgUzjAG01bhkjxhUBtESBUFWyhZh2cF07MVFE7pyq9SyAvuvcaYDThRDFcdsEVN2DYAQR0itRwEUutEbnZAYIxExDdBfCEcO1setTrtGSQNuSREy9mhIMopeMiZdF+twfAoASoWFKLGnv6qxjYBPHwE0k0EYIHu6PAO5jZQC8Rpz4bATLzFZyZR3ZIqyt7caI2GFxJeFREZejFC0MguwNNsYhVUNECeFUhEbIDGSPdu7R8Fbk7tawXFDZ+gynGuyZhEVo0FkqhQyA5kbVYoA7YUNS1ddQtSl81uQyHiutXUW/1rREtmlSI3Rsd8Vvls4suQrYAOMeHCWtwOhEiYzpXtEXT6GEvhAcPM6CAniRBzhE+fFUdS1f4OTajxzTK+HF5QLMQpwuSlReG1qDbZLqH0xXiycR6J7M/PbedJ1Q4h3YMk3pUw0w2Sqsf/7GK0xEoqxSqVVjWOLsNarUtlSekvswMdrvPXKRlqxvFT4Yy0LdR2BtIJ7CB0cFfHrWLVFAmIHas5qpk8MMx+rwrYRxw1gD70LFjVFrA/7QlB3QiFje32kR4OlGjrFVkfGtTr3R7i3s0Xch0ccQ+ciDbjhfUbkxLW1RB8LFPsHFMtVelc7c3OHxfTKTmwkRHyrQzhcwf9fjIVFgqo5kEwNtl+Wq0ReuHneS62B2rNCcC55hANVoWqH4wBsPL0iyiOuXL1Cq3BKVjIGsQzUILklfLIjqL50mFfKEbazis1dEK24PKbSnAQOS5ba7M2kejvHnM0mvKq67KujzM5XHCPnPKrpXKsbvE80O8zJOlIrq8+Z+M327APl+qx/4Jr1bIBtbAJxdwPqms/Mus8NDawH/c7/zLAkKwPkiX/c3IypqtHq3M3/HNAqhM/E3M4nIK/8fKzh3L9ZXNIOjbytLKvy/BQ/Ss0o8FRFpEPWoLQO4YM4Uxv4Rl5967W/4WvdvBxMixQF1qCrNFYLQIShxNRouy9D5G7/TufRYisQbjG3IfNVuPSIShyOQo2ONy1VkVVkCEPSgUDQEQjOLt1wlJW5kBVyoaS7ncW8WmSnhqRK8yzR5bbC/dARAgsUqdfEPZHAoUTYwrsPYQTSomzEiUEZw3sKgxGvZMGQ+CWjsEu8G2a4gcvXaX2kIwKVa73SwaelcZFitVW/qCvIShHIaMG/HP2P6Itpy3ClBPCk4xVIebROozHAhkQyKW2N69TAnnAA2+dYkqFtMOOP+2t0iDddY4vWV8PWWXx61WWIqM2OKCZacjqIrFvBEqnSorxUDGm7ZxHYbnrDKFzRH7bEvGVKsbzOPxevlEGfPAcZWkiyP0PbrB2R/9B7ZNN1tuW8NtQtUEWGeL0LfdZWyav9g6gsfhMHkns93vRoEPzdqAHgoO0KSUp0ZZ+cQ8H0fWn8zRp7G8BdhBGcDwZwXmD9hjj23Ge1r8XsKkxiOwuNzSxi0qI9zlBgrBntn6O9aCINzD+g40HO46Xmz01T4DEt3aeq5EBnOExOzvxmqoXqMTU+ni/Sifw34Ls64fGE5VOOAoxNaZvG5ZQ042cK5dAq5jueAmUOe19k5tHs5FfO5rJHL1mOvGZdhNbAVVdlS0H0bBjOFRW6zqBdIkaa6Gop5W9O5uW9uFDoczyH5iY1cUcxuq5bwWA+zZBpk3tO2jdxhkmHiZYucf9FFb8HML/yPebNCequjtCgkKcwnGFna2GCiBeNV1QSyepW/eivHpOhTsoy3kjnBxYEkRTI7niA7Ouxncty8ONrFus7QFgkvI4djZg7Oezk7OnbBOvA3qr0/O3CTu23EKbkzpLcDg0Li+f9/OnlHu6fdk4uIK/EqJjbbu4uRe8tYO/oHu1Due5osRpcK4cXl1zIprXfNn4/kRA9KBySqgyHZLVeroAAD5QCX9fi0Lq8VFRO6NajEd8qk8CYDogwqkXv6u/ZHuzq7uoFlb8f2fFitk6It8YkoNuoTcGurfLjfvH5DuzcnUd72rVyQfNRB2QE54dF1d1nob0VL5PpfpL/GW9BiFxMkZsARX941fXMFH+Jg1RUEb8MnMxR906YGK/vd97z2g7uR97taO/26ijw4k6UZv/zbS9Tas/yUv/2YVD28N7y8n7uK7/R8X737sz3hx/34Mzo9/Hva1/401r3US+SbvmYk5+PlZ+Ykg/54qz5f7/3ev/4og/6hH/5nR+ZVOk8aZCZmJn6AegGrK+JoVkGs78GtY8Gtz9DrFkGu78GvY8Gvw89tlkGw78GxY8Gxz9DwEkGy68GzX8Gz388y1kG02+cxCkH1S9F1WkG288G3Z8G3z9D31kG478G5Y8G5w897HkG64+Z6ikH7f+J/VkG878G9Y8G9z+i+r////wPAoA4kqV5oqm6sq37wjEb0LV947m+871t+oLCITEILCKTSt5x6XzmZNIptWq9YqmBLPe1LX274mp4VB6jZWfAOu0Wtd/yOb0OtIvXcbxbz//7/Y3tCRYaHt4hTgUqojE2OiZCak1WWtIRXpI8apJJdl5xgq5kjpqegqGeiKq2sLa6fsKmztailna+ug6M6qoM4Db6AggQvBAIoATwpgXbPhc6mxwo0BAwANuJCgQciHB7AzGLILONn2Rb1SCkcIJ/d5ukmw3MoxRbAQcUsNGwr34ycAOZsRH2SpRbdS4PtIaXpJFYEGACgAUNwmmTRSxAAhEF4olT+AuisoW0Nv+V4NYRwEeMBtscNIEvX5hl7TSa+1awRcKQzRwChURShMRkL4kV+JhgAQKbB/g5qMFgkUYBSQdMIBCPG8epHGl4QyYQrI1/LGkkTbZAwQSr1ZYCaEAD7iaTKE9+u5o1ntYABBYAS7DP64CP+8buG9GUhoECatkSEBzAAAAEkimTmGdTGc7NVpUC3lKMGwK5NIyKsFyDl2m4pgMk61bAQGGwAGqDNBN096GhIg70NRAaKYK1B5ryesqGoie8eQUYuNiNQYCpBozBJqYAQLnN5DCLSKdcudUFCxwLgJsANRy7up1bhS79QPkF64FNbdDAnD0EBVzONB4/BOxHHQMNUIb/gAJTHdXeTc45SJxx2VjFi1Xs9BRXQcuktwAA6wmgAIax7QeAAt5MsN2JAKQIIW8vzuFbRAk4QGFB/yEHAHkfCUcVhBcGsF03yt3Gj03AINAdM/aBF94Xaw2QgDczEWAAYpOB4R4csgAp5AFWfkPbF1bxFwYDK5IwE5RScmeUbDa4pJmWrHh24wE2igBmmyT8196VVmKmZGU3LLbOXTAiGuMUA1xT0X2i2clGWPyMgKYaVfHTQGwHGKhhTg4MGBtF9rHnpIfEJLAdMcYoSB9dPilQKhtcZrppfY6lkwBlywDj4ZkmpTdCeqqWM0EApTWZWU3MxAphG3V6dCekeZnn/xgJ+gFA3QAdCltAtbEx65KlLiZaLhe+lVbDfniyNOVc3lbD0amX/kgpHO521c8+vJQzFlc0jGNfYkXBQ0OJr7m0zpnzvndoXpuEZU1oc7GzjMAF9EUDCWdiSTB3NSSjmj8vJaawAgzP6iK07bIrsALWjsCAUjYhLPA+4IZnGD+42buluT8zZMswcwxwsk4yOCBryg7/UfSpGSIt69B0nOdSDDICnTW5p0z9Bo3C7hQKTnZ8TY7S6oytjTXNad22j7V0LXTau8Xdi9t30wv33A7VLffWsGCN989nQM3T2THExNnfUninLB9974JO4IzvTcVMTrKQ+AyCc745CYWzAP+6DOw+yPQJC/T1akmSP155Ramj7FMJmr/Rd1QoGj0og6s6vgLtKkzeOYyEH56C6IgHM3SS35Ji1++RLJ7aX+cVn5M8wV/t+ghrEVAQmsGC3ftIlAtfvnORMbYqaTW4BjI1HgZr2nY6e/UUbYZNi5jVda/HhmTeiKxxuNmCyCgzQPUdqzUeUqDnTLeC/n0lHgE8xwELWKQaIDBd8orLXGIHkOiRgBpNYYcDbsQet8grGyJzgAjklw2ZVc+B5uMc4QpUnQqRoCltKcCI2tWuC5mgACwMQImaRToAGGAlDVviCsCXHTI1YEPnMOIWEFSZBSmAhRQqgIXUIwBu9Y8U2vv/xkqemCkpkoCKcUkQFrUoGi6iykMg8mIsQDgCArCwHNQBTO6oRb1sYOtXQLxNdeDohRkiknj3mgkDMvalQCWjGBPgh54qgphd8WKEhORdiNDiLBck8VRO4UefrDcodmQDf9041iZn8qc/NZCJKgilg5RTSu9oMpVwYiW7XmmDZClOhicoVGI+BJ1kUUlMPuTOI1+Sxewh0nyKNBYCXNkRidDHW9SriAL6N8gDBECOmBRBs7ixKh0CAFSfXIFlmjTKuNhwipGsYpPKOa04Ckt1YgRhO+uio0zFM43zXKNAN8I7fJLRg6WTZQrAtxaKuGUh+GgVIOM5SGAULYbCjGbb/wgHsoMWbR/dcBnMHJC7vohIMrOxHji/wru+JGWdKmipJ98ps6+co6WCqYxkjtXSjxyUg7ZBWCx9tgKaliw5/LipYHI6FwL2FAE/vadQ40HUoi6NBTBD4n4k0rOCEXGTKyQHDRTwQgUAc6EcFRz27qhRsdlxDmTqAuTcMFe6jtFua+1cW1kUTkzkFQ1cMWvQNlqHwWqJEnHV617Z+oy6qgKyrZBsJfra2Mk+NrCA0+wsKDsJy172Fpld7BQut0nfBc6zLjDt807LNobqLbR3A20dJHs7FuWuKbtjbSlau0/DruC2KTqVbsPXoPGhjbS5kO1sRwtcFHDPe+EA39GOm/8C3wKPs0RRQPfIOV0lBtW1152caoXBXLdBIb1L0K4IWVlCj5ywAG8ZzliFatYtwJB8z0VBe0lowjTJN4VQpQEL7fvCrUJzE+pd8HrP62BL+AaPe9qj0wD8rYpmy6wXLWRis6vcO+YxGRTuI1IuXMUCaZiHTpJZhz384BfDOG8wICal1lPJ6lYpleEgQDOd9My3wZYFNBaBjZFZkBxvoZQ8riQwfgzkGEM5yh+MgUPZghTCpolVJ8Kwtjac0SdnFQZVhqh8JaplacEzWxxSMSG/DGYpwxnKQ9lqdCpSzDSpS6ySKTBKz5pWrPqGzl29s7DyrMI9kzVIfn5znBvtYNr/CkW7mHU0pV8MafN+eLOV3jRzL62I8jKW06Jeq6cRAWpQlHrUqtZ0DscVCi1h12yZEZFGUm3qVeNamiYwAAtblE5VOaBEMGjc7KQBNdMaNch0yzWzaViCpnhIIlNJ1bTf6k8UxHpPEWGl6Wzdm2aDG70lOIAS17OWpEnbgp/ZoPzMYZ/9KDAwgznLvP/VyMuMIIyyZDC/GRzufwPtDNARVgMmUPCCb8eKCmLAhYwzyOV404v4SfMIhKitOxoDSXkqlbcB7nFwCxw8Z0J3FlmoSvrY6cZBWsmf0lGeSxJJ1ppEIsc/bvObn2vc4FXAgj5kZSsa9z8P70YCjMEtzH3IpADgFOfFZc5tfScb51KfugvOAO0RNADYfw1gNSOFUncnYCkI0wdHECCyldq7HJqUiFmiTvW3w910vJ4FssMc97tTfQ2takXR2u52vAPe5h0HROALj/PBt87wigc44vHQ+MVD3rHlenzkK681ygPW8prndL8774TNgz70oh896Utv+tOjPvWqXz3rW+/618M+9rKfPe1rb/vb4z73ut8973sPtBAAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18830=[""].join("\n");
var outline_f18_24_18830=null;
var title_f18_24_18831="Pancoast tumor PA";
var content_f18_24_18831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superior sulcus tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior chest radiograph reveals opacification at the right apex due to a superior sulcus (Pancoast) tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Midthun, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_24_18831=[""].join("\n");
var outline_f18_24_18831=null;
